101
|
Wen W, Qian L, Xie Y, Zhang X, Wang J, Zhou J, Liu R, Yu J, Chen D. Targeting XPO1 Combined with Radiotherapy to Enhance Systemic Anti-tumor Effects in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e221-e222. [PMID: 37784904 DOI: 10.1016/j.ijrobp.2023.06.1124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The combination of radiation and radiosensitizing chemotherapeutic agents have shown promising anti-tumor effects in NSCLC. Acting as an oncogenic driver, XPO1 is frequently overexpressed and/or mutated in lung cancer. Thus, suppression of XPO1-mediated nuclear export presents a unique therapeutic strategy. We hypothesize that XPO1 inhibition combined with radiotherapy (XRT) may remodel the tumor immune microenvironment (TIME) and reduce radioresistance, thus enhance systemic anti-tumor effects. MATERIALS/METHODS Herein, we optimized a small molecule inhibitor, WJ01024, which can bind to XPO1 and antagonize its activity to inhibit nuclear export. In the C57BL/6 mouse subcutaneous tumor model, we evaluated the ability of different treatment regimens containing oral WJ01014 single or combined with XRT (one fractions of 15 Gy) in tumor control and tumor recurrence inhibition. The effects of each treatment regimen on the alterations of immunophenotypes, including the quantification, activation, proliferative capacity, exhaustion marker expression, and memory status, were evaluated by flow cytometry. RESULTS In our study, we found that the overexpression of XPO1 was associated with poor prognosis and survival in radioresistant patients with NSCLC. The combination therapy of WJ01024 and XRT resulted in an increase of apoptosis and a decrease of proliferation compared to monotherapy, which was closely correlated with tumor regression and improved survival in the C57BL/6 mouse subcutaneous tumor model. Notably, we found that WJ01024 were shown to enhance the therapeutic effect of XRT by remodeling TIME. Compared with XRT, the addition of WJ01024 increased the infiltration and proliferation of radiation-stimulated CD8+ T cells, which especially promoted the production of interferon-γ and granzyme B. Moreover, the combination therapy also reversed the immunosuppressive effect of radiation on the percentage of Tregs and exhausted T cells in mouse xenografts. Thus, the TIME was significantly improved in combination therapy. Strikingly, mechanistic studies suggested that the activation of cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS/STING) signaling pathway is required to reshape TIME and produce synergistic anti-tumor effect with the combination of WJ01024 and XRT. CONCLUSION Our findings suggest that WJ01024 might be a potential synergistic treatment for radiotherapy to control the proliferation of NSCLC cells, promote tumor regression and prolong survival in mouse model of NSCLC by activating cGAS/STING signaling, and this in turn potentiate the immune microenvironment.
Collapse
|
102
|
Zhang X, Olesinski EA, Duong Q, Truong MT, Lee S, Jang S, Mak KS, Parekh A, Hirsch AE. Development and Assessment of a Multi-Purpose Knowledge-Based Planning Model (RapidPlan) for Prostate Radiation. Int J Radiat Oncol Biol Phys 2023; 117:e497. [PMID: 37785565 DOI: 10.1016/j.ijrobp.2023.06.1737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) RapidPlan (RP) is a knowledge-based planning (KBP) tool to improve plan quality, planning speed, and reduce inter-patient plan variability. For small to medium institutions, it is difficult to find sufficient patient numbers to configure a reliable KBP-RP model. This study aimed to build a multi-purpose KBP-RP model for prostate cancers. MATERIALS/METHODS A total of 124 prostate plans from 2018-2022 at our institution were selected to configure the initial RP model. After model training, outliers were removed. 77 patients were used for the final RP model. Three fine-tuned RP sub-models with different optimized constraints corresponding to prostate bed, prostate + seminal vesicles (SV), and prostate boost plans were generated. RP models were validated by comparing plan quality with the original manually optimized plans (MP). 54 independent plans were selected to validate the RP models. Validation included: dose to 99% and 2% of PTV (D99%, D2%), PTV conformity index (CI); for organs at risk (OARs), volume receiving >70Gy and >60Gy (V70Gy, V60Gy) to bladder and rectum, maximum dose (Dmax) to femur heads (FHs) and small bowel. Statistical t-test analysis was performed with a significance of p<0.05. RESULTS A total of 48/54 model-based plans were clinically approved after single RP optimization. 6/54 failed plans were prostate bed plans and were deemed acceptable after additional minor constraint adjustments. For PTV, D99%, D2%, and CI were comparable (p>0.05) to MP. Bladder and rectum V70Gy were comparable (p>0.05), and V60Gy were significantly lower to MP (p<0.05), with an average Dmean of 23.21±14.58Gy and 16.41±10.63Gy vs 26.36±16.89Gy and 18.24±12.81Gy for RP and MP. RP significantly reduced Dmax to FHs and small bowel (p<0.05), with average Dmax of 34.95±6.06Gy and 35.62±18.99Gy vs 36.81±7.05Gy and 38.14±17.81Gy, respectively. CONCLUSION Multi-purpose prostate RP model was configured and approved plans were generated after single optimization. Prostate RP plans had equivalent PTV coverage with better or comparable OAR constraints.
Collapse
|
103
|
Ran X, Zhang X, Teng M, Alawi WB, Nahum S, He H, Lok BH. The Effect of PARP Inhibitor Radiosensitization on the mRNA Translational Regulation of T Cell Chemokines. Int J Radiat Oncol Biol Phys 2023; 117:S71-S72. [PMID: 37784561 DOI: 10.1016/j.ijrobp.2023.06.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Immunotherapy has modestly improved survival for small cell lung cancer (SCLC) patients. Low response rate and rapid disease progression remain an intractable challenge. One of the factors that contribute to immunotherapy resistance is the lack of cytotoxic T cell infiltration. The expression of chemoattractant cytokines, like CCL5 and CXCL10, are essential for T cell infiltration. The control of chemokine expression is not fully understood, but both transcriptional and translational control pathways could play a major role. Previous studies have shown a correlation between DNA damage and chemokine expression and that PARP inhibitors (PARPi) are radiosensitizers for SCLC that increases DNA damage. The objectives of this study were to define this potential PARPi immunogenic radiosensitizing relationship. MATERIALS/METHODS We identified doses of olaparib+ radiation treatment (RT) that conferred radiosensitization in SCLC cell-lines by cell viability and/or clonogenic assays. Olaparib+RT induced CCL5 and CXCL10 mRNA expression was measured by qPCR across SCLC cell-lines. Protein level of chemokines was assessed by immunoblotting. SBC5 cells were treated with olaparib+RT and submitted for RNA sequencing analysis. Genes with adjusted p value<0.05 were considered significant. Protein level changes and target gene knock-out (KO) were confirmed by immunoblotting. Chemokine CXCL10 mRNA and protein level in wildtype (WT) and KO cells were measured by qPCR and western blot, respectively. A mRNA decay assay and dual-luciferase reporter assay was used to identify the region of CXCL10 mRNA that confers mRNA stability control. In vivo anti-tumor efficacy and tumor T cell infiltration studies were done in B6129F mice bearing KP1 tumors. And the T cell infiltration was measured by immune profiling. RESULTS In vitro, olaparib+RT significantly increased CXCL10 mRNA in all four SCLC subtype cell-lines in comparison to vehicle control. Consistently, the increase of CXCL10 protein levels (3-fold) was observed in SBC5 cells. By RNA-Seq, a top-ranking translational repressor was EIF4E2 (4EHP) mRNA. The downregulation of EIF4E2 protein by olaparib+RT was validated in four SCLC subtypes by western blot. EIF4E2 KO in HEK293 and SBC5 cells increased CXCL10 mRNA and protein level. By mRNA decay assay and western blot, the absence of EIF4E2 stabilized CXCL10 mRNA and increased CXCL10 protein levels. The dual-luciferase assay demonstrated EIF4E2 destabilizes CXCL10 mRNA via the 3'UTR of CXCL10. In vivo, immune profiling showed olaparib+RT significantly increased the total T cell and CD8+ T cell infiltration. Finally, anti-PD-L1 inhibition potentiated olaparib + IR to improve tumor control in KP1 allograft. CONCLUSION Our study demonstrated olaparib + RT increases CXCL10 protein levels through downregulating EIF4E2 to subsequently increase T cell infiltration. Olaparib + RT enhanced anti-PD-L1 immunotherapy efficacy and has therapeutic potential as an immunogenic radiosensitizer.
Collapse
|
104
|
Tang W, Guo Q, Chen J, Wu Q, Zhang T, Wang Q, Zhang X, Xie P. The Predictive Value of Circulating Exosomal PD-L1 in Cervical Cancer Immunotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e548-e549. [PMID: 37785688 DOI: 10.1016/j.ijrobp.2023.06.1851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Programmed death ligand 1 (PD-L1) expression was wildly used as a predictor of immune Check-Point Inhibitors (ICIs) efficiency. However, emerging results showed that PD-L1 was of great heterogeneity in sampling time and site. Recently, some studies found that exosomal PD-L1(ExoPD-L1) was related to ICIs response. In this study, we aimed to explore the predictive value of ExoPD-L1 in ICIs treatment of cervical cancer (CC) for the first time. MATERIALS/METHODS A total of 40 primarily diagnosed CC patients who accepted radical radiotherapy (RT) from March 2021 to October 2022 were included. The consecutive tumor sample were collected before and during RT. Another 37 advanced CC patients who accepted ICIs combination therapy from June 2020 to October 2022 were enrolled in this study. Blood samples were collected from each participant before and during treatment. Exosomes were derived by differential centrifugation, which was further identified by Western blot (WB) (CD9/TSG101/Calnexin), transmission electron microscope analysis and nanoparticle tracking analysis. ExoPD-L1 detection was conducted by enzyme-linked immuno-sorbent assay (ELISA). The knockout of PD-L1 was conducted via CRISPR/Cas9 assay and the overexpress of PD-L1 was conducted by lentiviral transfection. CD8+ T cells were extracted from murine spleen by CD8+ T Cell Isolation Kit. Immune cells and cytokines markers were detected by multicolor flow cytometry. RESULTS The consecutive detection of PD-L1 showed a dynamic change during RT. Compared with the level before RT, PD-L1 expression elevated in most patients (87.5%, 35/40) after RT. And the responders (n = 18) had elevated ExoPD-L1 level at the first two circles in the ICIs combination therapy (P<0.001). Whereas the level of pre-treatment ExoPD-L1 couldn't stratified clinical responders and non-responders (P = 0.181). The median follow-up time was 14.13 months. The mPFS in increased group vs. decreased group: not reach vs.11.02 months (P = 0.025, HR: 0.218, 0.052-0.913). Continuous blood sampling of mice models also found that effective therapeutic intervention could increase ExoPD-L1 in the early stage. The combination of exosome inhibitor GW4869 and anti-PD-1 further inhibited tumor growth. Mice were injected with external ExoPD-L1OE and ExoPD-L1KO. The results showed that ExoPD-L1OE suppressed body immunity and promoted tumor growth. The results of flow cytometry showed that ExoPD-L1OE inhibited CD8+ T cells from releasing interferon-and granzyme B. And ExoPD-L1OE also suppressed the CD8+ T cells proliferation in murine spleen. The coculture of CD8+ T cells and exosomes in vitro also confirmed the above conclusion. CONCLUSION Compared with unstable and impressionable tumoral PD-L1, ExoPD-L1 seems to be better predictor for the efficacy of immunotherapy in CC, which was with easy accessibility and continuation. Exosome PD-L1 played an immunosuppressive role by inhibiting the proliferation and functional factor release of CD8+ T cell.
Collapse
|
105
|
Xiao C, Xie X, Chen X, Chen M, Lu J, Zhang X, Wei L, Wu M, Yu J, Chen D. RUNX1 as a Potential Target for Combined Radioimmunotherapy of Lung Adenocarcinoma. Int J Radiat Oncol Biol Phys 2023; 117:e268. [PMID: 37785017 DOI: 10.1016/j.ijrobp.2023.06.1231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Radioimmunotherapy for non-small cell lung cancer has good clinical application prospects. The role and mechanism of RUNX1 in DNA damage repair were explored for its potential role in lung adenocarcinoma radioimmunotherapy. MATERIALS/METHODS To study the effect of RUNX1 expression level on the expression of DNA damage repair system related factors and radiation sensitivity of lung adenocarcinoma cells. As an important nuclear transcription factor, RUNX1 was explored whether directly regulating the expression of Nrf2, Rad51, BRCA1, and verifying their respective DNA binding sites in the promoter region through relevant databases. To observe the effect of RUNX1 knockout and overexpression on the expression level of PD-L1 in tumor cells at the cell level; The effect of RUNX1 expression level on the sorting and presentation of PD-L1 cells was investigated by the method of nucleocytoplasmic separation. According to literature reports, CMTM6 and ALIX play a key role in the process of PD-L1 cell sorting and presentation, and explore whether RUNX1 plays a role through this factor. The effect of phosphorylation level of different splicing bodies of RUNX1 (RUNX1a/b/c) on the expression level and DNA damage repair system related factors on tumor radiosensitivity were also explored. RESULTS According to TCGA database, RUNX1 is highly expressed and phosphorylated in lung adenocarcinoma. Through gene comparison with the database, it was found that RUNX1 binding sites existed in the promoter region of several factors related to this study, including ALIX, Nrf2, BRCA1, RAD51, ATM, H2AX, etc. After being activated by MAPKp38 phosphorylation, RUNX1a can positively regulate Nrf2 signal pathway. The expression of RUNX1 and p-RUNX1 is time-dependent on ionizing radiation. At the same time, it was found that the expression of RUNX1 and p-RUNX1 was dose-dependent on ionizing radiation, and the expression trend of Nrf2 signal pathway related factors was consistent with RUNX1. RUNX1 regulates the expression of PD-L1, BRCA1, ALIX and Nrf2. Bioinformatics analysis and flow cytometry data show that RUNX1 has inhibitory effect on tumor microenvironment of lung adenocarcinoma. CONCLUSION RUNX1 regulates DNA damage repair system and has inhibitory effect on tumor immunity. Inhibiting the expression of RUNX1 in lung adenocarcinoma cells can enhance the effect of radioimmunotherapy.
Collapse
|
106
|
Liu YC, Zhang X, Zhang L, Sui J, Wang Y. Proposals for the Delineation of Neck Clinical Target Volume Specific to Oral Squamous Cell Cancer Based on Lymph Node Distribution. Int J Radiat Oncol Biol Phys 2023; 117:e601. [PMID: 37785814 DOI: 10.1016/j.ijrobp.2023.06.1963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To establish the regional lymph node (LN) distribution probability map and draw the neck clinical target volume specific to oral squamous cell cancer (OSCC). MATERIALS/METHODS A total of 293 patients with pathologically proven OSCC were enrolled from Jan 2014 to Jun 2022. The patients were divided into two groups according to the ≤1 cm or>1 cm of minimal distance from the lesion's edge to the midline of body. The center point of the LNs with a minimal axial diameter of ≥10 mm was marked on a single treatment planning computed tomography scan. The neck LN levels I to X were based on 2013 updated international consensus guidelines. LN distribution probability maps were established. The relationships between the LN distribution and consensus guidelines were analyzed to propose modifications for clinical target volume boundaries specific to OSCC. RESULTS A total of 1033 LNs were marked. Compared with the >1 cm group, The ≤1 cm group has following feature tendencies: strong addiction to smoking and drinking, predilection for tongue and oral floor cancer, larger primary lesion with mainly infiltrative growth pattern, more frequent extra-nodal extension with mainly contralateral LNs. For the ≤1cm group, the distribution probability of LNs was: ipsilateral II (42.67%), ipsilateral Ib (17.35%), contralateral II (11.18%), ipsilateral III (8.74%), contralateral Ib (7.46%), Ia (6.43%). The other group was: ipsilateral Ib (43.14%), ipsilateral II (37.64%), contralateral Ib (4.31%), ipsilateral III (3.92%), contralateral II (3.53%), Ia (0.78%). Accordingly, the proposals for the delineation of neck clinical target volume were: 1. the inferior boundary of level Ia extends until the level of the thyroid cartilage plate; 2. the upper boundary of level Ib descends to the level of the mandibular angle, and the inner posterior boundary only includes the lateral and posterior margin of the submandibular gland within 5mm; 3. the upper boundary of level II changes to the transverse process of the second cervical vertebra, and the posterior boundary retracts to the posterior edge of the levator scapula. 4. the anterior inner border of level IVa contains only the internal jugular arteriovenous sheath. CONCLUSION This is the first description of LN topographic spread patterns for OSCC. Optimization of CTV delineation is helpful to improve the treatment outcome and reduce adverse events.
Collapse
|
107
|
Wang H, Zhang X, Yang J, Wen Z, Rhee DJ, Sims C, Alsanea F, Lee A, Hunter R, Williamson T, Gunn GB, Frank SJ, Phan J. Proton Based Stereotactic Radiotherapy for Skull Base Patients: Dosimetric Comparison to 4 Modern Radiation Treatment Modalities. Int J Radiat Oncol Biol Phys 2023; 117:e733-e734. [PMID: 37786132 DOI: 10.1016/j.ijrobp.2023.06.2257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Re-irradiation with ablative doses to a smaller target volume and strict critical structure constraint is a challenge for modern radiation planning and delivery systems. Several advanced radiation treatment techniques can be used for fractionated stereotactic ablative radiosurgery (FSRS) in select patients with unresectable recurrent head and neck tumors. In this study, in order to better understand the dosimetry advantage of each technique, we compare the stereotactic treatment plans of our new small spot size Hitachi proton treatment unit to those of CyberKnife stereotactic radiosurgery (CK), Gamma Knife radiosurgery (GK), volumetric modulated arc therapy (VMAT), and MR Linac radiotherapy (MRL). MATERIALS/METHODS Ten FSRS skull base patients treated at our institution using VMAT (n = 5) or GK (n = 5) techniques. Intensity-modulated proton therapy (IMPT) plans were created in Raystation using Monte Carlo dose calculation algorithm. VMAT, CK, GK and MRL plans were generated in RayStation, Accuray Precision, Leksell Gamma Plan, and Monaco treatment planning systems, separately. Planning goals were to achieve the best target coverage of prescribed dose without compromising the critical organs at risk dose volume constraints of the clinical treatment plans. Plans were compared based on percent CTV coverage, Paddick conformity index (PCI), gradient index (GI, V50/V100), dose homogeneity index (HI, (D2-D98)/D50), low dose bath volume (LDBV, ratio of total volume irradiated between 20% and 50% prescription dose and the target volume), beam-on-time (BOT), and mean/maximum doses to brainstems. RESULTS The median target volume was 15.5 cm3 (range 1.0 - 36.23 cm3). The prescription was 45 Gy in 5 fractions for VMAT patients, and 21 - 27 Gy in 3 fractions for GK patients. The comparison of the treatment plans of these 5 delivery modalities was shown in table. All techniques achieved comparable CTV coverage. GI was superior for GK plans and outstanding in CK and IMPT plans. IMPT plans were also outstanding in regard to BOT and PCI. Significantly improved HI, LDBV and brainstem mean doses were achieved in IMPT plans. For adjacent brainstem and other OARs, maximum doses were comparable among all techniques. CONCLUSION In these five advanced radiation therapy modalities, proton therapy SBRT showed dosimetric advantage over other modalities to spare nearby OARs without sacrifice of target coverage. Further studies are needed to utilize this clinical benefit and investigate plan robustness.
Collapse
|
108
|
Zhao M, Zhang X, Wang F, Hu X, Xue Z, Yue J, Chen M. A Multiomics Analysis of the Close Connection between Intratumoral Microbiota and Immune Cell Infiltration in Colorectal Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e358. [PMID: 37785232 DOI: 10.1016/j.ijrobp.2023.06.2442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The colorectal intratumoral microbiome and its association with the expression of the tumor genome and immune cell infiltration remain poorly characterized. Our study aims to investigate the relationship between intratumoral microbiota with tumor immune infiltration, patient prognosis, and potential downstream signaling pathways. MATERIALS/METHODS We collected biopsy samples of tumor tissue and paracancerous tissue from 92 patients with colorectal cancer, and acquired microbiota profiling in these samples using 16s rRNA sequencing. Meanwhile, the immune markers including CD8, FOXP3, CD163, PD-1 and PD-L1 were stained by immunohistochemistry (IHC) to identify the immune infiltration in tumors. Furthermore, we used The Cancer Genome Atlas and The Cancer Microbiome Atlas databases to conduct multiomics analysis on tumor flora and patient survival, tumor gene expression profile and potential downstream pathways. RESULTS There was a significant difference in α-diversity (p = 0.00051) and β-diversity (p = 0.004) between tumor and paracancerous tissues. The β-diversity of intratumoral bacterial differed by colorectal cancer tumor stage (early vs. late stage, p = 0.049) and location (left vs. right colon, p = 0.04). Stage-related flora cluster (Porphyromonas, Lachnoclostridium, Bacteroides, Aggregatibacter, and Hungatella) were identified and found to be associated with poor prognosis in colorectal cancer patients (HR = 1.79, p = 0.015). By IHC staining, we found that expression of PD-1 and FOXP3 was significantly reduced at low abundance of stage-related bacterial cluster (p<0.05). Among of them, Hungatella was negatively associated with CD8+T cell infiltration (p<0.05) in tumor. Besides, tumor-location related flora cluster (Bacteroides and Blautia) were identified and found to be associated with good prognosis in colorectal cancer patients (HR = 0.52, p = 0.011). Expression of CD163 was decreased at high abundance of location-related bacterial cluster (p<0.05). Among of them, Blautia was negatively correlated with tumor-associated macrophage infiltration(p<0.05). Furthermore, we found that the stage-related flora cluster was positively connected with the pathway of bile acid metabolism, whereas the location-dependent cluster was negatively correlated with this pathway. CONCLUSION We found specific intratumoral bacterial clusters that were related to tumor stage and location, and the clusters were strongly associated with tumor immune infiltration and patient prognosis. Our findings may provide new viewpoint for future research between intratumoral microbiota, metabolism pathway and tumor microenvironment.
Collapse
|
109
|
Lu J, Chen X, Zhang X, Wang M, Wu M, Yu J, Chen D. IKBKE Promotes Radioresistance of Glioblastoma through AKT/FOXO3a Pathway. Int J Radiat Oncol Biol Phys 2023; 117:S139. [PMID: 37784354 DOI: 10.1016/j.ijrobp.2023.06.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Glioblastoma is an intracranial highly malignant primary tumor, and postoperative radiotherapy is a common treatment of glioblastoma. While radiotherapy resistance of glioblastoma is an important reason for treatment failure. IKBKE is overexpressed in gliomas, but its role in radiotherapy is unknown. This study confirmed that IKBKE can directly phosphorylate AKT protein to regulate FOXO3a, thus promoting the radioresistance of glioblastoma, and proposed a new therapeutic strategy to enhance the efficacy of radiotherapy. MATERIALS/METHODS We used flow cytometry, tunel staining, plate cloning, a cell counting kit and WB to confirm the effects of IKBKE and FOXO3a on radioresistance of glioblastoma, and immunofluorescence and WB were used to detect the expression of γ-H2AX. Subcutaneous tumor formation in mice and immunohistochemical staining was performed. IP combined with mass spectrometry, immunofluorescence, endogenous and exogenous IP were used to confirm the interaction between IKBKE and AKT. Point mutation, IP and WB were used to confirm the phosphorylation site of AKT. IP and some small molecule inhibitors were used to confirm the relationship between IKBKE, AKT and PI3K. The effect of IKBKE on FOXO3a was confirmed by WB and qPCR. The protein relationship among IKBKE, FOXO3a and 14-3-3 was confirmed by CHX, MG132, ubiquitin test, immunofluorescence and IP. The above experiments were carried out to verify the effect of Amlexanox, an IKBKE inhibitor, on glioblastoma. And its pharmacokinetics in the brain was determined by LC-MS to provide a theoretical basis for further clinical use. RESULTS It was found that IKBKE could increase the radioresistance of glioblastoma in vitro and in vivo. IKBKE could directly phosphorylate AKT, and its phosphorylation sites were Ser473 and Thr308. We also certified that IKBKE activated AKT independent of PI3K. IKBKE inhibited the expression of FOXO3a on protein level, promoted its ubiquitin degradation, enhanced its interaction with 14-3-3, and inhibited its transportation into the nucleus. FOXO3a can increase the radiosensitivity of glioblastoma. Amlexanox, an IKBKE inhibitor, can inhibit the radiosensitivity of glioblastoma and partially pass through the blood-brain barrier to enhance the radiosensitivity of intracranial tumors. CONCLUSION IKBKE can activate AKT independent of PI3K by directly phosphorylating AKT Ser473 and Thr308, thus increasing the phosphorylation of FOXO3a. Phosphorylated FOXO3a promoted its ubiquitin degradation, and inhibited its transportation into the nucleus, causing radioresistance in glioblastoma. IKBKE inhibitor Amlexanox can pass through the blood-brain barrier and increase the radiosensitivity of intracranial tumor cells.
Collapse
|
110
|
Zhang X, Xue Z, Yue J. Perturbation of Gut Microbiota Modulated the Abscopal Effects of Immunoradiotherapy in Rectal Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e357-e358. [PMID: 37785231 DOI: 10.1016/j.ijrobp.2023.06.2440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The abscopal effect-the regression of malignancies outside the irradiation zone-can be increased by combining radiotherapy (RT) with immunotherapy. In this study, we aimed to investigate whether the gut microbiota affected the abscopal effect following immunoradiotherapy (iRT) in rectal cancer. MATERIALS/METHODS Bilateral MC38 subcutaneous tumors (primary and abscopal tumor) were established in C57/B6 mice with or without oral antibiotic treatment (preadministration of vancomycin, streptomycin, and ampicillin 14 days before therapy). Mice with or without antibiotic therapy were then randomized into eight groups to receive one of four treatments: (1) RT to the primary tumor + anti-PD-1 therapy (iRT), (2) RT to the primary tumor (RT), (3) anti-PD-1 therapy (anti-PD-1), and (4) no treatment. Flow cytometry was used to determine the composition and function of immune cells in the primary and abscopal tumors as well as in the spleen. 16S rRNA sequencing was used to assess the gut microbiome alteration following antibiotic intervention. Multiple bioinformatics were then explored to investigate the impact of specific flora that related to abscopal antitumor effect. RESULTS We found that radiation on primary tumors exhibited cytotoxic effect in nonirradiated (abscopal) tumors (p=0.0057, RT vs. untreated group; p=0.0037, iRT vs. anti-PD-1 group). In contrast, abscopal tumors were resistant to the anticancer effects of RT when antibiotics were given (p=0.5374, RT + antibiotics vs. untreated group + antibiotics; p=0.42, iRT + antibiotics vs. anti-PD-1 + antibiotics group). Comparing the RT+antibiotics group to the RT group, we discovered that the number of CD8+CD44+ T cells decreased significantly in both abscopal tumors (p<0.001) and spleens (p=0.0061). In anti-PD-1-treated groups, antibiotics significantly reduced the number of CD8+GranzymeB+ T cells in primary tumors (p=0.0061) and CD4+CD25+ T cells in spleens (p<0.001). In iRT-treated groups, the antibiotic reduced the fraction of CD4+INF-γ+ cells in abscopal tumors (p=0.0134), and increased the number of CD4+PD-1+ T cells in spleens (p<0.001). Moreover, we found that both α- and β-diversity decreased significantly in the gut microbiota after antibiotic treatment (p=0.0079 and p<0.001, respectively). The abundance of g_Alistipes, g_Lactobacillus, g_Lachnospiraceae and g__Lactobacillus fell dramatically in the presence of antibiotics. In addition, functional analyses of Picrust2 and KEGG revealed that antibiotic therapy had the most profound impact on the D-Alanine metabolism pathway (p<0.001). CONCLUSION We found that the alteration of the gut microbiome by antibiotics significantly affects the local and systemic antitumoral effect of iRT, our results may provide new insight on how gut modification converts the local anticancer effects of RT into a systemic response that targets metastatic tumors.
Collapse
|
111
|
Kokossis D, Wei HJ, Gallitto M, Yoh N, McQuillan N, Tazhibi M, Berg X, Zhang X, Szalontay L, Gartrell R, Jovana P, Zhang Z, Molotkov A, Mintz A, Konofagou EE, Wu CC. Focused Ultrasound for Blood-Brain Barrier Opening and Delivery of Anti-PD1 in Diffuse Midline Gliomas. Int J Radiat Oncol Biol Phys 2023; 117:e523-e524. [PMID: 37785629 DOI: 10.1016/j.ijrobp.2023.06.1796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Diffuse midline glioma with H3K27 mutation is a fatal pediatric brain tumor, most commonly arising in the brainstem. This tumor remains universally fatal, despite a multitude of clinical trials, with a median overall survival of only 9-12 months. While immune-checkpoint inhibitors (ICIs) have transformed the treatment landscape of multiple solid tumors, delivery past the blood brain barrier (BBB) remains challenging. Programmed cell death protein 1 (PD1) is an immune checkpoint protein expressed on the surface of activated T cells; interaction with its ligand, PDL1, is tumor-protective, dampening T cell response. Recent phase I clinical trials have shown that ICIs targeting proteins along the PD1/PDL1 axis are well tolerated in patients with DMG; however, efficacy remains low. The blood-brain barrier (BBB) poses a major challenge to the efficacious delivery of therapeutic agents with large molecular size, such as anti-PD1. We hypothesize that BBB opening (BBBO) using focused ultrasound (FUS), a form of non-ionizing acoustic radiation, can enhance delivery and efficacy of anti-PD1 for treatment of DMG. MATERIALS/METHODS We established a syngeneic mouse DMG model with intracranial injection of cell line 4423 (PDGFB+, H3.3K27M, p53-/-). Magnetic resonance imaging (MRI) was utilized to evaluate BBBO and tumor progression. We measured delivery of anti-PD1 after BBBO using Western Blot and 3D in vivo optical fluorescent imaging/CT (OI/CT) of Cy7 labeled anti-PD1. RESULTS We demonstrate that delivery of anti-PD1 can be enhanced over 3.5-fold after reversible BBBO with FUS and concurrent microbubble administration. OI/CT revealed enhanced real-time antibody distribution peritumorally. Furthermore, we demonstrate that combined treatment of FUS and anti-PD1 led to benefit in local control of tumor growth using volumetric analysis of MRI. Preliminary survival studies suggest a positive trend for overall survival. CONCLUSION Our results support that FUS-mediated BBBO can increase treatment efficacy of anti-PD1 in a DMG murine model, due to improved targeted delivery to the tumoral region after systemic antibody administration. We consider these findings strong rationale for further investigation of the therapeutic effects of combinatorial treatment using FUS-mediated BBBO and ICIs for the treatment of DMG.
Collapse
|
112
|
Yuan X, Liu B, Cuevas P, Brunski J, Aellos F, Petersen J, Koehne T, Bröer S, Grüber R, LeBlanc A, Zhang X, Xu Q, Helms J. Linking the Mechanics of Chewing to Biology of the Junctional Epithelium. J Dent Res 2023; 102:1252-1260. [PMID: 37555395 PMCID: PMC10626588 DOI: 10.1177/00220345231185288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/10/2023] Open
Abstract
The capacity of a tissue to continuously alter its phenotype lies at the heart of how an animal is able to quickly adapt to changes in environmental stimuli. Within tissues, differentiated cells are rigid and play a limited role in adapting to new environments; however, differentiated cells are replenished by stem cells that are defined by their phenotypic plasticity. Here we demonstrate that a Wnt-responsive stem cell niche in the junctional epithelium is responsible for the capability of this tissue to quickly adapt to changes in the physical consistency of a diet. Mechanical input from chewing is required to both establish and maintain this niche. Since the junctional epithelium directly attaches to the tooth surface via hemidesmosomes, a soft diet requires minimal mastication, and consequently, lower distortional strains are produced in the tissue. This reduced strain state is accompanied by reduced mitotic activity in both stem cells and their progeny, leading to tissue atrophy. The atrophied junctional epithelium exhibits suboptimal barrier functions, allowing the ingression of bacteria into the underlying connective tissues, which in turn trigger inflammation and mild alveolar bone loss. These data link the mechanics of chewing to the biology of tooth-supporting tissues, revealing how a stem cell niche is responsible for the remarkable adaptability of the junctional epithelium to different diets.
Collapse
|
113
|
Zhang X, Yang M, Zhang J, Ye P, Wong RMY, Cheung WH, Armstrong E, Johansen A, Ivers R, Wu X, Tian M. Establishing a Chinese older hip fracture registry for older patients: a Delphi study to define the focus and key variables for this registry. Osteoporos Int 2023; 34:1763-1770. [PMID: 37341729 DOI: 10.1007/s00198-023-06832-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 06/09/2023] [Indexed: 06/22/2023]
Abstract
A national hip fracture registry does not yet exist in China. This is the first to recommend a core variable set for the establishment of a Chinese national hip fracture registry. Thousands of Chinese hospitals will build on this and improve the quality of management for older hip fracture patients. The rapidly ageing population of China already experiences over half a million hip fractures every year. Many countries have developed national hip fracture registries to improve the quality of hip fracture management, but such a registry does not exist in China. The study is aimed at determining the core variables of a national hip fracture registry for older hip fracture patients in China. A rapid literature review was conducted to develop a preliminary pool of variables from existing global hip fracture registries. Two rounds of an e-Delphi survey were conducted with experts. The e-Delphi survey used a Likert 5-point scale and boundary value analysis to filter the preliminary pool of variables. The list of core variables was finalised following an online consensus meeting with the experts. Thirty-one experts participated. Most of the experts have senior titles and have worked in a corresponding area for more than 15 years. The response rate of the e-Delphi was 100% for both rounds. The preliminary pool of 89 variables was established after reviewing 13 national hip fracture registries. With two rounds of the e-Delphi and the expert consensus meeting, 86 core variables were recommended for inclusion in the registry. This study is the first to recommend a core variable set for the establishment of a Chinese national hip fracture registry. The further development of a registry to routinely collect data from thousands of hospitals will build on this work and improve the quality of management for older hip fracture patients in China.
Collapse
|
114
|
Gu Y, Fan X, Zhang X, Zhang J, Lai S. A Comparative Population-Based Study of Tracheal and Lung Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys 2023; 117:e21. [PMID: 37784873 DOI: 10.1016/j.ijrobp.2023.06.693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Thoracic adenoid cystic carcinoma (ACC) is very rare, and its clinicopathological characteristics, treatment and prognosis have not been fully elucidated. Previous studies did not differentiate between tracheal and lung lesions. MATERIALS/METHODS We identified tracheal ACC (TACC) and lung and bronchus ACC (LACC) patients from our cancer center (from 2005 to 2022) and the Surveillance, Epidemiology, and End Results (SEER) database (from 2000 to 2009). Incidence was calculated and trends were quantified. Significant prognostic factors for overall survival (OS) were reviewed and analyzed by using Cox proportional hazards regression. Then, two nomograms predicting OS of TACC and LACC were constructed based on the SEER database and validated externally by using the separate cohort. RESULTS There was an upward trend from 2000 to 2019 for LACC while a downward trend from 2000 to 2009 was shown for TACC. Totally, 55 TACC and 25 LACC were included in our cohort, 121 TACC and 162 LACC included in the SEER cohort. There were larger tumor sizes, more lymph nodes and distant metastases for LACC patients than TACC patients. The proportion of patients receiving radiotherapy were higher for TACC than LACC. More patients with TACC received surgery and perioperative radiotherapy than those with LACC. Patients with LACC had significantly worse OS than patients with TACC (SEER cohort: 93.7 mons vs. 127.0 mons, p = 0.001, our cohort: 72.2 months vs. 130.8months, p = 0.061). Age, lymph node metastasis, distant metastasis and radiation and/or surgery were identified as independent prognostic factors for OS of TACC. Laterality, distant metastasis and surgery were identified for LACC. The discrimination of the nomogram revealed good prognostic accuracy and clinical applicability as indicated by C-index values of 0.753 and 0.833 for the training cohort and the external validation cohort for TACC, and 0.739 and 0.786 for LACC. CONCLUSION TACC and LACC are different in incidence, clinical features, prognosis. Compared with LACC, radiotherapy combined with surgery is more important for TACC. Two nomograms were established for TACC and LACC respectively to help physicians make more individualized survival predictions and clinical decisions.
Collapse
|
115
|
Zhu Z, Zhang X, Zhang Y, Hu X, Yue J. 18F-AlF-NOTA-FAPI-04 PET/CT can Predict Treatment Response and Survival in Patients with Inoperable Pancreatic Adenocarcinoma. Int J Radiat Oncol Biol Phys 2023; 117:e360. [PMID: 37785240 DOI: 10.1016/j.ijrobp.2023.06.2447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) We investigated whether uptake of 18F-AlF-NOTA-FAPI-04 on positron emission tomography/computed tomography (PET/CT) could predict treatment response and survival in patients with pancreatic adenocarcinoma (PAAD). MATERIALS/METHODS We prospectively evaluated 47 patients with histopathologically confirmed primary PAAD and pretreatment 18F-FAPI PET/CT scans to determine uptake of fibroblast activation protein (FAP) and compare the findings with those from blood tests and immunohistochemically stained tumor specimens. Cox regression and Kaplan-Meier methods were used to assess relationships between disease progression and potential predictors. Receiver operating characteristic (ROC) curve analysis was used to define the optimal cutoff points for distinguishing patients according to good response vs poor response per RECIST v. 1.1. RESULTS The FAPI PET variables maximum and mean standardized uptake values (SUVmax, SUVmean); metabolic tumor volume (MTV); and total lesion FAP expression (TLF) were positively correlated with cancer-associated fibroblast (CAF) markers (FAP, α-smooth muscle actin, vimentin, S100A4, and platelet-derived growth factor receptor α/β, all P<0.05). MTV and Log2TLF were associated with survival in patients with inoperable PAAD (all P<0.05). Analyses controlling for sex, age, cTNM, and performance status showed that MTV and Log2TLF were associated with overall survival (MTV hazard ratio [HR] = 1.016, P = 0.016 and Log2TLF HR = 4.093, P = 0.003). ROC cutoff analysis indicated that elevated MTV and TLF were associated with poorer survival. Greater changes from before to after chemotherapy in SUVmax, MTV, and TLF were associated with good treatment response (all P<0.05). ΔMTV, ΔTLF and ΔSUVmax had larger areas under the curve than ΔCA19-9 for predicting treatment response. Kaplan-Meier analysis showed that the extent of change in MTV and TLF from before to after treatment predicted progression-free survival, with cutoff values (based on medians) of -4.95 for ΔMTV (HR = 8.09, P = 0.013) and -77.83 for ΔTLF (HR = 4.62, P = 0.012). CONCLUSION Higher baseline MTV on 18F-FAPI-04 PET/CT scans was associated with poorer survival in patients with inoperable PAAD. ΔMTV was more sensitive for predicting response than ΔCA19-9. These results are clinically meaningful for identifying patients with PAAD who are at high risk of disease progression.
Collapse
|
116
|
Zhang H, Gao Y, Du M, Pan E, Wang X, Zhang X. CDC73 Impairment of MAPK1 Ubiquitination and Activation of the mTOR Signaling Pathway. Int J Radiat Oncol Biol Phys 2023; 117:e276. [PMID: 37785038 DOI: 10.1016/j.ijrobp.2023.06.1251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) CDC73 has been reported to be upregulated in breast cancer. This study aimed to illuminate the underlying mechanism by which CDC73 mediates breast cancer. MATERIALS/METHODS Here, a breast cancer tissue microarray and three breast cancer cell lines MDA-MB-231, BT-549 as well as MCF-7 were employed. Using RNAi method, we knocked down CDC73 and MAPK1 in breast cancer cells. CDC73 overexpression plasmids (LV-013) were generated through pMD2.G and pSPAX2 vectors. Cell events related to tumor development were analyzed through Celigo cell counting assay, a cell counting kit, wound healing assay, Transwell assay and flow cytometry analysis. The exploration on the underlying mechanism was based on PrimeView human gene expression array. Xenograft tumor models were constructed to visualize the effects of CDC73/MAPK2 on breast cancer progression. RESULTS CDC73 was abundantly expressed in breast cancer tissues and cell lines, and the expression of CDC73 was related to poor prognosis of patients. In breast cancer, CDC73 could promote the proliferation and migration of tumor cells, while disrupting apoptosis. Also, we found that CBL, an E3 ubiquitin ligase, could interact with CDC73 and promote MAPK1 ubiquitination and degradation of this protein. In addition, silencing MAPK1 led to a suppression of breast cancer cell growth in vitro and in vivo, and even abolished the promoting effects of CDC73 overexpression. We also found that mTOR pathway played a role in CDC73-mediated breast cancer. mTOR pathway inhibitor reversed cell phenotypes induced by CDC73 overexpression. CONCLUSION CDC73 promoted MAPK1 ubiquitination and degradation so that affected MAPK1 level and subsequently led to breast cancer progression, providing a novel therapeutic strategy to combat cancer.
Collapse
|
117
|
Luo R, Su Z, Kang K, Yu M, Zhou X, Wu Y, Yao Z, Xiu W, Zhang X, Yu Y, Zhou L, Na F, Li Y, Xu Y, Liu Y, Zou B, Peng F, Wang J, Zhong R, Gong Y, Huang M, Bai S, Xue J, Yan D, Lu Y. Hybrid Immuno-RT for Bulky Tumors: Standard Fractionation with Partial Tumor SBRT. Int J Radiat Oncol Biol Phys 2023; 117:S166. [PMID: 37784416 DOI: 10.1016/j.ijrobp.2023.06.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Bulky tumors remain challenging to be treated. Stereotactic body radiation therapy (SBRT) is effective against radioresistant tumor cells and can induce immunogenic cell death (ICD) that leads to T-cell-mediated antitumor effects. Low-dose radiation (LDRT) can inflame the tumor microenvironment (TME) by recruiting T cells. We designed a novel radiotherapy technique (RT, ERT) whose dose distribution map resembles the "eclipse" by concurrently delivering LDRT to the whole tumor, meanwhile SBRT to only a part of the same tumor. This study examined the safety and efficacy of ERT to bulky lesions with PD-1 inhibitors in mice and patients. MATERIALS/METHODS In mice with CT26 colon or LLC1 lung bulky tumors (400 - 500 cm3), the whole tumor was irradiated by LDRT (2 Gy x 3), meanwhile the tumor center was irradiated by SBRT (10 Gy x 3); αPD-1 was given weekly. The dependence of therapeutic effects on CD8+ T cells was determined using depleting antibodies. Frequencies of CD8+ T cells and M1 macrophages (Mφ) were determined by flow cytometry. Multiplex Immunohistochemistry (mIHC) was applied to analyze the number and the location of CD8+ T cells and their subpopulations, as well as the phospho-eIF2α level (the ICD marker) of tumor cells in TME. Patients with advanced lung or liver bulky tumors who failed standard treatment or with oncologic emergencies were treated. Kaplan-Meier method was applied to estimate patients' progression-free survival (PFS) and overall survival (OS). RESULTS ERT/αPD-1 is superior to SBRT/αPD-1 or LDRT/αPD-1 in controlling bulky tumors in both mouse models in a CD8+ T-cell dependent manner. In the CT26 model, ERT/αPD-1 resulted in complete tumor regression in 3/11 mice and induced more CD8+ T cells and M1 Mφ in TME compared to other groups. mIHC analysis showed that ERT/αPD-1 induced higher bulk, stem-like (TCF1+ TIM3- PD-1+), and more differentiated (TCF1- TIM3+ PD-1+) CD8+ T cells infiltration into the tumor center and periphery compared to other groups. Compared to untreated or LDRT-treated tumor centers, tumor centers irradiated with ERT or SBRT showed elevated phospho-eIF2α accompanied by higher dendritic cell infiltration. In total, 39 advanced cancer patients were treated with ERT/αPD-1 or plus chemotherapy. Radiation-induced pneumonitis occurred in 1 of 26 patients receiving thoracic ERT. There were two cases of grade III toxicity associated with PD-1 inhibitors. No toxicity above grade III was observed. The objective response rate was 38.5%. The median PFS was 5.6 months and median OS was not reached at a median follow-up of 11.7 months. CONCLUSION ERT/αPD-1 showed superior efficacy in controlling bulky tumor in two mouse models. The hybrid immuno-RT (ERT) combing PD-1 inhibitors was safe and effective in patients with bulky tumors. Further clinical trials in combination with bioimaging to identify the optimal SBRT target region for the bulky tumor are warranted.
Collapse
|
118
|
Zhang J, Zhang X, Zhang Q, Cheng XD, Wang LR, Jia LJ, Zhou S, Li BH, Yu NW. [Predictive value of plasma exosomal miR-124-3p for the risk of chronic cerebral hypoperfusion]. ZHONGHUA NEI KE ZA ZHI 2023; 62:1194-1199. [PMID: 37766438 DOI: 10.3760/cma.j.cn112138-20230510-00247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/29/2023]
Abstract
Objective: To investigate the predictive value of plasma exosomal microRNA (miR)-124-3p in the risk of chronic cerebral hypoperfusion (CCH). Methods: A case-control study. Thirty patients who were diagnosed with CCH (CCH group) based on cranial artery spin labeling (ASL) in the neurology outpatient clinic of Sichuan Provincial People's Hospital from March 2022 to June 2022 and 30 healthy volunteers (control group) were included. Age, gender, smoking history, alcohol consumption history, diabetes history, hypertension, hyperlipidemia history, uric acid, fasting blood glucose, homocysteine and plasma exosomal miR-124-3p expression level were compared between the two groups. Comparisons of categorical variables were analyzed by either χ2 test or Fisher's exact test. If the data of continuous variables followed a normal distribution, they were expressed as mean±standard deviation (SD) and compared by t-test for two independent samples; otherwise, the data were expressed as M(Q1, Q3), and analyzed by Mann-Whitney U test for comparison between two groups. The correlation between cerebral blood flow and exosomal miR-124-3p levels was analyzed by Pearson's correlation. Binary multifactorial logistic regression analysis was used to determine the risk factors associated with CCH, and corresponding odds ratios (OR) and 95% confidence intervals (CI) were calculated. P<0.05 was considered significant. Results: There was no significant difference in age (64±8 vs. 60±8 years old), gender (33.3% vs. 30.0%), history of smoking (20.0% vs. 3.3%), alcohol consumption (20.0% vs. 6.7%), diabetes mellitus (13.3% vs. 13.3%), hypertension (53.3% vs. 30.0%), history of hyperlipidemia (46.7% vs. 36.7%), uric acid (288±60 vs.319±67 μmol/L), and fasting glucose [4.99(4.63, 5.91) vs. 5.28(5.09, 6.05) mmol/L] and homocysteine [11.35(10.18, 13.08) vs.11.00(9.78, 13.03) μmol/L] between the CCH and control groups (P>0.05). Plasma exosomal miR-124-3p expression was significantly higher in the CCH group than in the control group [13.08 (8.59, 21.55) vs. 2.85 (1.44, 5.10), respectively; U=169.50, P<0.001]. Pearson's correlation test showed that the level of exosomal miR-124-3p was negatively correlated with cerebral blood flow in the hypoperfused region in patients with CCH (r=-0.932, P<0.001). Multi-factor logistic regression analysis showed that plasma exosomal miR-124-3p was independently associated with the risk of CCH (OR=1.169,95%CI 1.063-1.286,P=0.001). Conclusions: The expression of plasma exosomal miR-124-3p is negatively correlated with cerebral blood flow in areas of low perfusion and is an independent risk factor for CCH. Plasma exosomal miR-124-3p may thus serve as a valid biomarker for CCH risk prediction.
Collapse
|
119
|
Zhu YN, Zhang X, Lin Y, Lominska C, Gao H. An Effective Dose Rate Optimization Algorithm for Efficient Conventional-Dose-Rate Proton Therapy and Ultra-High-Dose-Rate FLASH Proton Therapy. Int J Radiat Oncol Biol Phys 2023; 117:S37-S38. [PMID: 37784486 DOI: 10.1016/j.ijrobp.2023.06.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The treatment delivery with high dose rate is desirable for efficient conventional-dose-rate proton therapy (IMPT and proton ARC) and essential for achieving biological sparing effect to normal tissues for ultra-high-dose-rate FLASH proton therapy. The minimum-monitor-unit (MMU) problem is mathematically fundamental to these high-dose-rate proton therapy problems, since the dose rate is proportionally associated with the MMU threshold. However, the MMU problem is nonconvex and larger MMU threshold that leads to higher dose rate makes the nonconvex problem more difficult to solve, for which the conventional optimization methods (e.g., alternating direction method of multipliers (ADMM) or proximal gradient descent (PGD) usually cannot satisfactorily solve. This work will develop an effective dose rate optimization algorithm for the MMU problem. MATERIALS/METHODS The new method is based on orthogonal matching pursuit (OMP), and consists of two essential components. First, the iterative convex relaxation method is used to determine the active sets for dose-volume planning constraints and decouple the MMU constraint from the rest. Second, a modified OMP optimization algorithm is used to handle the MMU constraint: the non-zero spots are greedily selected via OMP to form the solution set to be optimized, and then a convex constrained subproblem is formed and can be conveniently solved to optimize the spot weights restricted to this solution set via OMP. During this iterative process, the new non-zero spots localized via OMP will be adaptively added to or removed from the optimization objective. RESULTS The new method via OMP is validated in comparison with conventional methods (ADMM and PGD) and a recently proposed new method (called stochastic coordinate descent (SCD) method) for high-dose-rate IMPT, ARC, and FLASH problems of large MMU thresholds, and the results suggest that OMP substantially improved the plan quality from PGD, ADMM and SCD in terms of both target dose conformality (e.g., quantified by max target dose and conformity index) and normal tissue sparing (e.g., mean and max dose). A brain case is provided in the table: compared to PGD/ADMM/SCD, OMP improved the conformity index from 0.42/0.52/0.33 to 0.65 for IMPT and 0.46/0.60/0.61 to 0.83 for ARC. CONCLUSION A new dose rate optimization algorithm via OMP is developed to solve the MMU problem with large MMU thresholds, and validated using examples of IMPT, ARC, and FLASH with substantially improved plan quality from conventional methods (ADMM and PGD) and a recently proposed new method SCD.
Collapse
|
120
|
Zhou Z, Tong C, Tian L, Zhang X, Li Y, Xiao Y, Yan L. Retrospective study of preservation and transection of the round ligament of uterus during laparoscopic transabdominal preperitoneal inguinal hernia repair in adult women. Hernia 2023; 27:1195-1202. [PMID: 36949269 PMCID: PMC10533639 DOI: 10.1007/s10029-023-02765-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 03/01/2023] [Indexed: 03/24/2023]
Abstract
PURPOSE The processing of the round ligament of uterus in laparoscopic transabdominal preperitoneal (TAPP) repair of inguinal hernia in women has contended. This study aimed to explore whether there is any difference in the surgical outcome and postoperative complications between the two processing modalities, preservation, and transection of the round ligament of uterus, in adult female inguinal hernia patients undergoing TAPP. METHODS Retrospective analysis of 84 female patients (117 sides) who underwent TAPP in XXX Hospital from July 2013 to August 2022. Patient characteristics and technical details of the surgical procedure were collected and divided into two groups according to whether the round ligament of uterus was severed intraoperatively or not. There were 52 cases (77 sides) in the group with preservation of the round ligament of uterus and 32 cases (40 sides) in the group with transection of the round ligament of uterus, comparing the general condition, surgical condition, and the occurrence of postoperative related complications between the 2 groups. RESULTS The operative time for unilateral primary inguinal hernia was (129.2 ± 35.1) and (89.5 ± 42.6) minutes in the preservation and transection groups, respectively. There were no statistical differences between the two groups in terms of age, length of hospital stay, ASA, BMI, history of lower abdominal surgery, type and side of hernia, intraoperative bleeding, and time to surgery for primary bilateral hernia (P > 0.05). In addition, there was likewise no statistical difference in the occurrence of postoperative Clavien-Dindo classification, VAS, seroma, mesh infection, labia majora edema, chronic pain or abnormal sensation in the inguinal region, and hernia recurrence in the two groups as well (P > 0.05). CONCLUSION There is no evidence that the transection of the round ligament of the uterus during TAPP has an impact on postoperative complications in patients. However, given the important role of the uterine round ligament in the surgical management of patients with uterine prolapse and the high incidence of uterine prolapse in older women, hernia surgeons should also be aware of the need to protect the round ligament of uterus in older women.
Collapse
|
121
|
Xu XS, Ding H, Zhang X, Liao Y, Li H, Liu QY, Liu JZ, Zhang L, Huang J, Gong YP, Ma HB, Xiang B, Dai Y, Hou L, Shuai X, Niu T, Wu Y. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2023; 44:742-748. [PMID: 38049318 PMCID: PMC10630571 DOI: 10.3760/cma.j.issn.0253-2727.2023.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 05/07/2023] [Indexed: 12/06/2023]
Abstract
Objective: To investigate the clinical characteristics, cytogenetics, molecular biology, treatment, and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) secondary to malignancies. Methods: The clinical data of 86 patients with t-MDS/AML in West China Hospital of Sichuan University between January 2010 and April 2023 were retrospectively analyzed. The clinical characteristics, primary tumor types, and tumor-related therapies were analyzed. Results: The study enrolled a total of 86 patients with t-MDS/AML, including 67 patients with t-AML, including 1 patient with M(0), 6 with M(1), 27 with M(2), 9 with M(3), 12 with M(4), 10 with M(5), 1 with M(6), and 1 with M(7). Sixty-two patients could be genetically stratified, with a median overall survival (OS) of 36 (95% CI 22-52) months for 20 (29.9%) patients in the low-risk group and 6 (95% CI 3-9) months for 10 (14.9%) in the intermediate-risk group. The median OS time was 8 (95% CI 1-15) months in 32 (47.8%) patients in the high-risk group. For patients with non-acute promyelocytic leukemia (APL) and AML, the median OS of the low-risk group was 27 (95% CI 18-36) months, which was significantly longer than that of the non-low-risk group (χ(2)=5.534, P=0.019). All 9 APL cases were treated according to the initial treatment, and the median OS was not reached, and the 1-, 2-, and 3-year OS rates were 100.0%, (75.0±6.2) %, and (75.0±6.2) % respectively. Of the 58 patients with non-APL t-AML (89.7%), 52 received chemotherapy, and 16 achieved complete remission (30.8%) after the first induction chemotherapy. The 1-, 2-, and 3-year OS rates of the non-APL t-AML group were (42.0 ± 6.6) %, (22.9±5.7) %, and (13.4±4.7) %, respectively. The median OS of patients who achieved remission was 24 (95% CI 18-30) months, and the median OS of those who did not achieve remission was 6 (95% CI 3-9) months (χ(2)=10.170, P=0.001). Bone marrow CR was achieved in 7 (53.8%) of 13 patients treated with vineclar-containing chemotherapy, with a median OS of 12 (95% CI 9-15) months, which was not significantly different from that of vineclar-containing chemotherapy (χ(2)=0.600, P=0.437). In 19 patients with t-MDS, the 1-, 2-, and 3-year OS rates were (46.8±11.6) %, (17.5±9.1) %, and (11.7±9.1) % with a median OS of 12 (95% CI 7-17) months, which was not significantly different from that in t-AML (χ(2)=0.232, P=0.630) . Conclusions: Breast cancer, bowel cancer, and other primary tumors are common in patients with t-MDS/AML, which have a higher risk of adverse genetics. Patients with APL had a high induction remission rate and a good long-term prognosis, whereas patients without APL had a low remission rate and a poor long-term prognosis.
Collapse
|
122
|
Yang Y, Li H, Liu P, Zhang X, Wang Q, Li H, Cui N, Tian X, Long Y, He H, Su L. Emergence of hybrid airway neutrophils with increased mitochondrial metabolism and low inflammatory response in neutrophilic asthma: evidence supporting targeting inhibition of neutrophil glycolysis in this asthma sub-group. QJM 2023; 116:702-704. [PMID: 37184923 DOI: 10.1093/qjmed/hcad090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 05/07/2023] [Indexed: 05/16/2023] Open
|
123
|
Li Y, Lin HM, Zhang XX, Ou CX, Xie JX, Zhang QL. [A clinical observational study on the preliminary effect of dupilumab in the treatment of severe asthma]. ZHONGHUA JIE HE HE HU XI ZA ZHI = ZHONGHUA JIEHE HE HUXI ZAZHI = CHINESE JOURNAL OF TUBERCULOSIS AND RESPIRATORY DISEASES 2023; 46:909-915. [PMID: 37670644 DOI: 10.3760/cma.j.cn112147-20230713-00374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
Abstract
Objective: To investigate the effect and safety of dupilumab in the treatment of patients with severe asthma in a preliminary clinical observational study. Methods: This study retrospectively analyzed the clinical data of 20 patients with severe asthma who received dupilumab for 4-12 months between 2019 and 2022 at the First Hospital of Guangzhou Medical University, comparing pre-and post-treatment laboratory data, oral glucocorticoid dose (OCS), asthma control test (ACT) and adverse effects. The median age of the 20 patients was 48.5 (41.0-52.8) years, including 14 males and 6 females. The clinical data of 10 patients treated with other biologic agents were further analyzed to determine the reasons for switching to biologic drug treatment and the efficacy of dupilumab in these patients. Paired t-tests or Wilcoxon signed-rank tests were used for comparisons. Mann-Whitney analysis was used for inter-group comparison, and chi-square test or Fisher test was used for inter-group comparisons of count data. Results: A total of 20 patients were included in this study. All 20 severe asthma phenotypes were type 2 (T2)-high and completed at least the first 4 months of treatment, including 17 patients who completed 12 months of treatment. Among patients who completed 4 months of treatment, the asthma exacerbation score decreased from 1.0(0.3-1.0) episodes/4 months to 0.0(0.0-1.0) episodes/4 months, P<0.001, and FEV1/FVC increased from 58.4% (50.5%-69.0%) to 66.9% (59.6%-77.7%), P<0.01. The number of patients requiring OCS maintenance therapy decreased from 15 (75%) to 9 (45%), P<0.05. Among patients who completed 12 months of treatment, the asthma exacerbation score decreased from 1.0(0.5-1.0) episodes/4 months to 0.0 (0.0-0.0) episodes/4 months, P<0.01, and FEV1/FVC increased from 57.9% (49.6%-67.8%) to 72.7% (64.6%-78.7%), P<0.01. The number of patients requiring OCS maintenance therapy decreased from 13 (76%) to 6 (35%), P<0.01. In 10 patients with a history of previous biologic therapy, the most common reasons for switching to a biologic were a poor response to previous monoclonal antibodies (40%) and loss of control of asthma symptom control after discontinuation of monoclonal antibodies (30%). The remaining reasons were patients' uncontrolled symptoms of chronic rhinosinusitis (20%) and irregular or underdosed use of previous biologics (10%). After 4 months of switching to dupilumab, 10 patients experienced varying degrees of improvement in asthma control. Conclusions: The application of dupilumab for the treatment of T2-high severe asthma showed good efficacy and few adverse effects. Biologically targeted therapy is an important treatment approach to achieving better control of severe asthma.
Collapse
|
124
|
Shen L, Xing BL, Gu X, Zhang YY, Zhang X. [Primary salivary gland-type duct carcinoma of lung: report of a case]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2023; 52:958-960. [PMID: 37670632 DOI: 10.3760/cma.j.cn112151-20230106-00009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
|
125
|
Acharya S, Adamová D, Adler A, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akindinov A, Al-Turany M, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altsybeev I, Anaam MN, Andrei C, Andronic A, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arata C, Arcelli S, Aresti M, Arnaldi R, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Azmi MD, Badalà A, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Banerjee D, Banoo Z, Barbera R, Barile F, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Barreto L, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Becht P, Behera D, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat MA, Bhattacharjee B, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Biernat J, Bigot AP, Bilandzic A, Biro G, Biswas S, Bize N, Blair JT, Blau D, Blidaru MB, Bluhme N, Blume C, Boca G, Bock F, Bodova T, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Borquez Carcamo AG, Bossi H, Botta E, Bouziani YEM, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt JB, Bysiak SA, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camerini P, Canedo FDM, Carabas M, Carballo AA, Carnesecchi F, Caron R, Castillo Castellanos J, Catalano F, Ceballos Sanchez C, Chakaberia I, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chavez TG, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Chizzali ES, Cho J, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Ciacco M, Cicalo C, Cifarelli L, Cindolo F, Ciupek MR, Clai G, Colamaria F, Colburn JS, Colella D, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Crkovská J, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch MC, Danu A, Das P, Das P, Das S, Dash AR, Dash S, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Debski RJ, Deja KR, Del Grande R, Dello Stritto L, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dubey AK, Dubinski JM, Dubla A, Dudi S, Dupieux P, Durkac M, Dzalaiova N, Eder TM, Ehlers RJ, Eikeland VN, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fan W, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrer MB, Ferrero A, Ferrero C, Ferretti A, Feuillard VJG, Filova V, Finogeev D, Fionda FM, Flor F, Flores AN, Foertsch S, Fokin I, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Fusayasu T, Gaardhøje JJ, Gagliardi M, Gago AM, Galvan CD, Gangadharan DR, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gautam A, Gay Ducati MB, Germain M, Ghosh C, Ghosh SK, Giacalone M, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Glimos E, Goh DJQ, Gonzalez V, González-Trueba LH, Gorgon M, Gotovac S, Grabski V, Graczykowski LK, Grecka E, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Grosa F, Grosse-Oetringhaus JF, Grosso R, Grund D, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gundem T, Gunji T, Guo W, Gupta A, Gupta R, Guzman SP, Gyulai L, Habib MK, Hadjidakis C, Hamagaki H, Hamdi A, Hamid M, Han Y, Hannigan R, Haque MR, Harris JW, Harton A, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Heckel ST, Hellbär E, Helstrup H, Hemmer M, Herman T, Herrera Corral G, Herrmann F, Herrmann S, Hetland KF, Heybeck B, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong GH, Horst M, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Huhta LM, Hulse CV, Humanic TJ, Hushnud H, Hutson A, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Isidori T, Islam MS, Ivanov M, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jaffe L, Jahnke C, Jakubowska MJ, Janik MA, Janson T, Jercic M, Jimenez AAP, Jonas F, Jones PG, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kabus MJ, Kaewjai J, Kalinak P, Kalteyer AS, Kalweit A, Kaplin V, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kashyap V, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim JS, Kim J, Kim J, Kim M, Kim S, Kim T, Kimura K, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Kollegger T, Kondratyev A, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Kotliarov A, Kovalenko V, Kowalski M, Kozhuharov V, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Krupova DM, Kryshen E, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Legras G, Lehrbach J, Lemmon RC, León Monzón I, Lesch MM, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu DH, Liu J, Lofnes IM, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Lu P, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmoud T, Maire A, Makariev MV, Malaev M, Malfattore G, Malik NM, Malik QW, Malik SK, Malinina L, Mal'Kevich D, Mallick D, Mallick N, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Margagliotti GV, Margotti A, Marín A, Markert C, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mdhluli JE, Mechler AF, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohanty AP, Mohanty B, Mohisin Khan M, Molander MA, Moravcova Z, Mordasini C, Moreira De Godoy DA, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nambrath AI, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Naydenov MN, Neagu A, Negru A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nielsen EG, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Okorokov VA, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Panebianco S, Park H, Park J, Parkkila JE, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pennisi M, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrov V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Pradhan KK, Prasad SK, Prasad S, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Pucillo S, Pugelova Z, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Rancien TA, Rasa M, Räsänen SS, Rath R, Rauch MP, Ravasenga I, Read KF, Reckziegel C, Redelbach AR, Redlich K, Rehman A, Reidt F, Reme-Ness HA, Rescakova Z, Reygers K, Riabov A, Riabov V, Ricci R, Richert T, Richter M, Riedel AA, Riegler W, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rojas Torres S, Rokita PS, Romanenko G, Ronchetti F, Rosano A, Rosas ED, Rossi A, Roy A, Roy P, Roy S, Rubini N, Rueda OV, Ruggiano D, Rui R, Rumyantsev B, Russek PG, Russo R, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadhu S, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sajdakova K, Sakai S, Salvan MP, Sambyal S, Sanna I, Saramela TB, Sarkar D, Sarkar N, Sarma P, Sarritzu V, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schröter A, Schukraft J, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabetai A, Shahoyan R, Shangaraev A, Sharma A, Sharma D, Sharma H, Sharma M, Sharma N, Sharma S, Sharma S, Sharma U, Shatat A, Sheibani O, Shigaki K, Shimomura M, Shin J, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simantathammakul T, Simeonov R, Singh B, Singh B, Singh R, Singh R, Singh R, Singh S, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Solheim EH, Song J, Songmoolnak A, Soramel F, Spijkers R, Sputowska I, Staa J, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Stratmann P, Strazzi S, Stylianidis CP, Suaide AAP, Suire C, Sukhanov M, Suljic M, Sultanov R, Sumberia V, Sumowidagdo S, Swain S, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tapia Takaki JD, Tapus N, Tarasovicova LA, Tarzila MG, Tassielli GF, Tauro A, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tikhonov A, Timmins AR, Tkacik M, Tkacik T, Toia A, Tokumoto R, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres Ramos AG, Trifiró A, Triolo AS, Tripathy S, Tripathy T, Trogolo S, Trubnikov V, Trzaska WH, Trzcinski TP, Turrisi R, Tveter TS, Ullaland K, Ulukutlu B, Uras A, Urioni M, Usai GL, Vala M, Valle N, van Doremalen LVR, van Leeuwen M, van Veen CA, van Weelden RJG, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Wegrzynek A, Weiglhofer FT, Wenzel SC, Wessels JP, Weyhmiller SL, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Wright JR, Wu W, Wu Y, Xu R, Yadav A, Yadav AK, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yoo IK, Yoon JH, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanoli HJC, Zanone F, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang L, Zhang S, Zhang X, Zhang Y, Zhang Z, Zhao M, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zinovjev G, Zugravel SC, Zurlo N. Measurement of the Lifetime and Λ Separation Energy of _{Λ}^{3}H. PHYSICAL REVIEW LETTERS 2023; 131:102302. [PMID: 37739380 DOI: 10.1103/physrevlett.131.102302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 01/18/2023] [Accepted: 07/21/2023] [Indexed: 09/24/2023]
Abstract
The most precise measurements to date of the _{Λ}^{3}H lifetime τ and Λ separation energy B_{Λ} are obtained using the data sample of Pb-Pb collisions at sqrt[s_{NN}]=5.02 TeV collected by ALICE at the LHC. The _{Λ}^{3}H is reconstructed via its charged two-body mesonic decay channel (_{Λ}^{3}H→^{3}He+π^{-} and the charge-conjugate process). The measured values τ=[253±11(stat)±6(syst)] ps and B_{Λ}=[102±63(stat)±67(syst)] keV are compatible with predictions from effective field theories and confirm that the _{Λ}^{3}H structure is consistent with a weakly bound system.
Collapse
|
126
|
Zhang X, Tham S, Ek ET, McCombe D, Ackland DC. Scaphoid, lunate and capitate kinematics in the normal and ligament deficient wrist: A bi-plane X-ray fluoroscopy study. J Biomech 2023; 158:111685. [PMID: 37573806 DOI: 10.1016/j.jbiomech.2023.111685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 05/26/2023] [Accepted: 06/07/2023] [Indexed: 08/15/2023]
Abstract
The ligamentous structures of the wrist stabilise and constrain the interactions of the carpal bones during active wrist motion; however, the three-dimensional translations and rotations of the scaphoid, lunate and capitate in the normal and ligament deficient wrist during planar and oblique wrist motions remain poorly understood. This study employed a computer-controlled simulator to replicate physiological wrist motion by dynamic muscle force application, while carpal kinematics were simultaneously measured using bi-plane x-ray fluoroscopy. The aim was to quantify carpal kinematics in the native wrist and after sequential sectioning of the scapholunate interosseous ligament (SLIL) and secondary scapholunate ligament structures. Seven fresh-frozen cadaveric wrist specimens were harvested, and cycles of flexion-extension, radial-ulnar deviation and dart-thrower's motion were simulated. The results showed significant rotational and translational changes to these carpal bones in all stages of disruptions to the supporting ligaments (p < 0.05). Specifically, following the disruption of the dorsal SLIL (Stage II), the scaphoid became significantly more flexed, ulnarly deviated, and pronated relative to the radius, whereas the lunate became more extended, supinated and volarly translated (p < 0.05). Sectioning of the dorsal intercarpal (DIC), dorsal radiocarpal (DRC), and scaphotrapeziotrapezoid (STT) ligaments (Stage IV) caused the scaphoid to collapse further into flexion, ulnar deviation, and pronation. These findings highlight the importance of all the ligamentous attachments that relate to the stability of the scapholunate joint, but more importantly, the dorsal SLIL in maintaining scapholunate stability, and the preservation of the attachments of the DIC and DRC ligaments during dorsal surgical approaches. The findings will be useful in diagnosing wrist pathology and in surgical planning.
Collapse
|
127
|
Wei R, Wang Z, Zhang X, Wang X, Xu Y, Li Q. Burden and trends of iodine deficiency in Asia from 1990 to 2019. Public Health 2023; 222:75-84. [PMID: 37531713 DOI: 10.1016/j.puhe.2023.06.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 06/19/2023] [Accepted: 06/26/2023] [Indexed: 08/04/2023]
Abstract
OBJECTIVES Understanding iodine deficiency (ID) burdens and trends in Asia can help guide effective intervention strategies. This study aims to report the incidence, prevalence, and disability-adjusted life years (DALYs) of ID in 48 Asian countries during the period 1990-2019. STUDY DESIGN Data on ID were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 and estimated by age, sex, geographical region, and sociodemographic index (SDI). METHODS The estimated annual percentage change (EAPC) was calculated to evaluate the changing trend of age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALYs rate (ASDR) related to ID during the period 1990-2019. RESULTS In Asia, there were 126,983,965.8 cases with 5,466,213.1 new incidence and 1,765,995.5 DALYs of ID in 2019. Between 1999 and 2019, the EAPC in ASIR, ASPR and ASDR were -0.6 (95% confidence interval [CI], -0.8 to -0.4), -0.9 (95% CI, -1.2 to -0.7), and -1.6 (95% CI, -1.8 to -1.5), respectively. Malaysia charted the largest decrease in ASIR, ASPR, and ASDR (82.4%, 85.3%, and 80.9% separately), whereas the Philippines and Pakistan were the only two countries that witnessed an increase in ASIR and ASPR. ID burdens were more pronounced in women, countries located to the south of the Himalayas, and low-middle SDI regions. CONCLUSIONS The incidence, prevalence, and DALYs of ID in Asia substantially decreased from 1990 to 2019. Women and low-middle SDI countries have relatively high ID burdens. Governments need to pay constant attention to the implementation and monitoring of universal salt iodization.
Collapse
|
128
|
Khan I, Kaempf A, Raghuwanshi S, Chesnokov M, Zhang X, Wang Z, Domling A, Tyner JW, Camacho C, Gartel AL. Favorable outcomes of NPM1 mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance. Blood Cancer J 2023; 13:128. [PMID: 37607920 PMCID: PMC10444844 DOI: 10.1038/s41408-023-00898-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Revised: 07/21/2023] [Accepted: 08/01/2023] [Indexed: 08/24/2023] Open
|
129
|
Chang CD, Dong C, Zhao SX, Yuan XW, Zhang XX, Zhao DD, Dou Y, Nan YM. [Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B]. ZHONGHUA GAN ZANG BING ZA ZHI = ZHONGHUA GANZANGBING ZAZHI = CHINESE JOURNAL OF HEPATOLOGY 2023; 31:855-861. [PMID: 37723068 DOI: 10.3760/cma.j.cn501113-20230322-00124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
Objective: To clarify the clinical efficacy of first-line oral antiviral drugs tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), and entecavir (ETV) in the treatment of chronic hepatitis B (CHB) and their safety profiles with lipid, bone, and kidney metabolism. Methods: 458 CHB cases diagnosed and treated at the Department of Hepatology of Integrated Traditional Chinese and Western Medicine of the Third Hospital of Hebei Medical University from February 2010 to November 2022 were selected. TAF (175 cases), TDF (124 cases), and ETV (159 cases) were used as therapies. At 24 and 48 weeks, the virology, biochemical response, changes in liver stiffness measurement (LSM), and bone, kidney, and blood lipid metabolism safety profiles were compared and analyzed. Results: After 24 and 48 weeks of TAF, TDF, and ETV therapy, HBV DNA load decreased by 3.28, 2.69, and 3.14 log10 IU/ml and 3.28, 2.83, and 3.65 log10 IU/ml, respectively, compared with the baseline, and the differences between the three groups were statistically significant, P < 0.001. The complete virological response rates were 73.95%, 66.09%, 67.19%, and 82.22%, 72.48%, and 70.49%, respectively. The incidence rates of low-level viremia were 16.67%, 21.70%, and 23.08%, while poor response rates were 1.11%, 3.67%, and 4.10%. ALT normalization rates were 64.00%, 63.89%, 67.96%, and 85.33%, 80.56%, 78.64%, respectively, and there was no statistically significant difference among the groups. LSM was significantly improved in patients treated with TAF for 48 weeks, P = 0.022. Serum phosphorus level gradually decreased with the prolongation of TDF treatment. The TAF treatment group had a good safety profile for kidney, bone, and phosphorus metabolism, with no dyslipidemia or related occurrences of risk. Conclusion: There are some differences in the therapeutic effects of first-line anti-HBV drugs. TAF has the lowest incidence of low-level viremia after 48 weeks of treatment and has a good safety profile in kidney, bone, and blood lipid metabolism.
Collapse
|
130
|
Zhang X, Ma LN, Wang MT, Liu HJ, Tian YL, Luo X, Ding XC. [Short-term prognostic predictive value of the neutrophil/lymphocyte ratio combined with prognostic nutritional index in hepatitis B virus-related acute-on-chronic liver failure]. ZHONGHUA GAN ZANG BING ZA ZHI = ZHONGHUA GANZANGBING ZAZHI = CHINESE JOURNAL OF HEPATOLOGY 2023; 31:847-854. [PMID: 37723067 DOI: 10.3760/cma.j.cn501113-20220402-00159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
Objective: To explore the prognostic predictive value of neutrophil/lymphocyte ratio (NLR) combined with prognostic nutritional index (PNI) in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Methods: Clinical data from 149 HBV-ACLF patients admitted to the infectious diseases Department of the General Hospital of Ningxia Medical University were retrospectively analyzed. Demographic data of the enrolled patients and the initial clinical-related data after admission were collected. Patients were divided into survival (93 cases) and death groups (56 cases) according to their prognostic condition 90 days after discharge. Demographic and clinical differences were compared between the two groups data. Receiver operating characteristic (ROC) curves were plotted to determine the optimal cutoff values for NLR and PNI in predicting the 90-day mortality rate of HBV-ACLF patients. The COX regression model was used to conduct univariate and multivariate analyses to investigate the correlation between NLR and PNI and the prognosis of HBV-ACLF patients. Kaplan-Meier survival analysis was used to explore the effects of NLR and PNI on the survival of HBV-ACLF patients. Results: The death group NLR was higher than that of the survival group, while the PNI was lower than that of the survival group, with a statistically significant difference. The area under the receiver operating characteristic curve (0.842, 95% CI: 0.779-0.906) showed patients with adverse prognosis assessed by NLR combined with PNI had a superior prognosis than that of the Model for End-Stage Liver Disease (MELD) and its combined serum sodium (MELD-Na) and Child-Turcotte-Pugh (CTP) scores. COX regression analysis showed that NLR≥3.03 and MELD score were independent risk factors affecting the prognosis of HBV-ACLF patients. PNI > 36.13 was a protective factor for evaluating the prognosis of HBV-ACLF patients. Conclusion: NLR combined with PNI can enhance the prognostic predictive value of HBV-ACLF.
Collapse
|
131
|
Aad G, Abbott B, Abbott DC, Abeling K, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Abusleme Hoffman AC, Acharya BS, Achkar B, Adam L, Adam Bourdarios C, Adamczyk L, Adamek L, Addepalli SV, Adelman J, Adiguzel A, Adorni S, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra JA, Ahmad A, Ahmadov F, Ahmed WS, Ahuja S, Ai X, Aielli G, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Alconada Verzini MJ, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi A, Alfonsi F, Alhroob M, Ali B, Ali S, Aliev M, Alimonti G, Allaire C, Allbrooke BMM, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alunno Camelia E, Alvarez Estevez M, Alviggi MG, Amaral Coutinho Y, Ambler A, Amelung C, Ames CG, Amidei D, Amor Dos Santos SP, Amoroso S, Amos KR, Amrouche CS, Ananiev V, Anastopoulos C, Andari N, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Antrim DJA, Anulli F, Aoki M, Aparisi Pozo JA, Aparo MA, Aperio Bella L, Appelt C, Aranzabal N, Araujo Ferraz V, Arcangeletti C, Arce ATH, Arena E, Arguin JF, Argyropoulos S, Arling JH, Armbruster AJ, Arnaez O, Arnold H, Arrubarrena Tame ZP, Artoni G, Asada H, Asai K, Asai S, Asbah NA, Asimakopoulou EM, Assahsah J, Assamagan K, Astalos R, Atkin RJ, Atkinson M, Atlay NB, Atmani H, Atmasiddha PA, Augsten K, Auricchio S, Auriol AD, Austrup VA, Avner G, Avolio G, Axiotis K, Ayoub MK, Azuelos G, Babal D, Bachacou H, Bachas K, Bachiu A, Backman F, Badea A, Bagnaia P, Bahmani M, Bailey AJ, Bailey VR, Baines JT, Bakalis C, Baker OK, Bakker PJ, Bakos E, Bakshi Gupta D, Balaji S, Balasubramanian R, Baldin EM, Balek P, Ballabene E, Balli F, Baltes LM, Balunas WK, Balz J, Banas E, Bandieramonte M, Bandyopadhyay A, Bansal S, Barak L, Barberio EL, Barberis D, Barbero M, Barbour G, Barends KN, Barillari T, Barisits MS, Barkeloo J, Barklow T, Barnett RM, Baron P, Baron Moreno DA, Baroncelli A, Barone G, Barr AJ, Barranco Navarro L, Barreiro F, Barreiro Guimarães da Costa J, Barron U, Barros Teixeira MG, Barsov S, Bartels F, Bartoldus R, Barton AE, Bartos P, Basalaev A, Basan A, Baselga M, Bashta I, Bassalat A, Basso MJ, Basson CR, Bates RL, Batlamous S, Batley JR, Batool B, Battaglia M, Bauce M, Bauer P, Bayirli A, Beacham JB, Beau T, Beauchemin PH, Becherer F, Bechtle P, Beck HP, Becker K, Becot C, Beddall AJ, Bednyakov VA, Bee CP, Beemster LJ, Beermann TA, Begalli M, Begel M, Behera A, Behr JK, Beirao Da Cruz E Silva C, Beirer JF, Beisiegel F, Belfkir M, Bella G, Bellagamba L, Bellerive A, Bellos P, Beloborodov K, Belotskiy K, Belyaev NL, Benchekroun D, Bendebba F, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Bentvelsen S, Beresford L, Beretta M, Berge D, Bergeaas Kuutmann E, Berger N, Bergmann B, Beringer J, Berlendis S, Bernardi G, Bernius C, Bernlochner FU, Berry T, Berta P, Berthold A, Bertram IA, Bessidskaia Bylund O, Bethke S, Betti A, Bevan AJ, Bhamjee M, Bhatta S, Bhattacharya DS, Bhattarai P, Bhopatkar VS, Bi R, Bi R, Bianchi RM, Biebel O, Bielski R, Biglietti M, Billoud TRV, Bindi M, Bingul A, Bini C, Biondi S, Biondini A, Birch-Sykes CJ, Bird GA, Birman M, Bisanz T, Biswas D, Bitadze A, Bjørke K, Bloch I, Blocker C, Blue A, Blumenschein U, Blumenthal J, Bobbink GJ, Bobrovnikov VS, Boehler M, Bogavac D, Bogdanchikov AG, Bohm C, Boisvert V, Bokan P, Bold T, Bomben M, Bona M, Boonekamp M, Booth CD, Borbély AG, Borecka-Bielska HM, Borgna LS, Borissov G, Bortoletto D, Boscherini D, Bosman M, Bossio Sola JD, Bouaouda K, Boudreau J, Bouhova-Thacker EV, Boumediene D, Bouquet R, Boveia A, Boyd J, Boye D, Boyko IR, Bracinik J, Brahimi N, Brandt G, Brandt O, Braren F, Brau B, Brau JE, Breaden Madden WD, Brendlinger K, Brener R, Brenner L, Brenner R, Bressler S, Brickwedde B, Britton D, Britzger D, Brock I, Brooijmans G, Brooks WK, Brost E, Bruckman de Renstrom PA, Brüers B, Bruncko D, Bruni A, Bruni G, Bruschi M, Bruscino N, Bryngemark L, Buanes T, Buat Q, Buchholz P, Buckley AG, Budagov IA, Bugge MK, Bulekov O, Bullard BA, Burdin S, Burgard CD, Burger AM, Burghgrave B, Burr JTP, Burton CD, Burzynski JC, Busch EL, Büscher V, Bussey PJ, Butler JM, Buttar CM, Butterworth JM, Buttinger W, Buxo Vazquez CJ, Buzykaev AR, Cabras G, Cabrera Urbán S, Caforio D, Cai H, Cai Y, Cairo VMM, Cakir O, Calace N, Calafiura P, Calderini G, Calfayan P, Callea G, Caloba LP, Calvet D, Calvet S, Calvet TP, Calvetti M, Camacho Toro R, Camarda S, Camarero Munoz D, Camarri P, Camerlingo MT, Cameron D, Camincher C, Campanelli M, Camplani A, Canale V, Canesse A, Cano Bret M, Cantero J, Cao Y, Capocasa F, Capua M, Carbone A, Cardarelli R, Cardenas JCJ, Cardillo F, Carli T, Carlino G, Carlson BT, Carlson EM, Carminati L, Carnesale M, Caron S, Carquin E, Carrá S, Carratta G, Carrio Argos F, Carter JWS, Carter TM, Casado MP, Casha AF, Castiglia EG, Castillo FL, Castillo Garcia L, Castillo Gimenez V, Castro NF, Catinaccio A, Catmore JR, Cavaliere V, Cavalli N, Cavasinni V, Celebi E, Celli F, Centonze MS, Cerny K, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cervelli A, Cetin SA, Chadi Z, Chakraborty D, Chala M, Chan J, Chan WS, Chan WY, Chapman JD, Chargeishvili B, Charlton DG, Charman TP, Chatterjee M, Chekanov S, Chekulaev SV, Chelkov GA, Chen A, Chen B, Chen B, Chen C, Chen H, Chen H, Chen J, Chen J, Chen S, Chen SJ, Chen X, Chen X, Chen Y, Cheng CL, Cheng HC, Cheplakov A, Cheremushkina E, Cherepanova E, Cherkaoui El Moursli R, Cheu E, Cheung K, Chevalier L, Chiarella V, Chiarelli G, Chiodini G, Chisholm AS, Chitan A, Chiu YH, Chizhov MV, Choi K, Chomont AR, Chou Y, Chow EYS, Chowdhury T, Christopher LD, Chu KL, Chu MC, Chu X, Chudoba J, Chwastowski JJ, Cieri D, Ciesla KM, Cindro V, Ciocio A, Cirotto F, Citron ZH, Citterio M, Ciubotaru DA, Ciungu BM, Clark A, Clark PJ, Clavijo Columbie JM, Clawson SE, Clement C, Clercx J, Clissa L, Coadou Y, Cobal M, Coccaro A, Barrue RFC, Coelho Lopes De Sa R, Coelli S, Cohen H, Coimbra AEC, Cole B, Collot J, Conde Muiño P, Connell MP, Connell SH, Connelly IA, Conroy EI, Conventi F, Cooke HG, Cooper-Sarkar AM, Cormier F, Corpe LD, Corradi M, Corrigan EE, Corriveau F, Cortes-Gonzalez A, Costa MJ, Costanza F, Costanzo D, Cote BM, Cowan G, Cowley JW, Cranmer K, Crépé-Renaudin S, Crescioli F, Cristinziani M, Cristoforetti M, Croft V, Crosetti G, Cueto A, Cuhadar Donszelmann T, Cui H, Cui Z, Cukierman AR, Cunningham WR, Curcio F, Czodrowski P, Czurylo MM, De Sousa MJDCS, Da Fonseca Pinto JV, Da Via C, Dabrowski W, Dado T, Dahbi S, Dai T, Dallapiccola C, Dam M, D'amen G, D'Amico V, Damp J, Dandoy JR, Daneri MF, Danninger M, Dao V, Darbo G, Darmora S, Das SJ, Dattagupta A, D'Auria S, David C, Davidek T, Davis DR, Davis-Purcell B, Dawson I, De K, De Asmundis R, De Beurs M, De Castro S, De Groot N, de Jong P, De la Torre H, De Maria A, De Salvo A, De Sanctis U, De Santo A, De Vivie De Regie JB, Dedovich DV, Degens J, Deiana AM, Del Corso F, Del Peso J, Del Rio F, Deliot F, Delitzsch CM, Della Pietra M, Della Volpe D, Dell'Acqua A, Dell'Asta L, Delmastro M, Delsart PA, Demers S, Demichev M, Denisov SP, D'Eramo L, Derendarz D, Derue F, Dervan P, Desch K, Dette K, Deutsch C, Deviveiros PO, Di Bello FA, Di Ciaccio A, Di Ciaccio L, Di Domenico A, Di Donato C, Di Girolamo A, Di Gregorio G, Di Luca A, Di Micco B, Di Nardo R, Diaconu C, Dias FA, Vale TDD, Diaz MA, Diaz Capriles FG, Didenko M, Diehl EB, Diehl L, Díez Cornell S, Diez Pardos C, Dimitriadi C, Dimitrievska A, Ding W, Dingfelder J, Dinu IM, Dittmeier SJ, Dittus F, Djama F, Djobava T, Djuvsland JI, Dodsworth D, Doglioni C, Dolejsi J, Dolezal Z, Donadelli M, Dong B, Donini J, D'Onofrio A, D'Onofrio M, Dopke J, Doria A, Dova MT, Doyle AT, Draguet MA, Drechsler E, Dreyer E, Drivas-Koulouris I, Drobac AS, Du D, du Pree TA, Dubinin F, Dubovsky M, Duchovni E, Duckeck G, Ducu OA, Duda D, Dudarev A, D'uffizi M, Duflot L, Dührssen M, Dülsen C, Dumitriu AE, Dunford M, Dungs S, Dunne K, Duperrin A, Yildiz HD, Düren M, Durglishvili A, Dwyer BL, Dyckes GI, Dyndal M, Dysch S, Dziedzic BS, Earnshaw ZO, Eckerova B, Eggleston MG, Purcino De Souza EE, Ehrke LF, Eigen G, Einsweiler K, Ekelof T, Ekman PA, El Ghazali Y, El Jarrari H, El Moussaouy A, Ellajosyula V, Ellert M, Ellinghaus F, Elliot AA, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Emerman A, Enari Y, Ene I, Epari S, Erdmann J, Ereditato A, Erland PA, Errenst M, Escalier M, Escobar C, Etzion E, Evans G, Evans H, Evans MO, Ezhilov A, Ezzarqtouni S, Fabbri F, Fabbri L, Facini G, Fadeyev V, Fakhrutdinov RM, Falciano S, Falke PJ, Falke S, Faltova J, Fan Y, Fang Y, Fanourakis G, Fanti M, Faraj M, Farbin A, Farilla A, Farooque T, Farrington SM, Fassi F, Fassouliotis D, Faucci Giannelli M, Fawcett WJ, Fayard L, Fedin OL, Fedotov G, Feickert M, Feligioni L, Fell A, Fellers DE, Feng C, Feng M, Fenton MJ, Fenyuk AB, Ferencz L, Ferguson SW, Pretel J, Ferrando J, Ferrari A, Ferrari P, Ferrari R, Ferrere D, Ferretti C, Fiedler F, Filipčič A, Filmer EK, Filthaut F, Fiolhais MCN, Fiorini L, Fischer F, Fisher WC, Fitschen T, Fleck I, Fleischmann P, Flick T, Flores L, Flores M, Flores Castillo LR, Follega FM, Fomin N, Foo JH, Forland BC, Formica A, Forti AC, Fortin E, Fortman AW, Foti MG, Fountas L, Fournier D, Fox H, Francavilla P, Francescato S, Franchini M, Franchino S, Francis D, Franco L, Franconi L, Franklin M, Frattari G, Freegard AC, Freeman PM, Freund WS, Fritzsche N, Froch A, Froidevaux D, Frost JA, Fu Y, Fujimoto M, Fullana Torregrosa E, Fuster J, Gabrielli A, Gabrielli A, Gadow P, Gagliardi G, Gagnon LG, Gallardo GE, Gallas EJ, Gallop BJ, Gamboa Goni R, Gan KK, Ganguly S, Gao J, Gao Y, Garay Walls FM, Garcia B, García C, García Navarro JE, García Pascual JA, Garcia-Sciveres M, Gardner RW, Garg D, Garg RB, Gargiulo S, Garner CA, Garonne V, Gasiorowski SJ, Gaspar P, Gaudio G, Gautam V, Gauzzi P, Gavrilenko IL, Gavrilyuk A, Gay C, Gaycken G, Gazis EN, Geanta AA, Gee CM, Geisen J, Geisen M, Gemme C, Genest MH, Gentile S, George S, George WF, Geralis T, Gerlach LO, Gessinger-Befurt P, Ghasemi Bostanabad M, Ghneimat M, Ghosal A, Ghosh A, Ghosh A, Giacobbe B, Giagu S, Giangiacomi N, Giannetti P, Giannini A, Gibson SM, Gignac M, Gil DT, Gilbert AK, Gilbert BJ, Gillberg D, Gilles G, Gillwald NEK, Ginabat L, Gingrich DM, Giordani MP, Giraud PF, Giugliarelli G, Giugni D, Giuli F, Gkialas I, Gladilin LK, Glasman C, Gledhill GR, Glisic M, Gnesi I, Go Y, Goblirsch-Kolb M, Godin D, Goldfarb S, Golling T, Gololo MGD, Golubkov D, Gombas JP, Gomes A, Gomes Da Silva G, Gomez Delegido AJ, Goncalves Gama R, Gonçalo R, Gonella G, Gonella L, Gongadze A, Gonnella F, Gonski JL, González de la Hoz S, Gonzalez Fernandez S, Gonzalez Lopez R, Gonzalez Renteria C, Gonzalez Suarez R, Gonzalez-Sevilla S, Gonzalvo Rodriguez GR, González Andana RY, Goossens L, Gorasia NA, Gorbounov PA, Gorini B, Gorini E, Gorišek A, Goshaw AT, Gostkin MI, Gottardo CA, Gouighri M, Goumarre V, Goussiou AG, Govender N, Goy C, Grabowska-Bold I, Graham K, Gramstad E, Grancagnolo S, Grandi M, Gratchev V, Gravila PM, Gravili FG, Gray HM, Greco M, Grefe C, Gregor IM, Grenier P, Grieco C, Grillo AA, Grimm K, Grinstein S, Grivaz JF, Gross E, Grosse-Knetter J, Grud C, Grummer A, Grundy JC, Guan L, Guan W, Gubbels C, Guerrero Rojas JGR, Guerrieri G, Guescini F, Gugel R, Guhit JAM, Guida A, Guillemin T, Guilloton E, Guindon S, Guo F, Guo J, Guo L, Guo Y, Gupta R, Gurbuz S, Gurdasani SS, Gustavino G, Guth M, Gutierrez P, Gutierrez Zagazeta LF, Gutschow C, Guyot C, Gwenlan C, Gwilliam CB, Haaland ES, Haas A, Habedank M, Haber C, Hadavand HK, Hadef A, Hadzic S, Haleem M, Haley J, Hall JJ, Hallewell GD, Halser L, Hamano K, Hamdaoui H, Hamer M, Hamity GN, Han J, Han K, Han L, Han L, Han S, Han YF, Hanagaki K, Hance M, Hangal DA, Hank MD, Hankache R, Hansen JB, Hansen JD, Hansen PH, Hara K, Harada D, Harenberg T, Harkusha S, Harris YT, Harrison NM, Harrison PF, Hartman NM, Hartmann NM, Hasegawa Y, Hasib A, Haug S, Hauser R, Havranek M, Hawkes CM, Hawkings RJ, Hayashida S, Hayden D, Hayes C, Hayes RL, Hays CP, Hays JM, Hayward HS, He F, He Y, He Y, Heath MP, Hedberg V, Heggelund AL, Hehir ND, Heidegger C, Heidegger KK, Heidorn WD, Heilman J, Heim S, Heim T, Heinlein JG, Heinrich JJ, Heinrich L, Hejbal J, Helary L, Held A, Hellesund S, Helling CM, Hellman S, Helsens C, Henderson RCW, Henkelmann L, Henriques Correia AM, Herde H, Hernández Jiménez Y, Herr H, Herrmann MG, Herrmann T, Herten G, Hertenberger R, Hervas L, Hessey NP, Hibi H, Higón-Rodriguez E, Hillier SJ, Hinchliffe I, Hinterkeuser F, Hirose M, Hirose S, Hirschbuehl D, Hitchings TG, Hiti B, Hobbs J, Hobincu R, Hod N, Hodgkinson MC, Hodkinson BH, Hoecker A, Hofer J, Hohn D, Holm T, Holzbock M, Hommels LBAH, Honan BP, Hong J, Hong TM, Hong Y, Honig JC, Hönle A, Hooberman BH, Hopkins WH, Horii Y, Hou S, Howard AS, Howarth J, Hoya J, Hrabovsky M, Hrynevich A, Hryn'ova T, Hsu PJ, Hsu SC, Hu Q, Hu YF, Huang DP, Huang S, Huang X, Huang Y, Huang Y, Huang Z, Hubacek Z, Huebner M, Huegging F, Huffman TB, Huhtinen M, Huiberts SK, Hulsken R, Huseynov N, Huston J, Huth J, Hyneman R, Hyrych S, Iacobucci G, Iakovidis G, Ibragimov I, Iconomidou-Fayard L, Iengo P, Iguchi R, Iizawa T, Ikegami Y, Ilg A, Ilic N, Imam H, Ingebretsen Carlson T, Introzzi G, Iodice M, Ippolito V, Ishino M, Islam W, Issever C, Istin S, Ito H, Iturbe Ponce JM, Iuppa R, Ivina A, Izen JM, Izzo V, Jacka P, Jackson P, Jacobs RM, Jaeger BP, Jagfeld CS, Jäkel G, Jakobs K, Jakoubek T, Jamieson J, Janas KW, Jarlskog G, Jaspan AE, Javůrek T, Javurkova M, Jeanneau F, Jeanty L, Jejelava J, Jenni P, Jessiman CE, Jézéquel S, Jia J, Jia X, Jia X, Jia Z, Jiang Y, Jiggins S, Jimenez Pena J, Jin S, Jinaru A, Jinnouchi O, Jivan H, Johansson P, Johns KA, Johnson CA, Jones DM, Jones E, Jones P, Jones RWL, Jones TJ, Jovicevic J, Ju X, Junggeburth JJ, Juste Rozas A, Kabana S, Kaczmarska A, Kado M, Kagan H, Kagan M, Kahn A, Kahn A, Kahra C, Kaji T, Kajomovitz E, Kakati N, Kalderon CW, Kamenshchikov A, Kang NJ, Kano Y, Kar D, Karava K, Kareem MJ, Karentzos E, Karkanias I, Karpov SN, Karpova ZM, Kartvelishvili V, Karyukhin AN, Kasimi E, Kato C, Katzy J, Kaur S, Kawade K, Kawagoe K, Kawaguchi T, Kawamoto T, Kawamura G, Kay EF, Kaya FI, Kazakos S, Kazanin VF, Ke Y, Keaveney JM, Keeler R, Kehris GV, Keller JS, Kelly AS, Kelsey D, Kempster JJ, Kendrick J, Kennedy KE, Kepka O, Kerridge BP, Kersten S, Kerševan BP, Keszeghova L, Ketabchi Haghighat S, Khandoga M, Khanov A, Kharlamov AG, Kharlamova T, Khoda EE, Khoo TJ, Khoriauli G, Khubua J, Khwaira YAR, Kiehn M, Kilgallon A, Kim DW, Kim E, Kim YK, Kimura N, Kirchhoff A, Kirchmeier D, Kirfel C, Kirk J, Kiryunin AE, Kishimoto T, Kisliuk DP, Kitsaki C, Kivernyk O, Klassen M, Klein C, Klein L, Klein MH, Klein M, Klein U, Klimek P, Klimentov A, Klimpel F, Klingl T, Klioutchnikova T, Klitzner FF, Kluit P, Kluth S, Kneringer E, Knight TM, Knue A, Kobayashi D, Kobayashi R, Kocian M, Kodama T, Kodyš P, Koeck DM, Koenig PT, Koffas T, Köhler NM, Kolb M, Koletsou I, Komarek T, Köneke K, Kong AXY, Kono T, Konstantinidis N, Konya B, Kopeliansky R, Koperny S, Korcyl K, Kordas K, Koren G, Korn A, Korn S, Korolkov I, Korotkova N, Kortman B, Kortner O, Kortner S, Kostecka WH, Kostyukhin VV, Kotsokechagia A, Kotwal A, Koulouris A, Kourkoumeli-Charalampidi A, Kourkoumelis C, Kourlitis E, Kovanda O, Kowalewski R, Kozanecki W, Kozhin AS, Kramarenko VA, Kramberger G, Kramer P, Krasny MW, Krasznahorkay A, Kremer JA, Kresse T, Kretzschmar J, Kreul K, Krieger P, Krieter F, Krishnamurthy S, Krishnan A, Krivos M, Krizka K, Kroeninger K, Kroha H, Kroll J, Kroll J, Krowpman KS, Kruchonak U, Krüger H, Krumnack N, Kruse MC, Krzysiak JA, Kubota A, Kuchinskaia O, Kuday S, Kuechler D, Kuechler JT, Kuehn S, Kuhl T, Kukhtin V, Kulchitsky Y, Kuleshov S, Kumar M, Kumari N, Kuna M, Kupco A, Kupfer T, Kupich A, Kuprash O, Kurashige H, Kurchaninov LL, Kurochkin YA, Kurova A, Kuwertz ES, Kuze M, Kvam AK, Kvita J, Kwan T, Kwok KW, Lacasta C, Lacava F, Lacker H, Lacour D, Lad NN, Ladygin E, Laforge B, Lagouri T, Lai S, Lakomiec IK, Lalloue N, Lambert JE, Lammers S, Lampl W, Lampoudis C, Lancaster AN, Lançon E, Landgraf U, Landon MPJ, Lang VS, Langenberg RJ, Lankford AJ, Lanni F, Lantzsch K, Lanza A, Lapertosa A, Laporte JF, Lari T, Lasagni Manghi F, Lassnig M, Latonova V, Lau TS, Laudrain A, Laurier A, Lawlor SD, Lawrence Z, Lazzaroni M, Le B, Leban B, Lebedev A, LeBlanc M, LeCompte T, Ledroit-Guillon F, Lee ACA, Lee GR, Lee L, Lee SC, Lee S, Lee TF, Leeuw LL, Lefebvre HP, Lefebvre M, Leggett C, Lehmann K, Lehmann Miotto G, Leight WA, Leisos A, Leite MAL, Leitgeb CE, Leitner R, Leney KJC, Lenz T, Leone S, Leonidopoulos C, Leopold A, Leroy C, Les R, Lester CG, Levchenko M, Levêque J, Levin D, Levinson LJ, Lewicki MP, Lewis DJ, Li B, Li B, Li C, Li CQ, Li H, Li H, Li H, Li H, Li J, Li K, Li L, Li M, Li QY, Li S, Li T, Li X, Li Z, Li Z, Li Z, Li Z, Liang Z, Liberatore M, Liberti B, Lie K, Lieber Marin J, Lin K, Linck RA, Lindley RE, Lindon JH, Linss A, Lipeles E, Lipniacka A, Lister A, Little JD, Liu B, Liu BX, Liu D, Liu JB, Liu JKK, Liu K, Liu M, Liu MY, Liu P, Liu Q, Liu X, Liu Y, Liu Y, Liu YL, Liu YW, Livan M, Llorente Merino J, Lloyd SL, Lobodzinska EM, Loch P, Loffredo S, Lohse T, Lohwasser K, Lokajicek M, Long JD, Longarini I, Longo L, Longo R, Lopez Paz I, Lopez Solis A, Lorenz J, Lorenzo Martinez N, Lory AM, Lösle A, Lou X, Lou X, Lounis A, Love J, Love PA, Lozano Bahilo JJ, Lu G, Lu M, Lu S, Lu YJ, Lubatti HJ, Luci C, Lucio Alves FL, Lucotte A, Luehring F, Luise I, Lukianchuk O, Lundberg O, Lund-Jensen B, Luongo NA, Lutz MS, Lynn D, Lyons H, Lysak R, Lytken E, Lyu F, Lyubushkin V, Lyubushkina T, Ma H, Ma LL, Ma Y, Mac Donell DM, Maccarrone G, MacDonald JC, Madar R, Mader WF, Maeda J, Maeno T, Maerker M, Magerl V, Magro J, Maguire H, Mahon DJ, Maidantchik C, Maio A, Maj K, Majersky O, Majewski S, Makovec N, Maksimovic V, Malaescu B, Malecki P, Maleev VP, Malek F, Malito D, Mallik U, Malone C, Maltezos S, Malyukov S, Mamuzic J, Mancini G, Manco G, Mandalia JP, Mandić I, Manhaes de Andrade Filho L, Maniatis IM, Manisha M, Manjarres Ramos J, Mankad DC, Mankinen KH, Mann A, Manousos A, Mansoulie B, Manzoni S, Marantis A, Marchiori G, Marcisovsky M, Marcoccia L, Marcon C, Marinescu M, Marjanovic M, Marshall Z, Marti-Garcia S, Martin TA, Martin VJ, Martin Dit Latour B, Martinelli L, Martinez M, Martinez Agullo P, Martinez Outschoorn VI, Martinez Suarez P, Martin-Haugh S, Martoiu VS, Martyniuk AC, Marzin A, Maschek SR, Masetti L, Mashimo T, Masik J, Maslennikov AL, Massa L, Massarotti P, Mastrandrea P, Mastroberardino A, Masubuchi T, Mathisen T, Matic A, Matsuzawa N, Maurer J, Maček B, Maximov DA, Mazini R, Maznas I, Mazza M, Mazza SM, Mc Ginn C, Mc Gowan JP, Mc Kee SP, McCarthy TG, McCormack WP, McDonald EF, McDougall AE, Mcfayden JA, Mchedlidze G, Mckenzie RP, Mclachlan TC, Mclaughlin DJ, McLean KD, McMahon SJ, McNamara PC, McPherson RA, Mdhluli JE, Meehan S, Megy T, Mehlhase S, Mehta A, Meirose B, Melini D, Mellado Garcia BR, Melo AH, Meloni F, Gouveia EDM, Mendes Jacques Da Costa AM, Meng HY, Meng L, Menke S, Mentink M, Meoni E, Merlassino C, Merola L, Meroni C, Merz G, Meshkov O, Meshreki JKR, Metcalfe J, Mete AS, Meyer C, Meyer JP, Michetti M, Middleton RP, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Mildner H, Milic A, Milke CD, Miller DW, Miller LS, Milov A, Milstead DA, Min T, Minaenko AA, Minashvili IA, Mince L, Mincer AI, Mindur B, Mineev M, Minegishi Y, Mino Y, Mir LM, Miralles Lopez M, Mironova M, Mitani T, Mitra A, Mitsou VA, Miu O, Miyagawa PS, Miyazaki Y, Mizukami A, Mjörnmark JU, Mkrtchyan T, Mlynarikova M, Moa T, Mobius S, Mochizuki K, Moder P, Mogg P, Mohammed AF, Mohapatra S, Mokgatitswane G, Mondal B, Mondal S, Mönig K, Monnier E, Monsonis Romero L, Montejo Berlingen J, Montella M, Monticelli F, Morange N, De Carvalho ALM, Moreno Llácer M, Moreno Martinez C, Morettini P, Morgenstern S, Morii M, Morinaga M, Morisbak V, Morley AK, Morodei F, Morvaj L, Moschovakos P, Moser B, Mosidze M, Moskalets T, Moskvitina P, Moss J, Moyse EJW, Muanza S, Mueller J, Muenstermann D, Müller R, Mullier GA, Mullin JJ, Mungo DP, Munoz Martinez JL, Munoz Perez D, Munoz Sanchez FJ, Murin M, Murray WJ, Murrone A, Muse JM, Muškinja M, Mwewa C, Myagkov AG, Myers AJ, Myers AA, Myers G, Myska M, Nachman BP, Nackenhorst O, Nag A, Nagai K, Nagano K, Nagle JL, Nagy E, Nairz AM, Nakahama Y, Nakamura K, Nanjo H, Narayan R, Narayanan EA, Naryshkin I, Naseri M, Nass C, Navarro G, Navarro-Gonzalez J, Nayak R, Nechaeva PY, Nechansky F, Neep TJ, Negri A, Negrini M, Nellist C, Nelson C, Nelson K, Nemecek S, Nessi M, Neubauer MS, Neuhaus F, Neundorf J, Newhouse R, Newman PR, Ng CW, Ng YS, Ng YWY, Ngair B, Nguyen HDN, Nickerson RB, Nicolaidou R, Nielsen J, Niemeyer M, Nikiforou N, Nikolaenko V, Nikolic-Audit I, Nikolopoulos K, Nilsson P, Nindhito HR, Nisati A, Nishu N, Nisius R, Nitschke JE, Nkadimeng EK, Noacco Rosende SJ, Nobe T, Noel DL, Noguchi Y, Nommensen T, Nomura MA, Norfolk MB, Norisam RRB, Norman BJ, Novak J, Novak T, Novgorodova O, Novotny L, Novotny R, Nozka L, Ntekas K, Nurse E, Oakham FG, Ocariz J, Ochi A, Ochoa I, Oerdek S, Ogrodnik A, Oh A, Ohm CC, Oide H, Oishi R, Ojeda ML, Okazaki Y, O'Keefe MW, Okumura Y, Olariu A, Seabra LFO, Olivares Pino SA, Oliveira Damazio D, Oliveira Goncalves D, Oliver JL, Olsson MJR, Olszewski A, Olszowska J, Öncel ÖO, O'Neil DC, O'Neill AP, Onofre A, Onyisi PUE, Oreglia MJ, Orellana GE, Orestano D, Orlando N, Orr RS, O'Shea V, Ospanov R, Otero Y Garzon G, Otono H, Ott PS, Ottino GJ, Ouchrif M, Ouellette J, Ould-Saada F, Owen M, Owen RE, Oyulmaz KY, Ozcan VE, Ozturk N, Ozturk S, Pacalt J, Pacey HA, Pachal K, Pacheco Pages A, Padilla Aranda C, Padovano G, Pagan Griso S, Palacino G, Palazzo A, Palazzo S, Palestini S, Palka M, Pan J, Pan T, Panchal DK, Pandini CE, Panduro Vazquez JG, Pang H, Pani P, Panizzo G, Paolozzi L, Papadatos C, Parajuli S, Paramonov A, Paraskevopoulos C, Paredes Hernandez D, Park TH, Parker MA, Parodi F, Parrish EW, Parrish VA, Parsons JA, Parzefall U, Pascual Dias B, Pascual Dominguez L, Pascuzzi VR, Pasquali F, Pasqualucci E, Passaggio S, Pastore F, Pasuwan P, Pater JR, Patton J, Pauly T, Pearkes J, Pedersen M, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penski KE, Penzin M, Peralva BS, Peixoto APP, Pereira Sanchez L, Perepelitsa DV, Perez Codina E, Perganti M, Perini L, Pernegger H, Perrella S, Perrevoort A, Perrin O, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petousis V, Petridou C, Petrukhin A, Pettee M, Pettersson NE, Petukhov A, Petukhova K, Peyaud A, Pezoa R, Pezzotti L, Pezzullo G, Pham T, Phillips PW, Phipps MW, Piacquadio G, Pianori E, Piazza F, Piegaia R, Pietreanu D, Pilkington AD, Pinamonti M, Pinfold JL, Pereira BCP, Pitman Donaldson C, Pizzi DA, Pizzimento L, Pizzini A, Pleier MA, Plesanovs V, Pleskot V, Plotnikova E, Poddar G, Poettgen R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Polacek S, Polesello G, Poley A, Polifka R, Polini A, Pollard CS, Pollock ZB, Polychronakos V, Ponomarenko D, Pontecorvo L, Popa S, Popeneciu GA, Portillo Quintero DM, Pospisil S, Postolache P, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Pownall G, Pozo Astigarraga ME, Prades Ibanez A, Prapa MM, Price D, Primavera M, Principe Martin MA, Proffitt ML, Proklova N, Prokofiev K, Proto G, Protopopescu S, Proudfoot J, Przybycien M, Puddefoot JE, Pudzha D, Puzo P, Pyatiizbyantseva D, Qian J, Qin Y, Qiu T, Quadt A, Queitsch-Maitland M, Rabanal Bolanos G, Rafanoharana D, Ragusa F, Rainbolt JL, Raine JA, Rajagopalan S, Ramakoti E, Ran K, Raskina V, Rassloff DF, Rave S, Ravina B, Ravinovich I, Raymond M, Read AL, Readioff NP, Rebuzzi DM, Redlinger G, Reeves K, Reidelsturz JA, Reikher D, Reiss A, Rej A, Rembser C, Renardi A, Renda M, Rendel MB, Rennie AG, Resconi S, Ressegotti M, Resseguie ED, Rettie S, Reynolds B, Reynolds E, Rezaei Estabragh M, Rezanova OL, Reznicek P, Ricci E, Richter R, Richter S, Richter-Was E, Ridel M, Rieck P, Riedler P, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Rinn TT, Rinnagel MP, Ripellino G, Riu I, Rivadeneira P, Rivera Vergara JC, Rizatdinova F, Rizvi E, Rizzi C, Roberts BA, Roberts BR, Robertson SH, Robin M, Robinson D, Robles Gajardo CM, Robles Manzano M, Robson A, Rocchi A, Roda C, Rodriguez Bosca S, Rodriguez Garcia Y, Rodriguez Rodriguez A, Rodríguez Vera AM, Roe S, Roemer JT, Roepe-Gier AR, Roggel J, Røhne O, Rojas RA, Roland B, Roland CPA, Roloff J, Romaniouk A, Romano E, Romano M, Romero Hernandez AC, Rompotis N, Roos L, Rosati S, Rosser BJ, Rossi E, Rossi E, Rossi LP, Rossini L, Rosten R, Rotaru M, Rottler B, Rousseau D, Rousso D, Rovelli G, Roy A, Rozanov A, Rozen Y, Ruan X, Rubio Jimenez A, Ruby AJ, Ruelas Rivera VH, Ruggeri TA, Rühr F, Ruiz-Martinez A, Rummler A, Rurikova Z, Rusakovich NA, Russell HL, Rutherfoord JP, Rüttinger EM, Rybacki K, Rybar M, Rye EB, Ryzhov A, Sabater Iglesias JA, Sabatini P, Sabetta L, Sadrozinski HFW, Safai Tehrani F, Safarzadeh Samani B, Safdari M, Saha S, Sahinsoy M, Saimpert M, Saito M, Saito T, Salamani D, Salamanna G, Salnikov A, Salt J, Salvador Salas A, Salvatore D, Salvatore F, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Pineda A, Sanchez Sebastian V, Sandaker H, Sander CO, Sandesara JA, Sandhoff M, Sandoval C, Sankey DPC, Sansoni A, Santi L, Santoni C, Santos H, Santpur SN, Santra A, Saoucha KA, Saraiva JG, Sardain J, Sasaki O, Sato K, Sauer C, Sauerburger F, Sauvan E, Savard P, Sawada R, Sawyer C, Sawyer L, Sayago Galvan I, Sbarra C, Sbrizzi A, Scanlon T, Schaarschmidt J, Schacht P, Schaefer D, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schanet E, Scharf C, Schegelsky VA, Scheirich D, Schenck F, Schernau M, Scheulen C, Schiavi C, Schillaci ZM, Schioppa EJ, Schioppa M, Schlag B, Schleicher KE, Schlenker S, Schmieden K, Schmitt C, Schmitt S, Schoeffel L, Schoening A, Scholer PG, Schopf E, Schott M, Schovancova J, Schramm S, Schroeder F, Schultz-Coulon HC, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scuri F, Scutti F, Sebastiani CD, Sedlaczek K, Seema P, Seidel SC, Seiden A, Seidlitz BD, Seiss T, Seitz C, Seixas JM, Sekhniaidze G, Sekula SJ, Selem L, Semprini-Cesari N, Sen S, Sengupta D, Senthilkumar V, Serin L, Serkin L, Sessa M, Severini H, Sevova S, Sforza F, Sfyrla A, Shabalina E, Shaheen R, Shahinian JD, Shaikh NW, Shaked Renous D, Shan LY, Shapiro M, Sharma A, Sharma AS, Sharma P, Sharma S, Shatalov PB, Shaw K, Shaw SM, Shen Q, Sherwood P, Shi L, Shimmin CO, Shimogama Y, Shinner JD, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shochet MJ, Shojaii J, Shope DR, Shrestha S, Shrif EM, Shroff MJ, Sicho P, Sickles AM, Sideras Haddad E, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Sikora R, Sili F, Silva JM, Silva Oliveira MV, Silverstein SB, Simion S, Simoniello R, Simpson EL, Simpson ND, Simsek S, Sindhu S, Sinervo P, Sinetckii V, Singh S, Singh S, Sinha S, Sinha S, Sioli M, Siral I, Sivoklokov SY, Sjölin J, Skaf A, Skorda E, Skubic P, Slawinska M, Smakhtin V, Smart BH, Smiesko J, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith AC, Smith EA, Smith HA, Smith JL, Smith R, Smizanska M, Smolek K, Smykiewicz A, Snesarev AA, Snoek HL, Snyder S, Sobie R, Soffer A, Solans Sanchez CA, Soldatov EY, Soldevila U, Solodkov AA, Solomon S, Soloshenko A, Solovieva K, Solovyanov OV, Solovyev V, Sommer P, Sonay A, Song WY, Sopczak A, Sopio AL, Sopkova F, Sothilingam V, Sottocornola S, Soualah R, Soumaimi Z, South D, Spagnolo S, Spalla M, Spanò F, Sperlich D, Spigo G, Spina M, Spinali S, Spiteri DP, Spousta M, Staats EJ, Stabile A, Stamen R, Stamenkovic M, Stampekis A, Standke M, Stanecka E, Stanislaus B, Stanitzki MM, Stankaityte M, Stapf B, Starchenko EA, Stark GH, Stark J, Starko DM, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stavropoulos G, Steentoft J, Steinberg P, Steinhebel AL, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson TJ, Stewart GA, Stockton MC, Stoicea G, Stolarski M, Stonjek S, Straessner A, Strandberg J, Strandberg S, Strauss M, Strebler T, Strizenec P, Ströhmer R, Strom DM, Strom LR, Stroynowski R, Strubig A, Stucci SA, Stugu B, Stupak J, Styles NA, Su D, Su S, Su W, Su X, Sugizaki K, Sulin VV, Sullivan MJ, Sultan DMS, Sultanaliyeva L, Sultansoy S, Sumida T, Sun S, Sun S, Gudnadottir OS, Sutton MR, Svatos M, Swiatlowski M, Swirski T, Sykora I, Sykora M, Sykora T, Ta D, Tackmann K, Taffard A, Tafirout R, Tafoya Vargas JS, Taibah RHM, Takashima R, Takeda K, Takeva EP, Takubo Y, Talby M, Talyshev AA, Tam KC, Tamir NM, Tanaka A, Tanaka J, Tanaka R, Tanasini M, Tang J, Tao Z, Tapia Araya S, Tapprogge S, Tarek Abouelfadl Mohamed A, Tarem S, Tariq K, Tarna G, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tate AC, Tateno G, Tayalati Y, Taylor GN, Taylor W, Teagle H, Tee AS, Teixeira De Lima R, Teixeira-Dias P, Teoh JJ, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Thaler A, Theiner O, Themistokleous N, Theveneaux-Pelzer T, Thielmann O, Thomas DW, Thomas JP, Thompson EA, Thompson PD, Thomson E, Thorpe EJ, Tian Y, Tikhomirov V, Tikhonov YA, Timoshenko S, Ting EXL, Tipton P, Tisserant S, Tlou SH, Tnourji A, Todome K, Todorova-Nova S, Todt S, Togawa M, Tojo J, Tokár S, Tokushuku K, Tombs R, Tomoto M, Tompkins L, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toscani M, Tosciri C, Tovey DR, Traeet A, Trandafir IS, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trischuk DA, Trocmé B, Trofymov A, Troncon C, Truong L, Trzebinski M, Trzupek A, Tsai F, Tsai M, Tsiamis A, Tsiareshka PV, Tsigaridas S, Tsirigotis A, Tsiskaridze V, Tskhadadze EG, Tsopoulou M, Tsujikawa Y, Tsukerman II, Tsulaia V, Tsuno S, Tsur O, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tuna AN, Turchikhin S, Turk Cakir I, Turra R, Turtuvshin T, Tuts PM, Tzamarias S, Tzanis P, Tzovara E, Uchida K, Ukegawa F, Ulloa Poblete PA, Unal G, Unal M, Undrus A, Unel G, Uno K, Urban J, Urquijo P, Usai G, Ushioda R, Usman M, Uysal Z, Vacek V, Vachon B, Vadla KOH, Vafeiadis T, Valderanis C, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Vallier A, Valls Ferrer JA, Van Daalen TR, Van Gemmeren P, Van Rijnbach M, Van Stroud S, Van Vulpen I, Vanadia M, Vandelli W, Vandenbroucke M, Vandewall ER, Vannicola D, Vannoli L, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Varriale L, Varvell KE, Vasile ME, Vaslin L, Vasquez GA, Vazeille F, Vazquez Schroeder T, Veatch J, Vecchio V, Veen MJ, Veliscek I, Veloce LM, Veloso F, Veneziano S, Ventura A, Verbytskyi A, Verducci M, Vergis C, Verissimo De Araujo M, Verkerke W, Vermeulen JC, Vernieri C, Verschuuren PJ, Vessella M, Vesterbacka ML, Vetterli MC, Vgenopoulos A, Viaux Maira N, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Vigani L, Villa M, Villaplana Perez M, Villhauer EM, Vilucchi E, Vincter MG, Virdee GS, Vishwakarma A, Vittori C, Vivarelli I, Vladimirov V, Voevodina E, Vogel F, Vokac P, Von Ahnen J, Von Toerne E, Vormwald B, Vorobel V, Vorobev K, Vos M, Vossebeld JH, Vozak M, Vozdecky L, Vranjes N, Vranjes Milosavljevic M, Vreeswijk M, Vuillermet R, Vujinovic O, Vukotic I, Wada S, Wagner C, Wagner W, Wahdan S, Wahlberg H, Wakasa R, Wakida M, Walbrecht VM, Walder J, Walker R, Walkowiak W, Wang AM, Wang AZ, Wang C, Wang C, Wang H, Wang J, Wang P, Wang RJ, Wang R, Wang R, Wang SM, Wang S, Wang T, Wang WT, Wang WX, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Warburton A, Ward RJ, Warrack N, Watson AT, Watson MF, Watts G, Waugh BM, Webb AF, Weber C, Weber MS, Weber SA, Weber SM, Wei C, Wei Y, Weidberg AR, Weingarten J, Weirich M, Weiser C, Wells CJ, Wenaus T, Wendland B, Wengler T, Wenke NS, Wermes N, Wessels M, Whalen K, Wharton AM, White AS, White A, White MJ, Whiteson D, Wickremasinghe L, Wiedenmann W, Wiel C, Wielers M, Wieseotte N, Wiglesworth C, Wiik-Fuchs LAM, Wilbern DJ, Wilkens HG, Williams DM, Williams HH, Williams S, Willocq S, Windischhofer PJ, Winklmeier F, Winter BT, Wittgen M, Wobisch M, Wolf A, Wölker R, Wollrath J, Wolter MW, Wolters H, Wong VWS, Wongel AF, Worm SD, Wosiek BK, Woźniak KW, Wraight K, Wu J, Wu M, Wu SL, Wu X, Wu Y, Wu Z, Wuerzinger J, Wyatt TR, Wynne BM, Xella S, Xia L, Xia M, Xiang J, Xiao X, Xie M, Xie X, Xiong J, Xiotidis I, Xu D, Xu H, Xu H, Xu L, Xu R, Xu T, Xu W, Xu Y, Xu Z, Xu Z, Yabsley B, Yacoob S, Yamaguchi N, Yamaguchi Y, Yamauchi H, Yamazaki T, Yamazaki Y, Yan J, Yan S, Yan Z, Yang HJ, Yang HT, Yang S, Yang T, Yang X, Yang X, Yang Y, Yang Z, Yao WM, Yap YC, Ye H, Ye J, Ye S, Ye X, Yeh Y, Yeletskikh I, Yexley MR, Yin P, Yorita K, Young CJS, Young C, Yuan M, Yuan R, Yue L, Yue X, Zaazoua M, Zabinski B, Zaid E, Zakareishvili T, Zakharchuk N, Zambito S, Zang J, Zanzi D, Zaplatilek O, Zeißner SV, Zeitnitz C, Zeng JC, Zenger DT, Zenin O, Ženiš T, Zenz S, Zerradi S, Zerwas D, Zhang B, Zhang DF, Zhang G, Zhang J, Zhang K, Zhang L, Zhang P, Zhang R, Zhang S, Zhang T, Zhang X, Zhang X, Zhang Z, Zhang Z, Zhao H, Zhao P, Zhao T, Zhao Y, Zhao Z, Zhemchugov A, Zheng Z, Zhong D, Zhou B, Zhou C, Zhou H, Zhou N, Zhou Y, Zhu CG, Zhu C, Zhu HL, Zhu H, Zhu J, Zhu Y, Zhu Y, Zhuang X, Zhukov K, Zhulanov V, Zimine NI, Zinsser J, Ziolkowski M, Živković L, Zoccoli A, Zoch K, Zorbas TG, Zormpa O, Zou W, Zwalinski L. Strong Constraints on Jet Quenching in Centrality-Dependent p+Pb Collisions at 5.02 TeV from ATLAS. PHYSICAL REVIEW LETTERS 2023; 131:072301. [PMID: 37656838 DOI: 10.1103/physrevlett.131.072301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 10/04/2022] [Accepted: 11/17/2022] [Indexed: 09/03/2023]
Abstract
Jet quenching is the process of color-charged partons losing energy via interactions with quark-gluon plasma droplets created in heavy-ion collisions. The collective expansion of such droplets is well described by viscous hydrodynamics. Similar evidence of collectivity is consistently observed in smaller collision systems, including pp and p+Pb collisions. In contrast, while jet quenching is observed in Pb+Pb collisions, no evidence has been found in these small systems to date, raising fundamental questions about the nature of the system created in these collisions. The ATLAS experiment at the Large Hadron Collider has measured the yield of charged hadrons correlated with reconstructed jets in 0.36 nb^{-1} of p+Pb and 3.6 pb^{-1} of pp collisions at 5.02 TeV. The yields of charged hadrons with p_{T}^{ch}>0.5 GeV near and opposite in azimuth to jets with p_{T}^{jet}>30 or 60 GeV, and the ratios of these yields between p+Pb and pp collisions, I_{pPb}, are reported. The collision centrality of p+Pb events is categorized by the energy deposited by forward neutrons from the struck nucleus. The I_{pPb} values are consistent with unity within a few percent for hadrons with p_{T}^{ch}>4 GeV at all centralities. These data provide new, strong constraints that preclude almost any parton energy loss in central p+Pb collisions.
Collapse
|
132
|
Aad G, Abbott B, Abbott DC, Abed Abud A, Abeling K, Abhayasinghe DK, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Abusleme Hoffman AC, Acharya BS, Achkar B, Adam L, Adam Bourdarios C, Adamczyk L, Adamek L, Addepalli SV, Adelman J, Adiguzel A, Adorni S, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra JA, Ahmad A, Ahmadov F, Ahmed WS, Ai X, Aielli G, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Alconada Verzini MJ, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi A, Alfonsi F, Alhroob M, Ali B, Ali S, Aliev M, Alimonti G, Allaire C, Allbrooke BMM, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alunno Camelia E, Alvarez Estevez M, Alviggi MG, Amaral Coutinho Y, Ambler A, Ambroz L, Amelung C, Amidei D, Amor Dos Santos SP, Amoroso S, Amos KR, Amrouche CS, Ananiev V, Anastopoulos C, Andari N, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Antrim DJA, Anulli F, Aoki M, Aparisi Pozo JA, Aparo MA, Aperio Bella L, Appelt C, Aranzabal N, Araujo Ferraz V, Arcangeletti C, Arce ATH, Arena E, Arguin JF, Argyropoulos S, Arling JH, Armbruster AJ, Arnaez O, Arnold H, Arrubarrena Tame ZP, Artoni G, Asada H, Asai K, Asai S, Asbah NA, Asimakopoulou EM, Assahsah J, Assamagan K, Astalos R, Atkin RJ, Atkinson M, Atlay NB, Atmani H, Atmasiddha PA, Augsten K, Auricchio S, Austrup VA, Avner G, Avolio G, Ayoub MK, Azuelos G, Babal D, Bachacou H, Bachas K, Bachiu A, Backman F, Badea A, Bagnaia P, Bahmani M, Bailey AJ, Bailey VR, Baines JT, Bakalis C, Baker OK, Bakker PJ, Bakos E, Bakshi Gupta D, Balaji S, Balasubramanian R, Baldin EM, Balek P, Ballabene E, Balli F, Baltes LM, Balunas WK, Balz J, Banas E, Bandieramonte M, Bandyopadhyay A, Bansal S, Barak L, Barberio EL, Barberis D, Barbero M, Barbour G, Barends KN, Barillari T, Barisits MS, Barkeloo J, Barklow T, Barnett RM, Baron P, Baroncelli A, Barone G, Barr AJ, Barranco Navarro L, Barreiro F, Barreiro Guimarães da Costa J, Barron U, Barsov S, Bartels F, Bartoldus R, Bartolini G, Barton AE, Bartos P, Basalaev A, Basan A, Baselga M, Bashta I, Bassalat A, Basso MJ, Basson CR, Bates RL, Batlamous S, Batley JR, Batool B, Battaglia M, Bauce M, Bauer F, Bauer P, Bayirli A, Beacham JB, Beau T, Beauchemin PH, Becherer F, Bechtle P, Beck HP, Becker K, Becot C, Beddall AJ, Bednyakov VA, Bee CP, Beemster LJ, Beermann TA, Begalli M, Begel M, Behera A, Behr JK, Beirao Da Cruz E Silva C, Beirer JF, Beisiegel F, Belfkir M, Bella G, Bellagamba L, Bellerive A, Bellos P, Beloborodov K, Belotskiy K, Belyaev NL, Benchekroun D, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Bentvelsen S, Beresford L, Beretta M, Berge D, Bergeaas Kuutmann E, Berger N, Bergmann B, Beringer J, Berlendis S, Bernardi G, Bernius C, Bernlochner FU, Berry T, Berta P, Berthold A, Bertram IA, Bessidskaia Bylund O, Bethke S, Betti A, Bevan AJ, Bhatta S, Bhattacharya DS, Bhattarai P, Bhopatkar VS, Bi R, Bi R, Bianchi RM, Biebel O, Bielski R, Biesuz NV, Biglietti M, Billoud TRV, Bindi M, Bingul A, Bini C, Biondi S, Biondini A, Birch-Sykes CJ, Bird GA, Birman M, Bisanz T, Biswas D, Bitadze A, Bjørke K, Bloch I, Blocker C, Blue A, Blumenschein U, Blumenthal J, Bobbink GJ, Bobrovnikov VS, Boehler M, Bogavac D, Bogdanchikov AG, Bohm C, Boisvert V, Bokan P, Bold T, Bomben M, Bona M, Boonekamp M, Booth CD, Borbély AG, Borecka-Bielska HM, Borgna LS, Borissov G, Bortoletto D, Boscherini D, Bosman M, Bossio Sola JD, Bouaouda K, Boudreau J, Bouhova-Thacker EV, Boumediene D, Bouquet R, Boveia A, Boyd J, Boye D, Boyko IR, Bracinik J, Brahimi N, Brandt G, Brandt O, Braren F, Brau B, Brau JE, Breaden Madden WD, Brendlinger K, Brener R, Brenner L, Brenner R, Bressler S, Brickwedde B, Britton D, Britzger D, Brock I, Brooijmans G, Brooks WK, Brost E, Bruckman de Renstrom PA, Brüers B, Bruncko D, Bruni A, Bruni G, Bruschi M, Bruscino N, Bryngemark L, Buanes T, Buat Q, Buchholz P, Buckley AG, Budagov IA, Bugge MK, Bulekov O, Bullard BA, Burdin S, Burgard CD, Burger AM, Burghgrave B, Burr JTP, Burton CD, Burzynski JC, Busch EL, Büscher V, Bussey PJ, Butler JM, Buttar CM, Butterworth JM, Buttinger W, Buxo Vazquez CJ, Buzykaev AR, Cabras G, Cabrera Urbán S, Caforio D, Cai H, Cai Y, Cairo VMM, Cakir O, Calace N, Calafiura P, Calderini G, Calfayan P, Callea G, Caloba LP, Calvet D, Calvet S, Calvet TP, Calvetti M, Camacho Toro R, Camarda S, Camarero Munoz D, Camarri P, Camerlingo MT, Cameron D, Camincher C, Campanelli M, Camplani A, Canale V, Canesse A, Cano Bret M, Cantero J, Cao Y, Capocasa F, Capua M, Carbone A, Cardarelli R, Cardenas JCJ, Cardillo F, Carli T, Carlino G, Carlson BT, Carlson EM, Carminati L, Carnesale M, Caron S, Carquin E, Carrá S, Carratta G, Carter JWS, Carter TM, Casadei D, Casado MP, Casha AF, Castiglia EG, Castillo FL, Castillo Garcia L, Castillo Gimenez V, Castro NF, Catinaccio A, Catmore JR, Cavaliere V, Cavalli N, Cavasinni V, Celebi E, Celli F, Centonze MS, Cerny K, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cervelli A, Cetin SA, Chadi Z, Chakraborty D, Chala M, Chan J, Chan WS, Chan WY, Chapman JD, Chargeishvili B, Charlton DG, Charman TP, Chatterjee M, Chekanov S, Chekulaev SV, Chelkov GA, Chen A, Chen B, Chen B, Chen C, Chen H, Chen H, Chen J, Chen J, Chen S, Chen SJ, Chen X, Chen X, Chen Y, Cheng CL, Cheng HC, Cheplakov A, Cheremushkina E, Cherepanova E, Cherkaoui El Moursli R, Cheu E, Cheung K, Chevalier L, Chiarella V, Chiarelli G, Chiodini G, Chisholm AS, Chitan A, Chiu YH, Chizhov MV, Choi K, Chomont AR, Chou Y, Chow EYS, Chowdhury T, Christopher LD, Chu MC, Chu X, Chudoba J, Chwastowski JJ, Cieri D, Ciesla KM, Cindro V, Ciocio A, Cirotto F, Citron ZH, Citterio M, Ciubotaru DA, Ciungu BM, Clark A, Clark PJ, Clavijo Columbie JM, Clawson SE, Clement C, Clissa L, Coadou Y, Cobal M, Coccaro A, Barrue RFC, Coelho Lopes De Sa R, Coelli S, Cohen H, Coimbra AEC, Cole B, Collot J, Conde Muiño P, Connell SH, Connelly IA, Conroy EI, Conventi F, Cooke HG, Cooper-Sarkar AM, Cormier F, Corpe LD, Corradi M, Corrigan EE, Corriveau F, Costa MJ, Costanza F, Costanzo D, Cote BM, Cowan G, Cowley JW, Cranmer K, Crépé-Renaudin S, Crescioli F, Cristinziani M, Cristoforetti M, Croft V, Crosetti G, Cueto A, Cuhadar Donszelmann T, Cui H, Cui Z, Cukierman AR, Cunningham WR, Curcio F, Czodrowski P, Czurylo MM, De Sousa MJDCS, Da Fonseca Pinto JV, Da Via C, Dabrowski W, Dado T, Dahbi S, Dai T, Dallapiccola C, Dam M, D'amen G, D'Amico V, Damp J, Dandoy JR, Daneri MF, Danninger M, Dao V, Darbo G, Darmora S, Dattagupta A, D'Auria S, David C, Davidek T, Davis DR, Davis-Purcell B, Dawson I, De K, De Asmundis R, De Beurs M, De Castro S, De Groot N, de Jong P, De la Torre H, De Maria A, De Salvo A, De Sanctis U, De Santis M, De Santo A, De Vivie De Regie JB, Dedovich DV, Degens J, Deiana AM, Del Peso J, Del Rio F, Deliot F, Delitzsch CM, Della Pietra M, Della Volpe D, Dell'Acqua A, Dell'Asta L, Delmastro M, Delsart PA, Demers S, Demichev M, Denisov SP, D'Eramo L, Derendarz D, Derue F, Dervan P, Desch K, Dette K, Deutsch C, Deviveiros PO, Di Bello FA, Di Ciaccio A, Di Ciaccio L, Di Domenico A, Di Donato C, Di Girolamo A, Di Gregorio G, Di Luca A, Di Micco B, Di Nardo R, Diaconu C, Dias FA, Vale TDD, Diaz MA, Diaz Capriles FG, Didenko M, Diehl EB, Díez Cornell S, Diez Pardos C, Dimitriadi C, Dimitrievska A, Ding W, Dingfelder J, Dinu IM, Dittmeier SJ, Dittus F, Djama F, Djobava T, Djuvsland JI, Dodsworth D, Doglioni C, Dolejsi J, Dolezal Z, Donadelli M, Dong B, Donini J, D'Onofrio A, D'Onofrio M, Dopke J, Doria A, Dova MT, Doyle AT, Drechsler E, Dreyer E, Drobac AS, Du D, du Pree TA, Dubinin F, Dubovsky M, Duchovni E, Duckeck G, Ducu OA, Duda D, Dudarev A, D'uffizi M, Duflot L, Dührssen M, Dülsen C, Dumitriu AE, Dunford M, Dungs S, Dunne K, Duperrin A, Yildiz HD, Düren M, Durglishvili A, Dutta B, Dwyer BL, Dyckes GI, Dyndal M, Dysch S, Dziedzic BS, Eckerova B, Eggleston MG, Purcino De Souza EE, Ehrke LF, Eigen G, Einsweiler K, Ekelof T, El Ghazali Y, El Jarrari H, El Moussaouy A, Ellajosyula V, Ellert M, Ellinghaus F, Elliot AA, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Emerman A, Enari Y, Ene I, Erdmann J, Ereditato A, Erland PA, Errenst M, Escalier M, Escobar C, Etzion E, Evans G, Evans H, Evans MO, Ezhilov A, Ezzarqtouni S, Fabbri F, Fabbri L, Facini G, Fadeyev V, Fakhrutdinov RM, Falciano S, Falke PJ, Falke S, Faltova J, Fan Y, Fang Y, Fanourakis G, Fanti M, Faraj M, Farbin A, Farilla A, Farooque T, Farrington SM, Fassi F, Fassouliotis D, Faucci Giannelli M, Fawcett WJ, Fayard L, Fedin OL, Fedotov G, Feickert M, Feligioni L, Fell A, Fellers DE, Feng C, Feng M, Fenton MJ, Fenyuk AB, Ferguson SW, Pretel J, Ferrando J, Ferrari A, Ferrari P, Ferrari R, Ferrere D, Ferretti C, Fiedler F, Filipčič A, Filmer EK, Filthaut F, Fiolhais MCN, Fiorini L, Fischer F, Fisher WC, Fitschen T, Fleck I, Fleischmann P, Flick T, Flores L, Flores M, Flores Castillo LR, Follega FM, Fomin N, Foo JH, Forland BC, Formica A, Forti AC, Fortin E, Fortman AW, Foti MG, Fountas L, Fournier D, Fox H, Francavilla P, Francescato S, Franchini M, Franchino S, Francis D, Franco L, Franconi L, Franklin M, Frattari G, Freegard AC, Freeman PM, Freund WS, Freundlich EM, Froidevaux D, Frost JA, Fu Y, Fujimoto M, Fullana Torregrosa E, Fuster J, Gabrielli A, Gabrielli A, Gadow P, Gagliardi G, Gagnon LG, Galantzan S, Gallardo GE, Gallas EJ, Gallop BJ, Gamboa Goni R, Gan KK, Ganguly S, Gao J, Gao Y, Garay Walls FM, Garcia B, García C, García Navarro JE, García Pascual JA, Garcia-Sciveres M, Gardner RW, Garg D, Garg RB, Gargiulo S, Garner CA, Garonne V, Gasiorowski SJ, Gaspar P, Gaudio G, Gauzzi P, Gavrilenko IL, Gavrilyuk A, Gay C, Gaycken G, Gazis EN, Geanta AA, Gee CM, Geisen J, Geisen M, Gemme C, Genest MH, Gentile S, George S, George WF, Geralis T, Gerlach LO, Gessinger-Befurt P, Ghasemi Bostanabad M, Ghneimat M, Ghosal A, Ghosh A, Ghosh A, Giacobbe B, Giagu S, Giangiacomi N, Giannetti P, Giannini A, Gibson SM, Gignac M, Gil DT, Gilbert BJ, Gillberg D, Gilles G, Gillwald NEK, Ginabat L, Gingrich DM, Giordani MP, Giraud PF, Giugliarelli G, Giugni D, Giuli F, Gkialas I, Gkountoumis P, Gladilin LK, Glasman C, Gledhill GR, Glisic M, Gnesi I, Go Y, Goblirsch-Kolb M, Godin D, Goldfarb S, Golling T, Gololo MGD, Golubkov D, Gombas JP, Gomes A, Gomez Delegido AJ, Goncalves Gama R, Gonçalo R, Gonella G, Gonella L, Gongadze A, Gonnella F, Gonski JL, González de la Hoz S, Gonzalez Fernandez S, Gonzalez Lopez R, Gonzalez Renteria C, Gonzalez Suarez R, Gonzalez-Sevilla S, Gonzalvo Rodriguez GR, González Andana RY, Goossens L, Gorasia NA, Gorbounov PA, Gorini B, Gorini E, Gorišek A, Goshaw AT, Gostkin MI, Gottardo CA, Gouighri M, Goumarre V, Goussiou AG, Govender N, Goy C, Grabowska-Bold I, Graham K, Gramstad E, Grancagnolo S, Grandi M, Gratchev V, Gravila PM, Gravili FG, Gray HM, Grefe C, Gregor IM, Grenier P, Grevtsov K, Grieco C, Grillo AA, Grimm K, Grinstein S, Grivaz JF, Groh S, Gross E, Grosse-Knetter J, Grud C, Grummer A, Grundy JC, Guan L, Guan W, Gubbels C, Guerrero Rojas JGR, Guescini F, Gugel R, Guida A, Guillemin T, Guindon S, Guo F, Guo J, Guo L, Guo Y, Gupta R, Gurbuz S, Gustavino G, Guth M, Gutierrez P, Gutierrez Zagazeta LF, Gutschow C, Guyot C, Gwenlan C, Gwilliam CB, Haaland ES, Haas A, Habedank M, Haber C, Hadavand HK, Hadef A, Hadzic S, Haleem M, Haley J, Hall JJ, Hallewell GD, Halser L, Hamano K, Hamdaoui H, Hamer M, Hamity GN, Han J, Han K, Han L, Han L, Han S, Han YF, Hanagaki K, Hance M, Hangal DA, Hank MD, Hankache R, Hansen E, Hansen JB, Hansen JD, Hansen PH, Hara K, Harada D, Harenberg T, Harkusha S, Harris YT, Harrison PF, Hartman NM, Hartmann NM, Hasegawa Y, Hasib A, Haug S, Hauser R, Havranek M, Hawkes CM, Hawkings RJ, Hayashida S, Hayden D, Hayes C, Hayes RL, Hays CP, Hays JM, Hayward HS, He F, He Y, He Y, Heath MP, Hedberg V, Heggelund AL, Hehir ND, Heidegger C, Heidegger KK, Heidorn WD, Heilman J, Heim S, Heim T, Heinemann B, Heinlein JG, Heinrich JJ, Heinrich L, Hejbal J, Helary L, Held A, Hellesund S, Helling CM, Hellman S, Helsens C, Henderson RCW, Henkelmann L, Henriques Correia AM, Herde H, Hernández Jiménez Y, Herr H, Herrmann MG, Herrmann T, Herten G, Hertenberger R, Hervas L, Hessey NP, Hibi H, Higón-Rodriguez E, Hillier SJ, Hinchliffe I, Hinterkeuser F, Hirose M, Hirose S, Hirschbuehl D, Hiti B, Hladik O, Hobbs J, Hobincu R, Hod N, Hodgkinson MC, Hodkinson BH, Hoecker A, Hofer J, Hohn D, Holm T, Holzbock M, Hommels LBAH, Honan BP, Hong J, Hong TM, Hong Y, Honig JC, Hönle A, Hooberman BH, Hopkins WH, Horii Y, Horyn LA, Hou S, Howarth J, Hoya J, Hrabovsky M, Hrynevich A, Hryn'ova T, Hsu PJ, Hsu SC, Hu Q, Hu S, Hu YF, Huang DP, Huang X, Huang Y, Huang Y, Hubacek Z, Huebner M, Huegging F, Huffman TB, Huhtinen M, Huiberts SK, Hulsken R, Huseynov N, Huston J, Huth J, Hyneman R, Hyrych S, Iacobucci G, Iakovidis G, Ibragimov I, Iconomidou-Fayard L, Iengo P, Iguchi R, Iizawa T, Ikegami Y, Ilg A, Ilic N, Imam H, Ingebretsen Carlson T, Introzzi G, Iodice M, Ippolito V, Ishino M, Islam W, Issever C, Istin S, Ito H, Iturbe Ponce JM, Iuppa R, Ivina A, Izen JM, Izzo V, Jacka P, Jackson P, Jacobs RM, Jaeger BP, Jagfeld CS, Jäkel G, Jakobs K, Jakoubek T, Jamieson J, Janas KW, Jarlskog G, Jaspan AE, Javůrek T, Javurkova M, Jeanneau F, Jeanty L, Jejelava J, Jenni P, Jézéquel S, Jia J, Jia X, Jia Z, Jiang Y, Jiggins S, Jimenez Pena J, Jin S, Jinaru A, Jinnouchi O, Jivan H, Johansson P, Johns KA, Johnson CA, Jones DM, Jones E, Jones RWL, Jones TJ, Jovicevic J, Ju X, Junggeburth JJ, Juste Rozas A, Kabana S, Kaczmarska A, Kado M, Kagan H, Kagan M, Kahn A, Kahn A, Kahra C, Kaji T, Kajomovitz E, Kakati N, Kalderon CW, Kamenshchikov A, Kang NJ, Kano Y, Kar D, Karava K, Kareem MJ, Karentzos E, Karkanias I, Karpov SN, Karpova ZM, Kartvelishvili V, Karyukhin AN, Kasimi E, Kato C, Katzy J, Kaur S, Kawade K, Kawagoe K, Kawaguchi T, Kawamoto T, Kawamura G, Kay EF, Kaya FI, Kazakos S, Kazanin VF, Ke Y, Keaveney JM, Keeler R, Kehris GV, Keller JS, Kelly AS, Kelsey D, Kempster JJ, Kendrick J, Kennedy KE, Kepka O, Kersten S, Kerševan BP, Ketabchi Haghighat S, Khandoga M, Khanov A, Kharlamov AG, Kharlamova T, Khoda EE, Khoo TJ, Khoriauli G, Khubua J, Kiehn M, Kilgallon A, Kim E, Kim YK, Kimura N, Kirchhoff A, Kirchmeier D, Kirfel C, Kirk J, Kiryunin AE, Kishimoto T, Kisliuk DP, Kitsaki C, Kivernyk O, Klassen M, Klein C, Klein L, Klein MH, Klein M, Klein U, Klimek P, Klimentov A, Klimpel F, Klingl T, Klioutchnikova T, Klitzner FF, Kluit P, Kluth S, Kneringer E, Knight TM, Knue A, Kobayashi D, Kobayashi R, Kocian M, Kodama T, Kodyš P, Koeck DM, Koenig PT, Koffas T, Köhler NM, Kolb M, Koletsou I, Komarek T, Köneke K, Kong AXY, Kono T, Konstantinidis N, Konya B, Kopeliansky R, Koperny S, Korcyl K, Kordas K, Koren G, Korn A, Korn S, Korolkov I, Korotkova N, Kortman B, Kortner O, Kortner S, Kostecka WH, Kostyukhin VV, Kotsokechagia A, Kotwal A, Koulouris A, Kourkoumeli-Charalampidi A, Kourkoumelis C, Kourlitis E, Kovanda O, Kowalewski R, Kozanecki W, Kozhin AS, Kramarenko VA, Kramberger G, Kramer P, Krasny MW, Krasznahorkay A, Kremer JA, Kretzschmar J, Kreul K, Krieger P, Krieter F, Krishnamurthy S, Krishnan A, Krivos M, Krizka K, Kroeninger K, Kroha H, Kroll J, Kroll J, Krowpman KS, Kruchonak U, Krüger H, Krumnack N, Kruse MC, Krzysiak JA, Kubota A, Kuchinskaia O, Kuday S, Kuechler D, Kuechler JT, Kuehn S, Kuhl T, Kukhtin V, Kulchitsky Y, Kuleshov S, Kumar M, Kumari N, Kuna M, Kupco A, Kupfer T, Kuprash O, Kurashige H, Kurchaninov LL, Kurochkin YA, Kurova A, Kuwertz ES, Kuze M, Kvam AK, Kvita J, Kwan T, Kwok KW, Lacasta C, Lacava F, Lacker H, Lacour D, Lad NN, Ladygin E, Laforge B, Lagouri T, Lai S, Lakomiec IK, Lalloue N, Lambert JE, Lammers S, Lampl W, Lampoudis C, Lançon E, Landgraf U, Landon MPJ, Lang VS, Lange JC, Langenberg RJ, Lankford AJ, Lanni F, Lantzsch K, Lanza A, Lapertosa A, Laporte JF, Lari T, Lasagni Manghi F, Lassnig M, Latonova V, Lau TS, Laudrain A, Laurier A, Lavorgna M, Lawlor SD, Lawrence Z, Lazzaroni M, Le B, Leban B, Lebedev A, LeBlanc M, LeCompte T, Ledroit-Guillon F, Lee ACA, Lee GR, Lee L, Lee SC, Leeuw LL, Lefebvre B, Lefebvre HP, Lefebvre M, Leggett C, Lehmann K, Lehmann Miotto G, Leight WA, Leisos A, Leite MAL, Leitgeb CE, Leitner R, Leney KJC, Lenz T, Leone S, Leonidopoulos C, Leopold A, Leroy C, Les R, Lester CG, Levchenko M, Levêque J, Levin D, Levinson LJ, Lewis DJ, Li B, Li B, Li C, Li CQ, Li H, Li H, Li H, Li J, Li K, Li L, Li M, Li QY, Li S, Li T, Li X, Li Z, Li Z, Li Z, Li Z, Liang Z, Liberatore M, Liberti B, Lie K, Lieber Marin J, Lin K, Linck RA, Lindley RE, Lindon JH, Linss A, Lipeles E, Lipniacka A, Liss TM, Lister A, Little JD, Liu B, Liu BX, Liu D, Liu JB, Liu JKK, Liu K, Liu M, Liu MY, Liu P, Liu Q, Liu X, Liu Y, Liu Y, Liu YL, Liu YW, Livan M, Llorente Merino J, Lloyd SL, Lobodzinska EM, Loch P, Loffredo S, Lohse T, Lohwasser K, Lokajicek M, Long JD, Longarini I, Longo L, Longo R, Lopez Paz I, Lopez Solis A, Lorenz J, Lorenzo Martinez N, Lory AM, Lösle A, Lou X, Lou X, Lounis A, Love J, Love PA, Lozano Bahilo JJ, Lu G, Lu M, Lu S, Lu YJ, Lubatti HJ, Luci C, Lucio Alves FL, Lucotte A, Luehring F, Luise I, Lundberg O, Lund-Jensen B, Luongo NA, Lutz MS, Lynn D, Lyons H, Lysak R, Lytken E, Lyu F, Lyubushkin V, Lyubushkina T, Ma H, Ma LL, Ma Y, Mac Donell DM, Maccarrone G, MacDonald JC, Madar R, Mader WF, Maeda J, Maeno T, Maerker M, Magerl V, Magro J, Mahon DJ, Maidantchik C, Maio A, Maj K, Majersky O, Majewski S, Makovec N, Maksimovic V, Malaescu B, Malecki P, Maleev VP, Malek F, Malito D, Mallik U, Malone C, Maltezos S, Malyukov S, Mamuzic J, Mancini G, Mandalia JP, Mandić I, Manhaes de Andrade Filho L, Maniatis IM, Manisha M, Manjarres Ramos J, Mankad DC, Mankinen KH, Mann A, Manousos A, Mansoulie B, Manzoni S, Marantis A, Marchiori G, Marcisovsky M, Marcoccia L, Marcon C, Marinescu M, Marjanovic M, Marshall Z, Marti-Garcia S, Martin TA, Martin VJ, Martin Dit Latour B, Martinelli L, Martinez M, Martinez Agullo P, Martinez Outschoorn VI, Martinez Suarez P, Martin-Haugh S, Martoiu VS, Martyniuk AC, Marzin A, Maschek SR, Masetti L, Mashimo T, Masik J, Maslennikov AL, Massa L, Massarotti P, Mastrandrea P, Mastroberardino A, Masubuchi T, Mathisen T, Matic A, Matsuzawa N, Maurer J, Maček B, Maximov DA, Mazini R, Maznas I, Mazza M, Mazza SM, Mc Ginn C, Mc Gowan JP, Mc Kee SP, McCarthy TG, McCormack WP, McDonald EF, McDougall AE, Mcfayden JA, Mchedlidze G, McKay MA, Mckenzie RP, Mclaughlin DJ, McLean KD, McMahon SJ, McNamara PC, McPherson RA, Mdhluli JE, Meehan S, Megy T, Mehlhase S, Mehta A, Meirose B, Melini D, Mellado Garcia BR, Melo AH, Meloni F, Melzer A, Gouveia EDM, Mendes Jacques Da Costa AM, Meng HY, Meng L, Menke S, Mentink M, Meoni E, Merlassino C, Merola L, Meroni C, Merz G, Meshkov O, Meshreki JKR, Metcalfe J, Mete AS, Meyer C, Meyer JP, Michetti M, Middleton RP, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Mildner H, Milic A, Milke CD, Miller DW, Miller LS, Milov A, Milstead DA, Min T, Minaenko AA, Minashvili IA, Mince L, Mincer AI, Mindur B, Mineev M, Minegishi Y, Mino Y, Mir LM, Miralles Lopez M, Mironova M, Mitani T, Mitra A, Mitsou VA, Miu O, Miyagawa PS, Miyazaki Y, Mizukami A, Mjörnmark JU, Mkrtchyan T, Mlynarikova M, Moa T, Mobius S, Mochizuki K, Moder P, Mogg P, Mohammed AF, Mohapatra S, Mokgatitswane G, Mondal B, Mondal S, Mönig K, Monnier E, Monsonis Romero L, Montejo Berlingen J, Montella M, Monticelli F, Morange N, De Carvalho ALM, Moreno Llácer M, Moreno Martinez C, Morettini P, Morgenstern S, Mori D, Morii M, Morinaga M, Morisbak V, Morley AK, Morvaj L, Moschovakos P, Moser B, Mosidze M, Moskalets T, Moskvitina P, Moss J, Moyse EJW, Muanza S, Mueller J, Muenstermann D, Müller R, Mullier GA, Mullin JJ, Mungo DP, Munoz Martinez JL, Munoz Sanchez FJ, Murin M, Murray WJ, Murrone A, Muse JM, Muškinja M, Mwewa C, Myagkov AG, Myers AJ, Myers AA, Myers G, Myska M, Nachman BP, Nackenhorst O, Nag A, Nagai K, Nagano K, Nagle JL, Nagy E, Nairz AM, Nakahama Y, Nakamura K, Nanjo H, Narayan R, Narayanan EA, Naryshkin I, Naseri M, Nass C, Navarro G, Navarro-Gonzalez J, Nayak R, Nechaeva PY, Nechansky F, Neep TJ, Negri A, Negrini M, Nellist C, Nelson C, Nelson K, Nemecek S, Nessi M, Neubauer MS, Neuhaus F, Neundorf J, Newhouse R, Newman PR, Ng CW, Ng YS, Ng YWY, Ngair B, Nguyen HDN, Nickerson RB, Nicolaidou R, Nielsen DS, Nielsen J, Niemeyer M, Nikiforou N, Nikolaenko V, Nikolic-Audit I, Nikolopoulos K, Nilsson P, Nindhito HR, Nisati A, Nishu N, Nisius R, Noacco Rosende SJ, Nobe T, Noel DL, Noguchi Y, Nomidis I, Nomura MA, Norfolk MB, Norisam RRB, Novak J, Novak T, Novgorodova O, Novotny L, Novotny R, Nozka L, Ntekas K, Nurse E, Oakham FG, Ocariz J, Ochi A, Ochoa I, Ochoa-Ricoux JP, Oda S, Oerdek S, Ogrodnik A, Oh A, Ohm CC, Oide H, Oishi R, Ojeda ML, Okazaki Y, O'Keefe MW, Okumura Y, Olariu A, Seabra LFO, Olivares Pino SA, Oliveira Damazio D, Oliveira Goncalves D, Oliver JL, Olsson MJR, Olszewski A, Olszowska J, Öncel ÖO, O'Neil DC, O'Neill AP, Onofre A, Onyisi PUE, Oreamuno Madriz RG, Oreglia MJ, Orellana GE, Orestano D, Orlando N, Orr RS, O'Shea V, Ospanov R, Otero Y Garzon G, Otono H, Ott PS, Ottino GJ, Ouchrif M, Ouellette J, Ould-Saada F, Owen M, Owen RE, Oyulmaz KY, Ozcan VE, Ozturk N, Ozturk S, Pacalt J, Pacey HA, Pachal K, Pacheco Pages A, Padilla Aranda C, Pagan Griso S, Palacino G, Palazzo S, Palestini S, Palka M, Pan J, Panchal DK, Pandini CE, Panduro Vazquez JG, Pani P, Panizzo G, Paolozzi L, Papadatos C, Parajuli S, Paramonov A, Paraskevopoulos C, Paredes Hernandez D, Parida B, Park TH, Parker AJ, Parker MA, Parodi F, Parrish EW, Parrish VA, Parsons JA, Parzefall U, Pascual Dias B, Pascual Dominguez L, Pascuzzi VR, Pasquali F, Pasqualucci E, Passaggio S, Pastore F, Pasuwan P, Pater JR, Pathak A, Patton J, Pauly T, Pearkes J, Pedersen M, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penzin M, Peralva BS, Peixoto APP, Pereira Sanchez L, Perepelitsa DV, Perez Codina E, Perganti M, Perini L, Pernegger H, Perrella S, Perrevoort A, Perrin O, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petousis V, Petridou C, Petrukhin A, Pettee M, Pettersson NE, Petukhova K, Peyaud A, Pezoa R, Pezzotti L, Pezzullo G, Pham T, Phillips PW, Phipps MW, Piacquadio G, Pianori E, Piazza F, Piegaia R, Pietreanu D, Pilkington AD, Pinamonti M, Pinfold JL, Pitman Donaldson C, Pizzi DA, Pizzimento L, Pizzini A, Pleier MA, Plesanovs V, Pleskot V, Plotnikova E, Poddar G, Poettgen R, Poggi R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Polacek S, Polesello G, Poley A, Polifka R, Polini A, Pollard CS, Pollock ZB, Polychronakos V, Ponomarenko D, Pontecorvo L, Popa S, Popeneciu GA, Portillo Quintero DM, Pospisil S, Postolache P, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Pownall G, Pozo Astigarraga ME, Prades Ibanez A, Pralavorio P, Prapa MM, Price D, Primavera M, Principe Martin MA, Proffitt ML, Proklova N, Prokofiev K, Proto G, Protopopescu S, Proudfoot J, Przybycien M, Pudzha D, Puzo P, Pyatiizbyantseva D, Qian J, Qin Y, Qiu T, Quadt A, Queitsch-Maitland M, Rabanal Bolanos G, Rafanoharana D, Ragusa F, Raine JA, Rajagopalan S, Ran K, Raskina V, Rassloff DF, Rave S, Ravina B, Ravinovich I, Raymond M, Read AL, Readioff NP, Rebuzzi DM, Redlinger G, Reeves K, Reikher D, Reiss A, Rej A, Rembser C, Renardi A, Renda M, Rendel MB, Rennie AG, Resconi S, Ressegotti M, Resseguie ED, Rettie S, Reynolds B, Reynolds E, Rezaei Estabragh M, Rezanova OL, Reznicek P, Ricci E, Richter R, Richter S, Richter-Was E, Ridel M, Rieck P, Riedler P, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Rinn TT, Rinnagel MP, Ripellino G, Riu I, Rivadeneira P, Rivera Vergara JC, Rizatdinova F, Rizvi E, Rizzi C, Roberts BA, Roberts BR, Robertson SH, Robin M, Robinson D, Robles Gajardo CM, Robles Manzano M, Robson A, Rocchi A, Roda C, Rodriguez Bosca S, Rodriguez Garcia Y, Rodriguez Rodriguez A, Rodríguez Vera AM, Roe S, Roemer JT, Roepe-Gier AR, Roggel J, Røhne O, Rojas RA, Roland B, Roland CPA, Roloff J, Romaniouk A, Romano M, Romero Hernandez AC, Rompotis N, Ronzani M, Roos L, Rosati S, Rosser BJ, Rossi E, Rossi E, Rossi LP, Rossini L, Rosten R, Rotaru M, Rottler B, Rousseau D, Rousso D, Rovelli G, Roy A, Rozanov A, Rozen Y, Ruan X, Ruby AJ, Ruchayskiy O, Ruggeri TA, Rühr F, Ruiz-Martinez A, Rummler A, Rurikova Z, Rusakovich NA, Russell HL, Rustige L, Rutherfoord JP, Rüttinger EM, Rybacki K, Rybar M, Rye EB, Ryzhov A, Sabater Iglesias JA, Sabatini P, Sabetta L, Sadrozinski HFW, Safai Tehrani F, Safarzadeh Samani B, Safdari M, Saha S, Sahinsoy M, Sahu A, Saimpert M, Saito M, Saito T, Salamani D, Salamanna G, Salnikov A, Salt J, Salvador Salas A, Salvatore D, Salvatore F, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Pineda A, Sanchez Sebastian V, Sandaker H, Sander CO, Sanderswood IG, Sandesara JA, Sandhoff M, Sandoval C, Sankey DPC, Sansoni A, Santoni C, Santos H, Santpur SN, Santra A, Saoucha KA, Saraiva JG, Sardain J, Sasaki O, Sato K, Sauer C, Sauerburger F, Sauvan E, Savard P, Sawada R, Sawyer C, Sawyer L, Sayago Galvan I, Sbarra C, Sbrizzi A, Scanlon T, Schaarschmidt J, Schacht P, Schaefer D, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schanet E, Scharf C, Scharmberg N, Schegelsky VA, Scheirich D, Schenck F, Schernau M, Scheulen C, Schiavi C, Schillaci ZM, Schioppa EJ, Schioppa M, Schlag B, Schleicher KE, Schlenker S, Schmieden K, Schmitt C, Schmitt S, Schoeffel L, Schoening A, Scholer PG, Schopf E, Schott M, Schovancova J, Schramm S, Schroeder F, Schultz-Coulon HC, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scuri F, Scutti F, Sebastiani CD, Sedlaczek K, Seema P, Seidel SC, Seiden A, Seidlitz BD, Seiss T, Seitz C, Seixas JM, Sekhniaidze G, Sekula SJ, Selem L, Semprini-Cesari N, Sen S, Senthilkumar V, Serin L, Serkin L, Sessa M, Severini H, Sevova S, Sforza F, Sfyrla A, Shabalina E, Shaheen R, Shahinian JD, Shaikh NW, Shaked Renous D, Shan LY, Shapiro M, Sharma A, Sharma AS, Sharma S, Shatalov PB, Shaw K, Shaw SM, Sherwood P, Shi L, Shimmin CO, Shimogama Y, Shinner JD, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shochet MJ, Shojaii J, Shope DR, Shrestha S, Shrif EM, Shroff MJ, Sicho P, Sickles AM, Sideras Haddad E, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Sili F, Silva JM, Silva Oliveira MV, Silverstein SB, Simion S, Simoniello R, Simpson ND, Simsek S, Sindhu S, Sinervo P, Sinetckii V, Singh S, Singh S, Sinha S, Sinha S, Sioli M, Siral I, Sivoklokov SY, Sjölin J, Skaf A, Skorda E, Skubic P, Slawinska M, Smakhtin V, Smart BH, Smiesko J, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith EA, Smith HA, Smith R, Smizanska M, Smolek K, Smykiewicz A, Snesarev AA, Snoek HL, Snyder S, Sobie R, Soffer A, Solans Sanchez CA, Soldatov EY, Soldevila U, Solodkov AA, Solomon S, Soloshenko A, Solovieva K, Solovyanov OV, Solovyev V, Sommer P, Son H, Sonay A, Song WY, Sopczak A, Sopio AL, Sopkova F, Sothilingam V, Sottocornola S, Soualah R, Soumaimi Z, South D, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spigo G, Spina M, Spinali S, Spiteri DP, Spousta M, Staats EJ, Stabile A, Stamen R, Stamenkovic M, Stampekis A, Standke M, Stanecka E, Stanislaus B, Stanitzki MM, Stankaityte M, Stapf B, Starchenko EA, Stark GH, Stark J, Starko DM, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stavropoulos G, Steentoft J, Steinberg P, Steinhebel AL, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson TJ, Stewart GA, Stockton MC, Stoicea G, Stolarski M, Stonjek S, Straessner A, Strandberg J, Strandberg S, Strauss M, Strebler T, Strizenec P, Ströhmer R, Strom DM, Strom LR, Stroynowski R, Strubig A, Stucci SA, Stugu B, Stupak J, Styles NA, Su D, Su S, Su W, Su X, Sugizaki K, Sulin VV, Sullivan MJ, Sultan DMS, Sultanaliyeva L, Sultansoy S, Sumida T, Sun S, Sun S, Gudnadottir OS, Sutton MR, Svatos M, Swiatlowski M, Swirski T, Sykora I, Sykora M, Sykora T, Ta D, Tackmann K, Taffard A, Tafirout R, Taibah RHM, Takashima R, Takeda K, Takeva EP, Takubo Y, Talby M, Talyshev AA, Tam KC, Tamir NM, Tanaka A, Tanaka J, Tanaka R, Tang J, Tao Z, Tapia Araya S, Tapprogge S, Tarek Abouelfadl Mohamed A, Tarem S, Tariq K, Tarna G, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tastet JL, Tateno G, Tayalati Y, Taylor GN, Taylor W, Teagle H, Tee AS, Teixeira De Lima R, Teixeira-Dias P, Teoh JJ, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Themistokleous N, Theveneaux-Pelzer T, Thielmann O, Thomas DW, Thomas JP, Thompson EA, Thompson PD, Thomson E, Thorpe EJ, Tian Y, Tikhomirov V, Tikhonov YA, Timoshenko S, Ting EXL, Tipton P, Tisserant S, Tlou SH, Tnourji A, Todome K, Todorova-Nova S, Todt S, Togawa M, Tojo J, Tokár S, Tokushuku K, Tombs R, Tomoto M, Tompkins L, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toscani M, Tosciri C, Tovey DR, Traeet A, Trandafir IS, Treado CJ, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trischuk DA, Trocmé B, Trofymov A, Troncon C, Trovato F, Truong L, Trzebinski M, Trzupek A, Tsai F, Tsai M, Tsiamis A, Tsiareshka PV, Tsirigotis A, Tsiskaridze V, Tskhadadze EG, Tsopoulou M, Tsujikawa Y, Tsukerman II, Tsulaia V, Tsuno S, Tsur O, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tuna AN, Turchikhin S, Turk Cakir I, Turra R, Tuts PM, Tzamarias S, Tzanis P, Tzovara E, Uchida K, Ukegawa F, Ulloa Poblete PA, Unal G, Unal M, Undrus A, Unel G, Uno K, Urban J, Urquijo P, Usai G, Ushioda R, Usman M, Uysal Z, Vacek V, Vachon B, Vadla KOH, Vafeiadis T, Valderanis C, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Vallier A, Valls Ferrer JA, Van Daalen TR, Van Gemmeren P, Van Stroud S, Van Vulpen I, Vanadia M, Vandelli W, Vandenbroucke M, Vandewall ER, Vannicola D, Vannoli L, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Varvell KE, Vasile ME, Vaslin L, Vasquez GA, Vazeille F, Vazquez Furelos D, Vazquez Schroeder T, Veatch J, Vecchio V, Veen MJ, Veliscek I, Veloce LM, Veloso F, Veneziano S, Ventura A, Verbytskyi A, Verducci M, Vergis C, Verissimo De Araujo M, Verkerke W, Vermeulen JC, Vernieri C, Verschuuren PJ, Vessella M, Vesterbacka ML, Vetterli MC, Vgenopoulos A, Viaux Maira N, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Vigani L, Villa M, Villaplana Perez M, Villhauer EM, Vilucchi E, Vincter MG, Virdee GS, Vishwakarma A, Vittori C, Vivarelli I, Vladimirov V, Voevodina E, Vogel M, Vokac P, Von Ahnen J, Von Toerne E, Vormwald B, Vorobel V, Vorobev K, Vos M, Vossebeld JH, Vozak M, Vozdecky L, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vujinovic O, Vukotic I, Wada S, Wagner C, Wagner W, Wahdan S, Wahlberg H, Wakasa R, Wakida M, Walbrecht VM, Walder J, Walker R, Walkowiak W, Wang AM, Wang AZ, Wang C, Wang C, Wang H, Wang J, Wang P, Wang RJ, Wang R, Wang R, Wang SM, Wang S, Wang T, Wang WT, Wang WX, Wang X, Wang X, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Warburton A, Ward RJ, Warrack N, Watson AT, Watson MF, Watts G, Waugh BM, Webb AF, Weber C, Weber MS, Weber SA, Weber SM, Wei C, Wei Y, Weidberg AR, Weingarten J, Weirich M, Weiser C, Wenaus T, Wendland B, Wengler T, Wenke NS, Wermes N, Wessels M, Whalen K, Wharton AM, White AS, White A, White MJ, Whiteson D, Wickremasinghe L, Wiedenmann W, Wiel C, Wielers M, Wieseotte N, Wiglesworth C, Wiik-Fuchs LAM, Wilbern DJ, Wilkens HG, Williams DM, Williams HH, Williams S, Willocq S, Windischhofer PJ, Winklmeier F, Winter BT, Wittgen M, Wobisch M, Wolf A, Wölker R, Wollrath J, Wolter MW, Wolters H, Wong VWS, Wongel AF, Worm SD, Wosiek BK, Woźniak KW, Wraight K, Wu J, Wu SL, Wu X, Wu Y, Wu Z, Wuerzinger J, Wyatt TR, Wynne BM, Xella S, Xia L, Xia M, Xiang J, Xiao X, Xie M, Xie X, Xiotidis I, Xu D, Xu H, Xu H, Xu L, Xu R, Xu T, Xu W, Xu Y, Xu Z, Xu Z, Yabsley B, Yacoob S, Yamaguchi N, Yamaguchi Y, Yamauchi H, Yamazaki T, Yamazaki Y, Yan J, Yan S, Yan Z, Yang HJ, Yang HT, Yang S, Yang T, Yang X, Yang X, Yang Y, Yang Z, Yao WM, Yap YC, Ye H, Ye J, Ye S, Ye X, Yeletskikh I, Yexley MR, Yin P, Yorita K, Young CJS, Young C, Yuan M, Yuan R, Yue X, Zaazoua M, Zabinski B, Zacharis G, Zaid E, Zakareishvili T, Zakharchuk N, Zambito S, Zanzi D, Zaplatilek O, Zeißner SV, Zeitnitz C, Zeng JC, Zenger DT, Zenin O, Ženiš T, Zenz S, Zerradi S, Zerwas D, Zhang B, Zhang DF, Zhang G, Zhang J, Zhang K, Zhang L, Zhang M, Zhang R, Zhang S, Zhang X, Zhang X, Zhang Z, Zhao H, Zhao P, Zhao T, Zhao Y, Zhao Z, Zhemchugov A, Zheng Z, Zhong D, Zhou B, Zhou C, Zhou H, Zhou N, Zhou Y, Zhu CG, Zhu C, Zhu HL, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zhulanov V, Zieminska D, Zimine NI, Zimmermann S, Zinsser J, Ziolkowski M, Živković L, Zoccoli A, Zoch K, Zorbas TG, Zormpa O, Zou W, Zwalinski L. Search for Heavy Neutral Leptons in Decays of W Bosons Using a Dilepton Displaced Vertex in sqrt[s]=13 TeV pp Collisions with the ATLAS Detector. PHYSICAL REVIEW LETTERS 2023; 131:061803. [PMID: 37625051 DOI: 10.1103/physrevlett.131.061803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Accepted: 08/08/2022] [Indexed: 08/27/2023]
Abstract
A search for a long-lived, heavy neutral lepton (N) in 139 fb^{-1} of sqrt[s]=13 TeV pp collision data collected by the ATLAS detector at the Large Hadron Collider is reported. The N is produced via W→Nμ or W→Ne and decays into two charged leptons and a neutrino, forming a displaced vertex. The N mass is used to discriminate between signal and background. No signal is observed, and limits are set on the squared mixing parameters of the N with the left-handed neutrino states for the N mass range 3 GeV
Collapse
|
133
|
Aad G, Abbott B, Abbott DC, Abeling K, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Abusleme Hoffman AC, Acharya BS, Achkar B, Adam Bourdarios C, Adamczyk L, Adamek L, Addepalli SV, Adelman J, Adiguzel A, Adorni S, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra JA, Ahmad A, Ahmadov F, Ahmed WS, Ahuja S, Ai X, Aielli G, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi A, Alfonsi F, Alhroob M, Ali B, Ali S, Aliev M, Alimonti G, Alkakhi W, Allaire C, Allbrooke BMM, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alunno Camelia E, Alvarez Estevez M, Alviggi MG, Aly M, Amaral Coutinho Y, Ambler A, Amelung C, Amerl M, Ames CG, Amidei D, Amor Dos Santos SP, Amoroso S, Amos KR, Ananiev V, Anastopoulos C, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Antrim DJA, Anulli F, Aoki M, Aoki T, Aparisi Pozo JA, Aparo MA, Aperio Bella L, Appelt C, Aranzabal N, Araujo Ferraz V, Arcangeletti C, Arce ATH, Arena E, Arguin JF, Argyropoulos S, Arling JH, Armbruster AJ, Arnaez O, Arnold H, Arrubarrena Tame ZP, Artoni G, Asada H, Asai K, Asai S, Asbah NA, Assahsah J, Assamagan K, Astalos R, Atkin RJ, Atkinson M, Atlay NB, Atmani H, Atmasiddha PA, Augsten K, Auricchio S, Auriol AD, Austrup VA, Avner G, Avolio G, Axiotis K, Ayoub MK, Azuelos G, Babal D, Bachacou H, Bachas K, Bachiu A, Backman F, Badea A, Bagnaia P, Bahmani M, Bailey AJ, Bailey VR, Baines JT, Bakalis C, Baker OK, Bakker PJ, Bakos E, Bakshi Gupta D, Balaji S, Balasubramanian R, Baldin EM, Balek P, Ballabene E, Balli F, Baltes LM, Balunas WK, Balz J, Banas E, Bandieramonte M, Bandyopadhyay A, Bansal S, Barak L, Barberio EL, Barberis D, Barbero M, Barbour G, Barends KN, Barillari T, Barisits MS, Barklow T, Barnett RM, Baron P, Baron Moreno DA, Baroncelli A, Barone G, Barr AJ, Barranco Navarro L, Barreiro F, Barreiro Guimarães da Costa J, Barron U, Barros Teixeira MG, Barsov S, Bartels F, Bartoldus R, Barton AE, Bartos P, Basalaev A, Basan A, Baselga M, Bashta I, Bassalat A, Basso MJ, Basson CR, Bates RL, Batlamous S, Batley JR, Batool B, Battaglia M, Battulga D, Bauce M, Bauer P, Bayirli A, Beacham JB, Beau T, Beauchemin PH, Becherer F, Bechtle P, Beck HP, Becker K, Beddall AJ, Bednyakov VA, Bee CP, Beemster LJ, Beermann TA, Begalli M, Begel M, Behera A, Behr JK, Beirao Da Cruz E Silva C, Beirer JF, Beisiegel F, Belfkir M, Bella G, Bellagamba L, Bellerive A, Bellos P, Beloborodov K, Belotskiy K, Belyaev NL, Benchekroun D, Bendebba F, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Bentvelsen S, Beresford L, Beretta M, Berge D, Bergeaas Kuutmann E, Berger N, Bergmann B, Beringer J, Berlendis S, Bernardi G, Bernius C, Bernlochner FU, Berry T, Berta P, Berthold A, Bertram IA, Bethke S, Betti A, Bevan AJ, Bhamjee M, Bhatta S, Bhattacharya DS, Bhattarai P, Bhopatkar VS, Bi R, Bianchi RM, Biebel O, Bielski R, Biglietti M, Billoud TRV, Bindi M, Bingul A, Bini C, Biondi S, Biondini A, Birch-Sykes CJ, Bird GA, Birman M, Bisanz T, Bisceglie E, Biswas D, Bitadze A, Bjørke K, Bloch I, Blocker C, Blue A, Blumenschein U, Blumenthal J, Bobbink GJ, Bobrovnikov VS, Boehler M, Bogavac D, Bogdanchikov AG, Bohm C, Boisvert V, Bokan P, Bold T, Bomben M, Bona M, Boonekamp M, Booth CD, Borbély AG, Borecka-Bielska HM, Borgna LS, Borissov G, Bortoletto D, Boscherini D, Bosman M, Bossio Sola JD, Bouaouda K, Bouchhar N, Boudreau J, Bouhova-Thacker EV, Boumediene D, Bouquet R, Boveia A, Boyd J, Boye D, Boyko IR, Bracinik J, Brahimi N, Brandt G, Brandt O, Braren F, Brau B, Brau JE, Brendlinger K, Brener R, Brenner L, Brenner R, Bressler S, Brickwedde B, Britton D, Britzger D, Brock I, Brooijmans G, Brooks WK, Brost E, Bruckler TL, Bruckman de Renstrom PA, Brüers B, Bruncko D, Bruni A, Bruni G, Bruschi M, Bruscino N, Bryngemark L, Buanes T, Buat Q, Buchholz P, Buckley AG, Budagov IA, Bugge MK, Bulekov O, Bullard BA, Burdin S, Burgard CD, Burger AM, Burghgrave B, Burr JTP, Burton CD, Burzynski JC, Busch EL, Büscher V, Bussey PJ, Butler JM, Buttar CM, Butterworth JM, Buttinger W, Buxo Vazquez CJ, Buzykaev AR, Cabras G, Cabrera Urbán S, Caforio D, Cai H, Cai Y, Cairo VMM, Cakir O, Calace N, Calafiura P, Calderini G, Calfayan P, Callea G, Caloba LP, Calvet D, Calvet S, Calvet TP, Calvetti M, Camacho Toro R, Camarda S, Camarero Munoz D, Camarri P, Camerlingo MT, Cameron D, Camincher C, Campanelli M, Camplani A, Canale V, Canesse A, Cano Bret M, Cantero J, Cao Y, Capocasa F, Capua M, Carbone A, Cardarelli R, Cardenas JCJ, Cardillo F, Carli T, Carlino G, Carlotto JI, Carlson BT, Carlson EM, Carminati L, Carnesale M, Caron S, Carquin E, Carrá S, Carratta G, Carrio Argos F, Carter JWS, Carter TM, Casado MP, Casha AF, Castiglia EG, Castillo FL, Castillo Garcia L, Castillo Gimenez V, Castro NF, Catinaccio A, Catmore JR, Cavaliere V, Cavalli N, Cavasinni V, Celebi E, Celli F, Centonze MS, Cerny K, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cervelli A, Cetin SA, Chadi Z, Chakraborty D, Chala M, Chan J, Chan WY, Chapman JD, Chargeishvili B, Charlton DG, Charman TP, Chatterjee M, Chekanov S, Chekulaev SV, Chelkov GA, Chen A, Chen B, Chen B, Chen C, Chen H, Chen H, Chen J, Chen J, Chen S, Chen SJ, Chen X, Chen X, Chen Y, Cheng CL, Cheng HC, Cheong S, Cheplakov A, Cheremushkina E, Cherepanova E, Cherkaoui El Moursli R, Cheu E, Cheung K, Chevalier L, Chiarella V, Chiarelli G, Chiedde N, Chiodini G, Chisholm AS, Chitan A, Chitishvili M, Chiu YH, Chizhov MV, Choi K, Chomont AR, Chou Y, Chow EYS, Chowdhury T, Christopher LD, Chu KL, Chu MC, Chu X, Chudoba J, Chwastowski JJ, Cieri D, Ciesla KM, Cindro V, Ciocio A, Cirotto F, Citron ZH, Citterio M, Ciubotaru DA, Ciungu BM, Clark A, Clark PJ, Clavijo Columbie JM, Clawson SE, Clement C, Clercx J, Clissa L, Coadou Y, Cobal M, Coccaro A, Barrue RFC, Coelho Lopes De Sa R, Coelli S, Cohen H, Coimbra AEC, Cole B, Collot J, Conde Muiño P, Connell MP, Connell SH, Connelly IA, Conroy EI, Conventi F, Cooke HG, Cooper-Sarkar AM, Cormier F, Corpe LD, Corradi M, Corrigan EE, Corriveau F, Cortes-Gonzalez A, Costa MJ, Costanza F, Costanzo D, Cote BM, Cowan G, Cowley JW, Cranmer K, Crépé-Renaudin S, Crescioli F, Cristinziani M, Cristoforetti M, Croft V, Crosetti G, Cueto A, Cuhadar Donszelmann T, Cui H, Cui Z, Cukierman AR, Cunningham WR, Curcio F, Czodrowski P, Czurylo MM, De Sousa MJDCS, Da Fonseca Pinto JV, Da Via C, Dabrowski W, Dado T, Dahbi S, Dai T, Dallapiccola C, Dam M, D'amen G, D'Amico V, Damp J, Dandoy JR, Daneri MF, Danninger M, Dao V, Darbo G, Darmora S, Das SJ, D'Auria S, David C, Davidek T, Davis DR, Davis-Purcell B, Dawson I, De K, De Asmundis R, De Beurs M, De Biase N, De Castro S, De Groot N, de Jong P, De la Torre H, De Maria A, De Salvo A, De Sanctis U, De Santo A, De Vivie De Regie JB, Dedovich DV, Degens J, Deiana AM, Del Corso F, Del Peso J, Del Rio F, Deliot F, Delitzsch CM, Della Pietra M, Della Volpe D, Dell'Acqua A, Dell'Asta L, Delmastro M, Delsart PA, Demers S, Demichev M, Denisov SP, D'Eramo L, Derendarz D, Derue F, Dervan P, Desch K, Dette K, Deutsch C, Deviveiros PO, Di Bello FA, Di Ciaccio A, Di Ciaccio L, Di Domenico A, Di Donato C, Di Girolamo A, Di Gregorio G, Di Luca A, Di Micco B, Di Nardo R, Diaconu C, Dias FA, Vale TDD, Diaz MA, Diaz Capriles FG, Didenko M, Diehl EB, Diehl L, Díez Cornell S, Diez Pardos C, Dimitriadi C, Dimitrievska A, Ding W, Dingfelder J, Dinu IM, Dittmeier SJ, Dittus F, Djama F, Djobava T, Djuvsland JI, Doglioni C, Dolejsi J, Dolezal Z, Donadelli M, Dong B, Donini J, D'Onofrio A, D'Onofrio M, Dopke J, Doria A, Dova MT, Doyle AT, Draguet MA, Drechsler E, Dreyer E, Drivas-Koulouris I, Drobac AS, Drozdova M, Du D, du Pree TA, Dubinin F, Dubovsky M, Duchovni E, Duckeck G, Ducu OA, Duda D, Dudarev A, D'uffizi M, Duflot L, Dührssen M, Dülsen C, Dumitriu AE, Dunford M, Dungs S, Dunne K, Duperrin A, Yildiz HD, Düren M, Durglishvili A, Dwyer BL, Dyckes GI, Dyndal M, Dysch S, Dziedzic BS, Earnshaw ZO, Eckerova B, Eggleston MG, Purcino De Souza EE, Ehrke LF, Eigen G, Einsweiler K, Ekelof T, Ekman PA, El Ghazali Y, El Jarrari H, El Moussaouy A, Ellajosyula V, Ellert M, Ellinghaus F, Elliot AA, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Emerman A, Enari Y, Ene I, Epari S, Erdmann J, Ereditato A, Erland PA, Errenst M, Escalier M, Escobar C, Etzion E, Evans G, Evans H, Evans MO, Ezhilov A, Ezzarqtouni S, Fabbri F, Fabbri L, Facini G, Fadeyev V, Fakhrutdinov RM, Falciano S, Falke PJ, Falke S, Faltova J, Fan Y, Fang Y, Fanourakis G, Fanti M, Faraj M, Farbin A, Farilla A, Farooque T, Farrington SM, Fassi F, Fassouliotis D, Faucci Giannelli M, Fawcett WJ, Fayard L, Federicova P, Fedin OL, Fedotov G, Feickert M, Feligioni L, Fell A, Fellers DE, Feng C, Feng M, Feng Z, Fenton MJ, Fenyuk AB, Ferencz L, Ferguson SW, Pretel J, Ferrando J, Ferrari A, Ferrari P, Ferrari R, Ferrere D, Ferretti C, Fiedler F, Filipčič A, Filmer EK, Filthaut F, Fiolhais MCN, Fiorini L, Fischer F, Fisher WC, Fitschen T, Fleck I, Fleischmann P, Flick T, Flores L, Flores M, Flores Castillo LR, Follega FM, Fomin N, Foo JH, Forland BC, Formica A, Forti AC, Fortin E, Fortman AW, Foti MG, Fountas L, Fournier D, Fox H, Francavilla P, Francescato S, Franchini M, Franchino S, Francis D, Franco L, Franconi L, Franklin M, Frattari G, Freegard AC, Freeman PM, Freund WS, Fritzsche N, Froch A, Froidevaux D, Frost JA, Fu Y, Fujimoto M, Fullana Torregrosa E, Fuster J, Gabrielli A, Gabrielli A, Gadow P, Gagliardi G, Gagnon LG, Gallardo GE, Gallas EJ, Gallop BJ, Gamboa Goni R, Gan KK, Ganguly S, Gao J, Gao Y, Garay Walls FM, Garcia B, García C, García Navarro JE, García Pascual JA, Garcia-Sciveres M, Gardner RW, Garg D, Garg RB, Gargiulo S, Garner CA, Garonne V, Gasiorowski SJ, Gaspar P, Gaudio G, Gautam V, Gauzzi P, Gavrilenko IL, Gavrilyuk A, Gay C, Gaycken G, Gazis EN, Geanta AA, Gee CM, Geisen J, Geisen M, Gemme C, Genest MH, Gentile S, George S, George WF, Geralis T, Gerlach LO, Gessinger-Befurt P, Ghasemi Bostanabad M, Ghneimat M, Ghorbanian K, Ghosal A, Ghosh A, Ghosh A, Giacobbe B, Giagu S, Giangiacomi N, Giannetti P, Giannini A, Gibson SM, Gignac M, Gil DT, Gilbert AK, Gilbert BJ, Gillberg D, Gilles G, Gillwald NEK, Ginabat L, Gingrich DM, Giordani MP, Giraud PF, Giugliarelli G, Giugni D, Giuli F, Gkialas I, Gladilin LK, Glasman C, Gledhill GR, Glisic M, Gnesi I, Go Y, Goblirsch-Kolb M, Gocke B, Godin D, Goldfarb S, Golling T, Gololo MGD, Golubkov D, Gombas JP, Gomes A, Gomes Da Silva G, Gomez Delegido AJ, Goncalves Gama R, Gonçalo R, Gonella G, Gonella L, Gongadze A, Gonnella F, Gonski JL, González de la Hoz S, Gonzalez Fernandez S, Gonzalez Lopez R, Gonzalez Renteria C, Gonzalez Suarez R, Gonzalez-Sevilla S, Gonzalvo Rodriguez GR, González Andana RY, Goossens L, Gorasia NA, Gorbounov PA, Gorini B, Gorini E, Gorišek A, Goshaw AT, Gostkin MI, Gottardo CA, Gouighri M, Goumarre V, Goussiou AG, Govender N, Goy C, Grabowska-Bold I, Graham K, Gramstad E, Grancagnolo S, Grandi M, Gratchev V, Gravila PM, Gravili FG, Gray HM, Greco M, Grefe C, Gregor IM, Grenier P, Grieco C, Grillo AA, Grimm K, Grinstein S, Grivaz JF, Gross E, Grosse-Knetter J, Grud C, Grummer A, Grundy JC, Guan L, Guan W, Gubbels C, Guerrero Rojas JGR, Guerrieri G, Guescini F, Gugel R, Guhit JAM, Guida A, Guillemin T, Guilloton E, Guindon S, Guo F, Guo J, Guo L, Guo Y, Gupta R, Gurbuz S, Gurdasani SS, Gustavino G, Guth M, Gutierrez P, Gutierrez Zagazeta LF, Gutschow C, Guyot C, Gwenlan C, Gwilliam CB, Haaland ES, Haas A, Habedank M, Haber C, Hadavand HK, Hadef A, Hadzic S, Haines EH, Haleem M, Haley J, Hall JJ, Hallewell GD, Halser L, Hamano K, Hamdaoui H, Hamer M, Hamity GN, Han J, Han K, Han L, Han L, Han S, Han YF, Hanagaki K, Hance M, Hangal DA, Hanif H, Hank MD, Hankache R, Hansen JB, Hansen JD, Hansen PH, Hara K, Harada D, Harenberg T, Harkusha S, Harris YT, Harrison NM, Harrison PF, Hartman NM, Hartmann NM, Hasegawa Y, Hasib A, Haug S, Hauser R, Havranek M, Hawkes CM, Hawkings RJ, Hayashida S, Hayden D, Hayes C, Hayes RL, Hays CP, Hays JM, Hayward HS, He F, He Y, He Y, Heath MP, Hedberg V, Heggelund AL, Hehir ND, Heidegger C, Heidegger KK, Heidorn WD, Heilman J, Heim S, Heim T, Heinlein JG, Heinrich JJ, Heinrich L, Hejbal J, Helary L, Held A, Hellesund S, Helling CM, Hellman S, Helsens C, Henderson RCW, Henkelmann L, Henriques Correia AM, Herde H, Hernández Jiménez Y, Herrmann MG, Herrmann T, Herten G, Hertenberger R, Hervas L, Hessey NP, Hibi H, Higón-Rodriguez E, Hillier SJ, Hinchliffe I, Hinterkeuser F, Hirose M, Hirose S, Hirschbuehl D, Hitchings TG, Hiti B, Hobbs J, Hobincu R, Hod N, Hodgkinson MC, Hodkinson BH, Hoecker A, Hofer J, Hohn D, Holm T, Holzbock M, Hommels LBAH, Honan BP, Hong J, Hong TM, Hong Y, Honig JC, Hönle A, Hooberman BH, Hopkins WH, Horii Y, Hou S, Howard AS, Howarth J, Hoya J, Hrabovsky M, Hrynevich A, Hryn'ova T, Hsu PJ, Hsu SC, Hu Q, Hu YF, Huang DP, Huang S, Huang X, Huang Y, Huang Y, Huang Z, Hubacek Z, Huebner M, Huegging F, Huffman TB, Huhtinen M, Huiberts SK, Hulsken R, Huseynov N, Huston J, Huth J, Hyneman R, Hyrych S, Iacobucci G, Iakovidis G, Ibragimov I, Iconomidou-Fayard L, Iengo P, Iguchi R, Iizawa T, Ikegami Y, Ilg A, Ilic N, Imam H, Ingebretsen Carlson T, Introzzi G, Iodice M, Ippolito V, Ishino M, Islam W, Issever C, Istin S, Ito H, Iturbe Ponce JM, Iuppa R, Ivina A, Izen JM, Izzo V, Jacka P, Jackson P, Jacobs RM, Jaeger BP, Jagfeld CS, Jäkel G, Jakobs K, Jakoubek T, Jamieson J, Janas KW, Jarlskog G, Jaspan AE, Javurkova M, Jeanneau F, Jeanty L, Jejelava J, Jenni P, Jessiman CE, Jézéquel S, Jia J, Jia X, Jia X, Jia Z, Jiang Y, Jiggins S, Jimenez Pena J, Jin S, Jinaru A, Jinnouchi O, Johansson P, Johns KA, Jones DM, Jones E, Jones P, Jones RWL, Jones TJ, Joshi R, Jovicevic J, Ju X, Junggeburth JJ, Juste Rozas A, Kabana S, Kaczmarska A, Kado M, Kagan H, Kagan M, Kahn A, Kahn A, Kahra C, Kaji T, Kajomovitz E, Kakati N, Kalderon CW, Kamenshchikov A, Kanayama S, Kang NJ, Kano Y, Kar D, Karava K, Kareem MJ, Karentzos E, Karkanias I, Karpov SN, Karpova ZM, Kartvelishvili V, Karyukhin AN, Kasimi E, Kato C, Katzy J, Kaur S, Kawade K, Kawagoe K, Kawamoto T, Kawamura G, Kay EF, Kaya FI, Kazakos S, Kazanin VF, Ke Y, Keaveney JM, Keeler R, Kehris GV, Keller JS, Kelly AS, Kelsey D, Kempster JJ, Kennedy KE, Kennedy PD, Kepka O, Kerridge BP, Kersten S, Kerševan BP, Keshri S, Keszeghova L, Ketabchi Haghighat S, Khandoga M, Khanov A, Kharlamov AG, Kharlamova T, Khoda EE, Khoo TJ, Khoriauli G, Khubua J, Khwaira YAR, Kiehn M, Kilgallon A, Kim DW, Kim E, Kim YK, Kimura N, Kirchhoff A, Kirchmeier D, Kirfel C, Kirk J, Kiryunin AE, Kishimoto T, Kisliuk DP, Kitsaki C, Kivernyk O, Klassen M, Klein C, Klein L, Klein MH, Klein M, Klein SB, Klein U, Klimek P, Klimentov A, Klimpel F, Klingl T, Klioutchnikova T, Klitzner FF, Kluit P, Kluth S, Kneringer E, Knight TM, Knue A, Kobayashi D, Kobayashi R, Kocian M, Kodyš P, Koeck DM, Koenig PT, Koffas T, Köhler NM, Kolb M, Koletsou I, Komarek T, Köneke K, Kong AXY, Kono T, Konstantinidis N, Konya B, Kopeliansky R, Koperny S, Korcyl K, Kordas K, Koren G, Korn A, Korn S, Korolkov I, Korotkova N, Kortman B, Kortner O, Kortner S, Kostecka WH, Kostyukhin VV, Kotsokechagia A, Kotwal A, Koulouris A, Kourkoumeli-Charalampidi A, Kourkoumelis C, Kourlitis E, Kovanda O, Kowalewski R, Kozanecki W, Kozhin AS, Kramarenko VA, Kramberger G, Kramer P, Krasny MW, Krasznahorkay A, Kremer JA, Kresse T, Kretzschmar J, Kreul K, Krieger P, Krieter F, Krishnamurthy S, Krishnan A, Krivos M, Krizka K, Kroeninger K, Kroha H, Kroll J, Kroll J, Krowpman KS, Kruchonak U, Krüger H, Krumnack N, Kruse MC, Krzysiak JA, Kubota A, Kuchinskaia O, Kuday S, Kuechler D, Kuechler JT, Kuehn S, Kuhl T, Kukhtin V, Kulchitsky Y, Kuleshov S, Kumar M, Kumari N, Kupco A, Kupfer T, Kupich A, Kuprash O, Kurashige H, Kurchaninov LL, Kurochkin YA, Kurova A, Kuze M, Kvam AK, Kvita J, Kwan T, Kwok KW, Kyriacou NG, Laatu LAO, Lacasta C, Lacava F, Lacker H, Lacour D, Lad NN, Ladygin E, Laforge B, Lagouri T, Lai S, Lakomiec IK, Lalloue N, Lambert JE, Lammers S, Lampl W, Lampoudis C, Lancaster AN, Lançon E, Landgraf U, Landon MPJ, Lang VS, Langenberg RJ, Lankford AJ, Lanni F, Lantzsch K, Lanza A, Lapertosa A, Laporte JF, Lari T, Lasagni Manghi F, Lassnig M, Latonova V, Lau TS, Laudrain A, Laurier A, Lawlor SD, Lawrence Z, Lazzaroni M, Le B, Leban B, Lebedev A, LeBlanc M, LeCompte T, Ledroit-Guillon F, Lee ACA, Lee GR, Lee L, Lee SC, Lee S, Lee TF, Leeuw LL, Lefebvre HP, Lefebvre M, Leggett C, Lehmann K, Lehmann Miotto G, Leigh M, Leight WA, Leisos A, Leite MAL, Leitgeb CE, Leitner R, Leney KJC, Lenz T, Leone S, Leonidopoulos C, Leopold A, Leroy C, Les R, Lester CG, Levchenko M, Levêque J, Levin D, Levinson LJ, Lewicki MP, Lewis DJ, Li A, Li B, Li B, Li C, Li CQ, Li H, Li H, Li H, Li H, Li J, Li K, Li L, Li M, Li QY, Li S, Li T, Li X, Li Z, Li Z, Li Z, Li Z, Li Z, Liang Z, Liberatore M, Liberti B, Lie K, Lieber Marin J, Lin K, Linck RA, Lindley RE, Lindon JH, Linss A, Lipeles E, Lipniacka A, Lister A, Little JD, Liu B, Liu BX, Liu D, Liu JB, Liu JKK, Liu K, Liu M, Liu MY, Liu P, Liu Q, Liu X, Liu Y, Liu Y, Liu YL, Liu YW, Livan M, Llorente Merino J, Lloyd SL, Lobodzinska EM, Loch P, Loffredo S, Lohse T, Lohwasser K, Lokajicek M, Long JD, Longarini I, Longo L, Longo R, Lopez Paz I, Lopez Solis A, Lorenz J, Lorenzo Martinez N, Lory AM, Lösle A, Lou X, Lou X, Lounis A, Love J, Love PA, Lozano Bahilo JJ, Lu G, Lu M, Lu S, Lu YJ, Lubatti HJ, Luci C, Lucio Alves FL, Lucotte A, Luehring F, Luise I, Lukianchuk O, Lundberg O, Lund-Jensen B, Luongo NA, Lutz MS, Lynn D, Lyons H, Lysak R, Lytken E, Lyu F, Lyubushkin V, Lyubushkina T, Ma H, Ma LL, Ma Y, Mac Donell DM, Maccarrone G, MacDonald JC, Madar R, Mader WF, Maeda J, Maeno T, Maerker M, Magerl V, Magro J, Maguire H, Mahon DJ, Maidantchik C, Maio A, Maj K, Majersky O, Majewski S, Makovec N, Maksimovic V, Malaescu B, Malecki P, Maleev VP, Malek F, Malito D, Mallik U, Malone C, Maltezos S, Malyukov S, Mamuzic J, Mancini G, Manco G, Mandalia JP, Mandić I, Manhaes de Andrade Filho L, Maniatis IM, Manisha M, Manjarres Ramos J, Mankad DC, Mann A, Mansoulie B, Manzoni S, Marantis A, Marchiori G, Marcisovsky M, Marcoccia L, Marcon C, Marinescu M, Marjanovic M, Marshall Z, Marti-Garcia S, Martin TA, Martin VJ, Martin Dit Latour B, Martinelli L, Martinez M, Martinez Agullo P, Martinez Outschoorn VI, Martinez Suarez P, Martin-Haugh S, Martoiu VS, Martyniuk AC, Marzin A, Maschek SR, Masetti L, Mashimo T, Masik J, Maslennikov AL, Massa L, Massarotti P, Mastrandrea P, Mastroberardino A, Masubuchi T, Mathisen T, Matsuzawa N, Maurer J, Maček B, Maximov DA, Mazini R, Maznas I, Mazza M, Mazza SM, Mc Ginn C, Mc Gowan JP, Mc Kee SP, McCormack WP, McDonald EF, McDougall AE, Mcfayden JA, Mchedlidze G, Mckenzie RP, Mclachlan TC, Mclaughlin DJ, McLean KD, McMahon SJ, McNamara PC, Mcpartland CM, McPherson RA, Megy T, Mehlhase S, Mehta A, Meirose B, Melini D, Mellado Garcia BR, Melo AH, Meloni F, Gouveia EDM, Mendes Jacques Da Costa AM, Meng HY, Meng L, Menke S, Mentink M, Meoni E, Merlassino C, Merola L, Meroni C, Merz G, Meshkov O, Meshreki JKR, Metcalfe J, Mete AS, Meyer C, Meyer JP, Michetti M, Middleton RP, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Mildner H, Milic A, Milke CD, Miller DW, Miller LS, Milov A, Milstead DA, Min T, Minaenko AA, Minashvili IA, Mince L, Mincer AI, Mindur B, Mineev M, Mino Y, Mir LM, Miralles Lopez M, Mironova M, Missio MC, Mitani T, Mitra A, Mitsou VA, Miu O, Miyagawa PS, Miyazaki Y, Mizukami A, Mjörnmark JU, Mkrtchyan T, Mlinarevic T, Mlynarikova M, Moa T, Mobius S, Mochizuki K, Moder P, Mogg P, Mohammed AF, Mohapatra S, Mokgatitswane G, Mondal B, Mondal S, Mönig K, Monnier E, Monsonis Romero L, Montejo Berlingen J, Montella M, Monticelli F, Morange N, De Carvalho ALM, Moreno Llácer M, Moreno Martinez C, Morettini P, Morgenstern S, Morii M, Morinaga M, Morisbak V, Morley AK, Morodei F, Morvaj L, Moschovakos P, Moser B, Mosidze M, Moskalets T, Moskvitina P, Moss J, Moyse EJW, Muanza S, Mueller J, Muenstermann D, Müller R, Mullier GA, Mullin JJ, Mungo DP, Munoz Martinez JL, Munoz Perez D, Munoz Sanchez FJ, Murin M, Murray WJ, Murrone A, Muse JM, Muškinja M, Mwewa C, Myagkov AG, Myers AJ, Myers AA, Myers G, Myska M, Nachman BP, Nackenhorst O, Nag A, Nagai K, Nagano K, Nagle JL, Nagy E, Nairz AM, Nakahama Y, Nakamura K, Nanjo H, Narayan R, Narayanan EA, Naryshkin I, Naseri M, Nass C, Navarro G, Navarro-Gonzalez J, Nayak R, Nayaz A, Nechaeva PY, Nechansky F, Nedic L, Neep TJ, Negri A, Negrini M, Nellist C, Nelson C, Nelson K, Nemecek S, Nessi M, Neubauer MS, Neuhaus F, Neundorf J, Newhouse R, Newman PR, Ng CW, Ng YS, Ng YWY, Ngair B, Nguyen HDN, Nickerson RB, Nicolaidou R, Nielsen J, Niemeyer M, Nikiforou N, Nikolaenko V, Nikolic-Audit I, Nikolopoulos K, Nilsson P, Nindhito HR, Nisati A, Nishu N, Nisius R, Nitschke JE, Nkadimeng EK, Noacco Rosende SJ, Nobe T, Noel DL, Noguchi Y, Nommensen T, Nomura MA, Norfolk MB, Norisam RRB, Norman BJ, Novak J, Novak T, Novgorodova O, Novotny L, Novotny R, Nozka L, Ntekas K, Nunes De Moura Junior NMJ, Nurse E, Oakham FG, Ocariz J, Ochi A, Ochoa I, Oerdek S, Ogrodnik A, Oh A, Ohm CC, Oide H, Oishi R, Ojeda ML, Okazaki Y, O'Keefe MW, Okumura Y, Olariu A, Seabra LFO, Olivares Pino SA, Oliveira Damazio D, Oliveira Goncalves D, Oliver JL, Olsson MJR, Olszewski A, Olszowska J, Öncel ÖO, O'Neil DC, O'Neill AP, Onofre A, Onyisi PUE, Oreglia MJ, Orellana GE, Orestano D, Orlando N, Orr RS, O'Shea V, Ospanov R, Otero Y Garzon G, Otono H, Ott PS, Ottino GJ, Ouchrif M, Ouellette J, Ould-Saada F, Owen M, Owen RE, Oyulmaz KY, Ozcan VE, Ozturk N, Ozturk S, Pacalt J, Pacey HA, Pachal K, Pacheco Pages A, Padilla Aranda C, Padovano G, Pagan Griso S, Palacino G, Palazzo A, Palazzo S, Palestini S, Palka M, Pan J, Pan T, Panchal DK, Pandini CE, Panduro Vazquez JG, Pang H, Pani P, Panizzo G, Paolozzi L, Papadatos C, Parajuli S, Paramonov A, Paraskevopoulos C, Paredes Hernandez D, Park TH, Parker MA, Parodi F, Parrish EW, Parrish VA, Parsons JA, Parzefall U, Pascual Dias B, Pascual Dominguez L, Pascuzzi VR, Pasquali F, Pasqualucci E, Passaggio S, Pastore F, Pasuwan P, Patel P, Pater JR, Patton J, Pauly T, Pearkes J, Pedersen M, Pedro R, Peleganchuk SV, Penc O, Pender EA, Peng C, Peng H, Penski KE, Penzin M, Peralva BS, Peixoto APP, Pereira Sanchez L, Perepelitsa DV, Perez Codina E, Perganti M, Perini L, Pernegger H, Perrella S, Perrevoort A, Perrin O, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petousis V, Petridou C, Petrukhin A, Pettee M, Pettersson NE, Petukhov A, Petukhova K, Peyaud A, Pezoa R, Pezzotti L, Pezzullo G, Pham TM, Pham T, Phillips PW, Phipps MW, Piacquadio G, Pianori E, Piazza F, Piegaia R, Pietreanu D, Pilkington AD, Pinamonti M, Pinfold JL, Pereira BCP, Pitman Donaldson C, Pizzi DA, Pizzimento L, Pizzini A, Pleier MA, Plesanovs V, Pleskot V, Plotnikova E, Poddar G, Poettgen R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Polacek S, Polesello G, Poley A, Polifka R, Polini A, Pollard CS, Pollock ZB, Polychronakos V, Pompa Pacchi E, Ponomarenko D, Pontecorvo L, Popa S, Popeneciu GA, Portillo Quintero DM, Pospisil S, Postolache P, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Pozo Astigarraga ME, Prades Ibanez A, Prapa MM, Price D, Primavera M, Principe Martin MA, Privara R, Proffitt ML, Proklova N, Prokofiev K, Proto G, Protopopescu S, Proudfoot J, Przybycien M, Puddefoot JE, Pudzha D, Puzo P, Pyatiizbyantseva D, Qian J, Qichen D, Qin Y, Qiu T, Quadt A, Queitsch-Maitland M, Quetant G, Rabanal Bolanos G, Rafanoharana D, Ragusa F, Rainbolt JL, Raine JA, Rajagopalan S, Ramakoti E, Ran K, Rapheeha NP, Raskina V, Rassloff DF, Rave S, Ravina B, Ravinovich I, Raymond M, Read AL, Readioff NP, Rebuzzi DM, Redlinger G, Reeves K, Reidelsturz JA, Reikher D, Reiss A, Rej A, Rembser C, Renardi A, Renda M, Rendel MB, Renner F, Rennie AG, Resconi S, Ressegotti M, Resseguie ED, Rettie S, Reynolds B, Reynolds E, Rezaei Estabragh M, Rezanova OL, Reznicek P, Ricci E, Richter R, Richter S, Richter-Was E, Ridel M, Rieck P, Riedler P, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Rinn TT, Rinnagel MP, Ripellino G, Riu I, Rivadeneira P, Rivera Vergara JC, Rizatdinova F, Rizvi E, Rizzi C, Roberts BA, Roberts BR, Robertson SH, Robin M, Robinson D, Robles Gajardo CM, Robles Manzano M, Robson A, Rocchi A, Roda C, Rodriguez Bosca S, Rodriguez Garcia Y, Rodriguez Rodriguez A, Rodríguez Vera AM, Roe S, Roemer JT, Roepe-Gier AR, Roggel J, Røhne O, Rojas RA, Roland B, Roland CPA, Roloff J, Romaniouk A, Romano E, Romano M, Romero Hernandez AC, Rompotis N, Roos L, Rosati S, Rosser BJ, Rossi E, Rossi E, Rossi LP, Rossini L, Rosten R, Rotaru M, Rottler B, Rousseau D, Rousso D, Rovelli G, Roy A, Rozanov A, Rozen Y, Ruan X, Rubio Jimenez A, Ruby AJ, Ruelas Rivera VH, Ruggeri TA, Rühr F, Ruiz-Martinez A, Rummler A, Rurikova Z, Rusakovich NA, Russell HL, Rutherfoord JP, Rybacki K, Rybar M, Rye EB, Ryzhov A, Sabater Iglesias JA, Sabatini P, Sabetta L, Sadrozinski HFW, Safai Tehrani F, Safarzadeh Samani B, Safdari M, Saha S, Sahinsoy M, Saimpert M, Saito M, Saito T, Salamani D, Salamanna G, Salnikov A, Salt J, Salvador Salas A, Salvatore D, Salvatore F, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Pineda A, Sanchez Sebastian V, Sandaker H, Sander CO, Sandesara JA, Sandhoff M, Sandoval C, Sankey DPC, Sansoni A, Santi L, Santoni C, Santos H, Santpur SN, Santra A, Saoucha KA, Saraiva JG, Sardain J, Sasaki O, Sato K, Sauer C, Sauerburger F, Sauvan E, Savard P, Sawada R, Sawyer C, Sawyer L, Sayago Galvan I, Sbarra C, Sbrizzi A, Scanlon T, Schaarschmidt J, Schacht P, Schaefer D, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schanet E, Scharf C, Schefer MM, Schegelsky VA, Scheirich D, Schenck F, Schernau M, Scheulen C, Schiavi C, Schillaci ZM, Schioppa EJ, Schioppa M, Schlag B, Schleicher KE, Schlenker S, Schmidt MA, Schmieden K, Schmitt C, Schmitt S, Schoeffel L, Schoening A, Scholer PG, Schopf E, Schott M, Schovancova J, Schramm S, Schroeder F, Schultz-Coulon HC, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scuri F, Scutti F, Sebastiani CD, Sedlaczek K, Seema P, Seidel SC, Seiden A, Seidlitz BD, Seiss T, Seitz C, Seixas JM, Sekhniaidze G, Sekula SJ, Selem L, Semprini-Cesari N, Sen S, Sengupta D, Senthilkumar V, Serin L, Serkin L, Sessa M, Severini H, Sevova S, Sforza F, Sfyrla A, Shabalina E, Shaheen R, Shahinian JD, Shaikh NW, Shaked Renous D, Shan LY, Shapiro M, Sharma A, Sharma AS, Sharma P, Sharma S, Shatalov PB, Shaw K, Shaw SM, Shen Q, Sherwood P, Shi L, Shimmin CO, Shimogama Y, Shinner JD, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shochet MJ, Shojaii J, Shope DR, Shrestha S, Shrif EM, Shroff MJ, Sicho P, Sickles AM, Sideras Haddad E, Sidoti A, Siegert F, Sijacki D, Sikora R, Sili F, Silva JM, Silva Oliveira MV, Silverstein SB, Simion S, Simoniello R, Simpson EL, Simpson ND, Simsek S, Sindhu S, Sinervo P, Sinetckii V, Singh S, Singh S, Sinha S, Sinha S, Sioli M, Siral I, Sivoklokov SY, Sjölin J, Skaf A, Skorda E, Skubic P, Slawinska M, Smakhtin V, Smart BH, Smiesko J, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith AC, Smith EA, Smith HA, Smith JL, Smith R, Smizanska M, Smolek K, Smykiewicz A, Snesarev AA, Snoek HL, Snyder S, Sobie R, Soffer A, Solans Sanchez CA, Soldatov EY, Soldevila U, Solodkov AA, Solomon S, Soloshenko A, Solovieva K, Solovyanov OV, Solovyev V, Sommer P, Sonay A, Song WY, Sopczak A, Sopio AL, Sopkova F, Sothilingam V, Sottocornola S, Soualah R, Soumaimi Z, South D, Spagnolo S, Spalla M, Spanò F, Sperlich D, Spigo G, Spina M, Spinali S, Spiteri DP, Spousta M, Staats EJ, Stabile A, Stamen R, Stamenkovic M, Stampekis A, Standke M, Stanecka E, Stange MV, Stanislaus B, Stanitzki MM, Stankaityte M, Stapf B, Starchenko EA, Stark GH, Stark J, Starko DM, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stavropoulos G, Steentoft J, Steinberg P, Steinhebel AL, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson TJ, Stewart GA, Stockton MC, Stoicea G, Stolarski M, Stonjek S, Straessner A, Strandberg J, Strandberg S, Strauss M, Strebler T, Strizenec P, Ströhmer R, Strom DM, Strom LR, Stroynowski R, Strubig A, Stucci SA, Stugu B, Stupak J, Styles NA, Su D, Su S, Su W, Su X, Sugizaki K, Sulin VV, Sullivan MJ, Sultan DMS, Sultanaliyeva L, Sultansoy S, Sumida T, Sun S, Sun S, Gudnadottir OS, Sutton MR, Svatos M, Swiatlowski M, Swirski T, Sykora I, Sykora M, Sykora T, Ta D, Tackmann K, Taffard A, Tafirout R, Tafoya Vargas JS, Taibah RHM, Takashima R, Takeda K, Takeva EP, Takubo Y, Talby M, Talyshev AA, Tam KC, Tamir NM, Tanaka A, Tanaka J, Tanaka R, Tanasini M, Tang J, Tao Z, Tapia Araya S, Tapprogge S, Tarek Abouelfadl Mohamed A, Tarem S, Tariq K, Tarna G, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tate AC, Tateno G, Tayalati Y, Taylor GN, Taylor W, Teagle H, Tee AS, Teixeira De Lima R, Teixeira-Dias P, Teoh JJ, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Thaler A, Theiner O, Themistokleous N, Theveneaux-Pelzer T, Thielmann O, Thomas DW, Thomas JP, Thompson EA, Thompson PD, Thomson E, Thorpe EJ, Tian Y, Tikhomirov V, Tikhonov YA, Timoshenko S, Ting EXL, Tipton P, Tisserant S, Tlou SH, Tnourji A, Todome K, Todorova-Nova S, Todt S, Togawa M, Tojo J, Tokár S, Tokushuku K, Tombs R, Tomoto M, Tompkins L, Topolnicki KW, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toscani M, Tosciri C, Tovey DR, Traeet A, Trandafir IS, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trischuk DA, Trocmé B, Trofymov A, Troncon C, Truong L, Trzebinski M, Trzupek A, Tsai F, Tsai M, Tsiamis A, Tsiareshka PV, Tsigaridas S, Tsirigotis A, Tsiskaridze V, Tskhadadze EG, Tsopoulou M, Tsujikawa Y, Tsukerman II, Tsulaia V, Tsuno S, Tsur O, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tuna AN, Turchikhin S, Turk Cakir I, Turra R, Turtuvshin T, Tuts PM, Tzamarias S, Tzanis P, Tzovara E, Uchida K, Ukegawa F, Ulloa Poblete PA, Unal G, Unal M, Undrus A, Unel G, Urban J, Urquijo P, Usai G, Ushioda R, Usman M, Uysal Z, Vacek V, Vachon B, Vadla KOH, Vafeiadis T, Valderanis C, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Vallier A, Valls Ferrer JA, Van Daalen TR, Van Gemmeren P, Van Rijnbach M, Van Stroud S, Van Vulpen I, Vanadia M, Vandelli W, Vandenbroucke M, Vandewall ER, Vannicola D, Vannoli L, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Varriale L, Varvell KE, Vasile ME, Vaslin L, Vasquez GA, Vazeille F, Vazquez Schroeder T, Veatch J, Vecchio V, Veen MJ, Veliscek I, Veloce LM, Veloso F, Veneziano S, Ventura A, Verbytskyi A, Verducci M, Vergis C, Verissimo De Araujo M, Verkerke W, Vermeulen JC, Vernieri C, Verschuuren PJ, Vessella M, Vetterli MC, Vgenopoulos A, Viaux Maira N, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Vigani L, Villa M, Villaplana Perez M, Villhauer EM, Vilucchi E, Vincter MG, Virdee GS, Vishwakarma A, Vittori C, Vivarelli I, Vladimirov V, Voevodina E, Vogel F, Vokac P, Von Ahnen J, Von Toerne E, Vormwald B, Vorobel V, Vorobev K, Vos M, Vossebeld JH, Vozak M, Vozdecky L, Vranjes N, Vranjes Milosavljevic M, Vreeswijk M, Vuillermet R, Vujinovic O, Vukotic I, Wada S, Wagner C, Wagner W, Wahdan S, Wahlberg H, Wakasa R, Wakida M, Walbrecht VM, Walder J, Walker R, Walkowiak W, Wang AM, Wang AZ, Wang C, Wang C, Wang H, Wang J, Wang P, Wang RJ, Wang R, Wang R, Wang SM, Wang S, Wang T, Wang WT, Wang WX, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Warburton A, Ward RJ, Warrack N, Watson AT, Watson H, Watson MF, Watts G, Waugh BM, Webb AF, Weber C, Weber MS, Weber SM, Wei C, Wei Y, Weidberg AR, Weingarten J, Weirich M, Weiser C, Wells CJ, Wenaus T, Wendland B, Wengler T, Wenke NS, Wermes N, Wessels M, Whalen K, Wharton AM, White AS, White A, White MJ, Whiteson D, Wickremasinghe L, Wiedenmann W, Wiel C, Wielers M, Wieseotte N, Wiglesworth C, Wiik-Fuchs LAM, Wilbern DJ, Wilkens HG, Williams DM, Williams HH, Williams S, Willocq S, Windischhofer PJ, Winklmeier F, Winter BT, Winter JK, Wittgen M, Wobisch M, Wölker R, Wollrath J, Wolter MW, Wolters H, Wong VWS, Wongel AF, Worm SD, Wosiek BK, Woźniak KW, Wraight K, Wu J, Wu M, Wu M, Wu SL, Wu X, Wu Y, Wu Z, Wuerzinger J, Wyatt TR, Wynne BM, Xella S, Xia L, Xia M, Xiang J, Xiao X, Xie M, Xie X, Xin S, Xiong J, Xiotidis I, Xu D, Xu H, Xu H, Xu L, Xu R, Xu T, Xu W, Xu Y, Xu Z, Xu Z, Yabsley B, Yacoob S, Yamaguchi N, Yamaguchi Y, Yamauchi H, Yamazaki T, Yamazaki Y, Yan J, Yan S, Yan Z, Yang HJ, Yang HT, Yang S, Yang T, Yang X, Yang X, Yang Y, Yang Z, Yao WM, Yap YC, Ye H, Ye H, Ye J, Ye S, Ye X, Yeh Y, Yeletskikh I, Yeo BK, Yexley MR, Yin P, Yorita K, Young CJS, Young C, Yuan M, Yuan R, Yue L, Yue X, Zaazoua M, Zabinski B, Zaid E, Zakareishvili T, Zakharchuk N, Zambito S, Zamora Saa JA, Zang J, Zanzi D, Zaplatilek O, Zeißner SV, Zeitnitz C, Zeng JC, Zenger DT, Zenin O, Ženiš T, Zenz S, Zerradi S, Zerwas D, Zhang B, Zhang DF, Zhang G, Zhang J, Zhang J, Zhang K, Zhang L, Zhang P, Zhang R, Zhang S, Zhang T, Zhang X, Zhang X, Zhang Y, Zhang Z, Zhang Z, Zhao H, Zhao P, Zhao T, Zhao Y, Zhao Z, Zhemchugov A, Zheng X, Zheng Z, Zhong D, Zhou B, Zhou C, Zhou H, Zhou N, Zhou Y, Zhu CG, Zhu C, Zhu HL, Zhu H, Zhu J, Zhu Y, Zhu Y, Zhuang X, Zhukov K, Zhulanov V, Zimine NI, Zinsser J, Ziolkowski M, Živković L, Zoccoli A, Zoch K, Zorbas TG, Zormpa O, Zou W, Zwalinski L. Test of CP Invariance in Higgs Boson Vector-Boson-Fusion Production Using the H→γγ Channel with the ATLAS Detector. PHYSICAL REVIEW LETTERS 2023; 131:061802. [PMID: 37625052 DOI: 10.1103/physrevlett.131.061802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 02/03/2023] [Indexed: 08/27/2023]
Abstract
A test of CP invariance in Higgs boson production via vector-boson fusion has been performed in the H→γγ channel using 139 fb^{-1} of proton-proton collision data at sqrt[s]=13 TeV collected by the ATLAS detector at the LHC. The optimal observable method is used to probe the CP structure of interactions between the Higgs boson and electroweak gauge bosons, as described by an effective field theory. No sign of CP violation is observed in the data. Constraints are set on the parameters describing the strength of the CP-odd component in the coupling between the Higgs boson and the electroweak gauge bosons in two effective field theory bases: d[over ˜] in the HISZ basis and c_{HW[over ˜]} in the Warsaw basis. The results presented are the most stringent constraints on CP violation in the coupling between Higgs and weak bosons. The 95% C.L. constraint on d[over ˜] is derived for the first time and the 95% C.L. constraint on c_{HW[over ˜]} has been improved by a factor of 5 compared to the previous measurement.
Collapse
|
134
|
Gao XX, Wang LM, Zhang X, Zhao ZP, Li C, Huang ZJ, Liu CY, Xue TT, Jiang B, Guan YQ, Zhang M. [The prevalence of insufficient physical activity and the influencing factors among Chinese adults in 2018]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2023; 44:1190-1197. [PMID: 37661608 DOI: 10.3760/cma.j.cn112338-20221125-01000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
Objective: To understand the prevalence of insufficient physical activity among adults aged ≥18 years in China and to explore the influencing factors. Methods: The China Chronic Disease and Risk Factor Surveillance was conducted in 298 counties/districts in China in 2018, covering 31 provinces (autonomous regions, municipalities). A multi-stage stratified cluster random sampling method was used to select permanent residents aged ≥18 years. A questionnaire including Global Physical Activity Questionnaire was used to collect information about the participants' demographic characteristics and physical activity through face-to-face interview. A total of 183 769 participants completed the survey. After complex data weighting, the prevalence of insufficient physical activity, occupation, transportation, and leisure-time physical activity time was analyzed. Multivariate logistic regression models were used to analyze the influencing factors related to insufficient physical activity. Results: The prevalence of insufficient physical activity among adults aged ≥18 years was 22.3% (95%CI: 20.9%-23.7%) in China in 2018, with males [24.4% (95%CI: 23.0%-25.8%)] significantly higher than females [20.2% (95%CI: 18.6%-21.8%)]. Adults aged 70 years and above [28.4% (95%CI: 26.9%-29.9%)] were significantly higher than adults in other age groups, followed by adults aged 18-29 years [26.4% (95%CI: 24.4%- 28.3%)] and 30-39 years [23.4% (95%CI: 21.5%-25.3%)], and tended to increase with increasing education and total sedentary behavior time (P<0.001). The weekly occupation, transportation, and leisure-time physical activity time appeared 958.6 (95%CI: 911.4-1 005.8) minutes, 234.5 (95%CI: 224.7- 244.2) minutes, and 88.6 (95%CI: 83.5-93.7) minutes, respectively. Multivariate logistic regression analysis showed that males, adults living in rural areas or northern China, ≥70 years, with junior high school education, an annual household income per capita <6 000 yuan and institutional/clerical/ technical occupation and longer total sedentary behavior time were related to a higher prevalence of insufficient physical activity. Conclusions: In China, over one-fifth of the adults had lower physical activity levels. Adults who are male, young adults, more educated, institutional/clerical/technical occupation, and with more extended total sedentary behavior are the populations that need to be focused on to promote physical activity-related health.
Collapse
|
135
|
Geng ZY, Chen NX, You W, Liu K, Gu X, Wei J, Ma L, Zhang XX. [Efficacy of non-surgical comprehensive treatment for locally advanced hypopharyngeal carcinoma with cervical esophagus invasion]. ZHONGHUA ER BI YAN HOU TOU JING WAI KE ZA ZHI = CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY 2023; 58:773-780. [PMID: 37599238 DOI: 10.3760/cma.j.cn115330-20221108-00670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 08/22/2023]
Abstract
Objective: To analyze the treatment effects and side effects of non-surgical comprehensive treatment for locally advanced hypopharyngeal carcinoma invading cervical esophagus. Methods: A retrospective analysis was performed on sixty-six patients with locally advanced hypopharyngeal carcinoma invade the esophagus. These patients were treated in the Department of Otolaryngology, Head and Neck Surgery of Chinese People's Liberation Army General Hospital between January 2011 and May 2022, including sixty-five males and one female, aged 43-71 years. Treatment regimen consisted of induction chemotherapy and concurrent chemoradiothrapy and epidermal growth factor receptor (EGFR)-targeted therapy, three of these cases were treated with programmed cell death 1 (PD-1) immunotherapy. The Kaplan-Meier method was used for survival analysis. Side effects were evaluated with the established CTCAE (Common Terminology Criteria for Adverse Events) 5.0 criteria. The factors affecting prognosis were analyzed by Cox multivariate regression analysis. Results: Sixty-four (97.0%, 64/66) patients completed the radiotherapy and chemotherapy plan. The most common grade three side effects were radioactive oropharyngeal mucositis (89.1%, 57/64) and leukopenia (23.4%, 15/64). Five (7.8%, 5/64) patients showed grade three hoarseness; two patients (3.1%, 2/64) suffered from grade three swallowing dysfunction and required feeding tube and intravenous nutrition; the remaining patients(89.1%) retained good vocal and swallowing functions. The overall survival (OS) of all patients was 81.5% after one year, 54.0% after three years, and 39.9% after five years; the progression-free survival (PFS) was 78.3% after one year, 54.9% after three years, and 42.6% after five years; local control rate (LCR) was 80.9% after one year, 62.5% after three years, and 52.0% after five years. T4a patients showed better OS, PFS and LCR than T4b patients, with statistically significant differences (χ2=8.10, 8.27, and 6.64, respectively, all P<0.05). Cox multivariate regression analysis showed that lymph node metastasis was an independent factor affecting prognosis (χ2=10.21, P<0.05). Conclusion: Non-surgical comprehensive treatment can provide with another option of radical treatment for locally advanced hypopharyngeal carcinoma with cervical esophagus invasion, offering the patients higher rate of larynx and esophageal preservation with tolerable side effects.
Collapse
|
136
|
Acharya S, Adamová D, Adler A, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akindinov A, Al-Turany M, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altsybeev I, Anaam MN, Andrei C, Andronic A, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Banerjee D, Banoo Z, Barbera R, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Barreto L, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Becht P, Behera D, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat IR, Bhat MA, Bhattacharjee B, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Biernat J, Bilandzic A, Biro G, Biswas S, Blair JT, Blau D, Blidaru MB, Bluhme N, Blume C, Boca G, Bock F, Bodova T, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt JB, Bylinkin A, Bysiak SA, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Carabas M, Carnesecchi F, Caron R, Castillo Castellanos J, Catalano F, Ceballos Sanchez C, Chakaberia I, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chavez TG, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Chizzali ES, Cho J, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Ciacco M, Cicalo C, Cifarelli L, Cindolo F, Ciupek MR, Clai G, Colamaria F, Colburn JS, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch MC, Danu A, Das P, Das P, Das S, Dash S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Del Grande R, Dello Stritto L, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dubey AK, Dubinski JM, Dubla A, Dudi S, Dupieux P, Durkac M, Dzalaiova N, Eder TM, Ehlers RJ, Eikeland VN, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fan W, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrer MB, Ferrero A, Ferretti A, Feuillard VJG, Figiel J, Filova V, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Fokin I, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gauger EF, Gautam A, Gay Ducati MB, Germain M, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Glimos E, Goh DJQ, Gonzalez V, González-Trueba LH, Gorbunov S, Gorgon M, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Grecka E, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Grosa F, Grosse-Oetringhaus JF, Grosso R, Grund D, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gunji T, Guo W, Gupta A, Gupta R, Guzman SP, Gyulai L, Habib MK, Hadjidakis C, Hamagaki H, Hamid M, Han Y, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Heckel ST, Hellbär E, Helstrup H, Herman T, Herrera Corral G, Herrmann F, Hetland KF, Heybeck B, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong GH, Horak D, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Huhta LM, Hulse CV, Humanic TJ, Hushnud H, Hutson A, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Isidori T, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaffe L, Jahnke C, Janik MA, Janson T, Jercic M, Jevons O, Jimenez AAP, Jonas F, Jones PG, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kabus MJ, Kaewjai J, Kalinak P, Kalteyer AS, Kalweit A, Kaplin V, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kashyap V, Kazantsev A, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim JS, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Kotliarov A, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Krupova DM, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lehrbach J, Lemmon RC, León Monzón I, Lesch MM, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu DH, Liu J, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Lu P, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmoud T, Maire A, Malaev M, Malik NM, Malik QW, Malik SK, Malinina L, Mal'Kevich D, Mallick D, Mallick N, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mdhluli JE, Mechler AF, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohanty AP, Mohanty B, Khan MM, Molander MA, Moravcova Z, Mordasini C, Moreira De Godoy DA, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Neagu A, Negru A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nielsen EG, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Okorokov VA, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Panebianco S, Park J, Parkkila JE, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrov V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Prasad S, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Rancien TA, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Reme-Ness HA, Rescakova Z, Reygers K, Riabov A, Riabov V, Ricci R, Richert T, Richter M, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rojas Torres S, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Rossi A, Roy A, Roy P, Roy S, Rubini N, Rueda OV, Ruggiano D, Rui R, Rumyantsev B, Russek PG, Russo R, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sajdakova K, Sakai S, Salvan MP, Sambyal S, Saramela TB, Sarkar D, Sarkar N, Sarma P, Sarritzu V, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schukraft J, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma D, Sharma H, Sharma M, Sharma N, Sharma S, Sharma U, Shatat A, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simantathammakul T, Simeonov R, Simonetti G, Singh B, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Solheim EH, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Spijkers R, Sputowska I, Staa J, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Storetvedt MM, Stratmann P, Strazzi S, Stylianidis CP, Suaide AAP, Suire C, Sukhanov M, Suljic M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tapia Takaki JD, Tapus N, Tarasovicova LA, Tarzila MG, Tauro A, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins AR, Tkacik M, Tkacik T, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres Ramos AG, Trifiró A, Triolo AS, Tripathy S, Tripathy T, Trogolo S, Trubnikov V, Trzaska WH, Trzcinski TP, Turrisi R, Tveter TS, Ullaland K, Ulukutlu B, Uras A, Urioni M, Usai GL, Vala M, Valle N, Vallero S, van Doremalen LVR, van Leeuwen M, van Veen CA, van Weelden RJG, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Weber M, Wegrzynek A, Weiglhofer FT, Wenzel SC, Wessels JP, Weyhmiller SL, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Wright JR, Wu W, Wu Y, Xu R, Yadav AK, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yoo IK, Yoon JH, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanoli HJC, Zanone F, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang S, Zhang X, Zhang Y, Zhao M, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zinovjev G, Zurlo N. Measurement of the J/ψ Polarization with Respect to the Event Plane in Pb-Pb Collisions at the LHC. PHYSICAL REVIEW LETTERS 2023; 131:042303. [PMID: 37566833 DOI: 10.1103/physrevlett.131.042303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 02/09/2023] [Accepted: 03/28/2023] [Indexed: 08/13/2023]
Abstract
We study the polarization of inclusive J/ψ produced in Pb-Pb collisions at sqrt[s_{NN}]=5.02 TeV at the LHC in the dimuon channel, via the measurement of the angular distribution of its decay products. We perform the study in the rapidity region 2.5
Collapse
|
137
|
Acharya S, Adamová D, Adler A, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akindinov A, Al-Turany M, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altsybeev I, Anaam MN, Andrei C, Andronic A, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Banerjee D, Banoo Z, Barbera R, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Barreto L, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Becht P, Behera D, Belikov I, Bell Hechavarria ADC, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat IR, Bhat MA, Bhattacharjee B, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Biernat J, Bilandzic A, Biro G, Biswas S, Blair JT, Blau D, Blidaru MB, Bluhme N, Blume C, Boca G, Bock F, Bodova T, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt JB, Bylinkin A, Bysiak SA, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Carabas M, Carnesecchi F, Caron R, Castillo Castellanos J, Catalano F, Ceballos Sanchez C, Chakaberia I, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chavez TG, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Chizzali ES, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Ciacco M, Cicalo C, Cifarelli L, Cindolo F, Ciupek MR, Clai G, Colamaria F, Colburn JS, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch MC, Danu A, Das P, Das P, Das S, Dash S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Del Grande R, Dello Stritto L, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dubey AK, Dubinski JM, Dubla A, Dudi S, Dupieux P, Durkac M, Dzalaiova N, Eder TM, Ehlers RJ, Eikeland VN, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fan W, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrer MB, Ferrero A, Ferretti A, Feuillard VJG, Figiel J, Filova V, Finogeev D, Fiorenza G, Flor F, Flores AN, Foertsch S, Fokin I, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gauger EF, Gautam A, Gay Ducati MB, Germain M, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Glimos E, Goh DJQ, Gonzalez V, González-Trueba LH, Gorbunov S, Gorgon M, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Grecka E, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Grosa F, Grosse-Oetringhaus JF, Grosso R, Grund D, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gunji T, Guo W, Gupta A, Gupta R, Guzman SP, Gyulai L, Habib MK, Hadjidakis C, Hamagaki H, Hamid M, Han Y, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Heckel ST, Hellbär E, Helstrup H, Herman T, Herrera Corral G, Herrmann F, Hetland KF, Heybeck B, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong GH, Horak D, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Huhta LM, Hulse CV, Humanic TJ, Hushnud H, Hutson A, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Isidori T, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaffe L, Jahnke C, Janik MA, Janson T, Jercic M, Jevons O, Jimenez AAP, Jonas F, Jones PG, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kabus MJ, Kaewjai J, Kalinak P, Kalteyer AS, Kalweit A, Kaplin V, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kashyap V, Kazantsev A, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim JS, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Kotliarov A, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Krupova DM, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lehrbach J, Lemmon RC, León Monzón I, Lesch MM, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu DH, Liu J, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Lu P, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmoud T, Maire A, Malaev M, Malik NM, Malik QW, Malik SK, Malinina L, Mal'Kevich D, Mallick D, Mallick N, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mdhluli JE, Mechler AF, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohanty AP, Mohanty B, Mohisin Khan M, Molander MA, Moravcova Z, Mordasini C, Moreira De Godoy DA, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Nayak TK, Neagu A, Negru A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nielsen EG, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Okorokov VA, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Panebianco S, Park J, Parkkila JE, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrov V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Prasad S, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Rancien TA, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Reme-Ness HA, Rescakova Z, Reygers K, Riabov A, Riabov V, Ricci R, Richert T, Richter M, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rojas Torres S, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Rossi A, Roy A, Roy P, Roy S, Rubini N, Rueda OV, Ruggiano D, Rui R, Rumyantsev B, Russek PG, Russo R, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sakai S, Salvan MP, Sambyal S, Saramela TB, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schukraft J, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma D, Sharma H, Sharma M, Sharma N, Sharma S, Sharma U, Shatat A, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simantathammakul T, Simonetti G, Singh B, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Solheim EH, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Spijkers R, Sputowska I, Staa J, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Storetvedt MM, Stratmann P, Strazzi S, Stylianidis CP, Suaide AAP, Suire C, Sukhanov M, Suljic M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tapia Takaki JD, Tapus N, Tarasovicova LA, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins AR, Tkacik M, Tkacik T, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres Ramos AG, Trifiró A, Triolo AS, Tripathy S, Tripathy T, Trogolo S, Trubnikov V, Trzaska WH, Trzcinski TP, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Ulukutlu B, Uras A, Urioni M, Usai GL, Vala M, Valle N, Vallero S, van Doremalen LVR, van Leeuwen M, van Veen CA, van Weelden RJG, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Weber M, Wegrzynek A, Weiglhofer FT, Wenzel SC, Wessels JP, Weyhmiller SL, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Wright JR, Wu W, Wu Y, Xu R, Yadav AK, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yoo IK, Yoon JH, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanoli HJC, Zanone F, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang S, Zhang X, Zhang Y, Zhao M, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zinovjev G, Zurlo N. First Measurement of Antideuteron Number Fluctuations at Energies Available at the Large Hadron Collider. PHYSICAL REVIEW LETTERS 2023; 131:041901. [PMID: 37566856 DOI: 10.1103/physrevlett.131.041901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 07/01/2022] [Accepted: 09/15/2022] [Indexed: 08/13/2023]
Abstract
The first measurement of event-by-event antideuteron number fluctuations in high energy heavy-ion collisions is presented. The measurements are carried out at midrapidity (|η|<0.8) as a function of collision centrality in Pb-Pb collisions at sqrt[s_{NN}]=5.02 TeV using the ALICE detector. A significant negative correlation between the produced antiprotons and antideuterons is observed in all collision centralities. The results are compared with a state-of-the-art coalescence calculation. While it describes the ratio of higher order cumulants of the antideuteron multiplicity distribution, it fails to describe quantitatively the magnitude of the correlation between antiproton and antideuteron production. On the other hand, thermal-statistical model calculations describe all the measured observables within uncertainties only for correlation volumes that are different with respect to those describing proton yields and a similar measurement of net-proton number fluctuations.
Collapse
|
138
|
Acharya S, Adamová D, Adler A, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akindinov A, Al-Turany M, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altsybeev I, Anaam MN, Andrei C, Andronic A, Anguelov V, Antinori F, Antonioli P, Apadula N, Aphecetche L, Appelshäuser H, Arata C, Arcelli S, Aresti M, Arnaldi R, Arneiro JGMCA, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Azmi MD, Badalà A, Bae J, Baek YW, Bai X, Bailhache R, Bailung Y, Balbino A, Baldisseri A, Balis B, Banerjee D, Banoo Z, Barbera R, Barile F, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Barreto L, Bartels C, Barth K, Bartsch E, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Becht P, Behera D, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat MA, Bhattacharjee B, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Biernat J, Bigot AP, Bilandzic A, Biro G, Biswas S, Bize N, Blair JT, Blau D, Blidaru MB, Bluhme N, Blume C, Boca G, Bock F, Bodova T, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Borquez Carcamo AG, Bossi H, Botta E, Bouziani YEM, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Bysiak SA, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camerini P, Canedo FDM, Carabas M, Carballo AA, Carnesecchi F, Caron R, Carvalho LAD, Castillo Castellanos J, Catalano F, Ceballos Sanchez C, Chakaberia I, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chavez TG, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Chizzali ES, Cho J, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Ciacco M, Cicalo C, Cindolo F, Ciupek MR, Clai G, Colamaria F, Colburn JS, Colella D, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Cot C, Crkovská J, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Dainese A, Danisch MC, Danu A, Das P, Das P, Das S, Dash AR, Dash S, David RMH, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Debski RJ, Deja KR, Del Grande R, Dello Stritto L, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dubinski JM, Dubla A, Dudi S, Dupieux P, Durkac M, Dzalaiova N, Eder TM, Ehlers RJ, Eikeland VN, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fan W, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrandi L, Ferrer MB, Ferrero A, Ferrero C, Ferretti A, Feuillard VJG, Filova V, Finogeev D, Fionda FM, Flor F, Flores AN, Foertsch S, Fokin I, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Fusayasu T, Gaardhøje JJ, Gagliardi M, Gago AM, Galvan CD, Gangadharan DR, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garner K, Gasik P, Gautam A, Gay Ducati MB, Germain M, Ghimouz A, Ghosh C, Giacalone M, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Glimos E, Goh DJQ, Gonzalez V, González-Trueba LH, Gorgon M, Gotovac S, Grabski V, Graczykowski LK, Grecka E, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Grosa F, Grosse-Oetringhaus JF, Grosso R, Grund D, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gundem T, Gunji T, Guo W, Gupta A, Gupta R, Guzman SP, Gyulai L, Habib MK, Hadjidakis C, Haider FU, Hamagaki H, Hamdi A, Hamid M, Han Y, Hannigan R, Haque MR, Harris JW, Harton A, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Heckel ST, Hellbär E, Helstrup H, Hemmer M, Herman T, Herrera Corral G, Herrmann F, Herrmann S, Hetland KF, Heybeck B, Hillemanns H, Hills C, Hippolyte B, Hoffmann FW, Hofman B, Hohlweger B, Hong GH, Horst M, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Huhta LM, Hulse CV, Humanic TJ, Hutson A, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Isidori T, Islam MS, Ivanov M, Ivanov M, Ivanov V, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jaffe L, Jahnke C, Jakubowska MJ, Janik MA, Janson T, Jercic M, Jia S, Jimenez AAP, Jonas F, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kabus MJ, Kaewjai J, Kalinak P, Kalteyer AS, Kalweit A, Kaplin V, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kidson MB, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim JS, Kim J, Kim M, Kim S, Kim T, Kimura K, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Kotliarov A, Kovalenko V, Kowalski M, Kozhuharov V, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Krupova DM, Kryshen E, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lee H, Legras G, Lehrbach J, Lemmon RC, León Monzón I, Lesch MM, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Likmeta I, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu DH, Liu J, Lofnes IM, Loizides C, Lokos S, Lomker J, Loncar P, Lopez JA, Lopez X, López Torres E, Lu P, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmoud T, Maire A, Makariev MV, Malaev M, Malfattore G, Malik NM, Malik QW, Malik SK, Malinina L, Mal'Kevich D, Mallick D, Mallick N, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Margagliotti GV, Margotti A, Marín A, Markert C, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mdhluli JE, Mechler AF, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohanty AP, Mohanty B, Mohisin Khan M, Molander MA, Moravcova Z, Mordasini C, Moreira De Godoy DA, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nambrath AI, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Naydenov MN, Neagu A, Negru A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nielsen EG, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Okorokov VA, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Panebianco S, Park H, Park H, Park J, Parkkila JE, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pennisi M, Pereira LG, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrov V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Pozdniakov V, Pradhan KK, Prasad SK, Prasad S, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Pucillo S, Pugelova Z, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Rancien TA, Rasa M, Räsänen SS, Rath R, Rauch MP, Ravasenga I, Read KF, Reckziegel C, Redelbach AR, Redlich K, Reetz CA, Rehman A, Reidt F, Reme-Ness HA, Rescakova Z, Reygers K, Riabov A, Riabov V, Ricci R, Richter M, Riedel AA, Riegler W, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rojas Torres S, Rokita PS, Romanenko G, Ronchetti F, Rosano A, Rosas ED, Roslon K, Rossi A, Roy A, Roy S, Rubini N, Rueda OV, Ruggiano D, Rui R, Rumyantsev B, Russek PG, Russo R, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadhu S, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sajdakova K, Sakai S, Salvan MP, Sambyal S, Sanna I, Saramela TB, Sarkar D, Sarkar N, Sarma P, Sarritzu V, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schröter A, Schukraft J, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabetai A, Shahoyan R, Shangaraev A, Sharma A, Sharma B, Sharma D, Sharma H, Sharma M, Sharma S, Sharma S, Sharma U, Shatat A, Sheibani O, Shigaki K, Shimomura M, Shin J, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simantathammakul T, Simeonov R, Singh B, Singh B, Singh R, Singh R, Singh R, Singh S, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Solheim EH, Song J, Songmoolnak A, Soramel F, Spijkers R, Sputowska I, Staa J, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Stratmann P, Strazzi S, Stylianidis CP, Suaide AAP, Suire C, Sukhanov M, Suljic M, Sultanov R, Sumberia V, Sumowidagdo S, Swain S, Szarka I, Szymkowski M, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tapia Takaki JD, Tapus N, Tarasovicova LA, Tarzila MG, Tassielli GF, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tikhonov A, Timmins AR, Tkacik M, Tkacik T, Toia A, Tokumoto R, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres Ramos AG, Trifiró A, Triolo AS, Tripathy S, Tripathy T, Trogolo S, Trubnikov V, Trzaska WH, Trzcinski TP, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Ulukutlu B, Uras A, Urioni M, Usai GL, Vala M, Valle N, van Doremalen LVR, van Leeuwen M, van Veen CA, van Weelden RJG, Vande Vyvre P, Varga D, Varga Z, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Villani A, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Vozniuk N, Vrláková J, Wang C, Wang D, Wang Y, Wegrzynek A, Weiglhofer FT, Wenzel SC, Wessels JP, Weyhmiller SL, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Wright JR, Wu W, Wu Y, Xu R, Yadav A, Yadav AK, Yalcin S, Yamaguchi Y, Yang S, Yano S, Yin Z, Yoo IK, Yoon JH, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanone F, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang L, Zhang S, Zhang X, Zhang Y, Zhang Z, Zhao M, Zherebchevskii V, Zhi Y, Zhou D, Zhou Y, Zhu J, Zhu Y, Zugravel SC, Zurlo N. Enhanced Deuteron Coalescence Probability in Jets. PHYSICAL REVIEW LETTERS 2023; 131:042301. [PMID: 37566840 DOI: 10.1103/physrevlett.131.042301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 04/07/2023] [Accepted: 06/05/2023] [Indexed: 08/13/2023]
Abstract
The transverse-momentum (p_{T}) spectra and coalescence parameters B_{2} of (anti)deuterons are measured in p-p collisions at sqrt[s]=13 TeV for the first time in and out of jets. In this measurement, the direction of the leading particle with the highest p_{T} in the event (p_{T}^{lead}>5 GeV/c) is used as an approximation for the jet axis. The event is consequently divided into three azimuthal regions, and the jet signal is obtained as the difference between the toward region, that contains jet fragmentation products in addition to the underlying event (UE), and the transverse region, which is dominated by the UE. The coalescence parameter in the jet is found to be approximately a factor of 10 larger than that in the underlying event. This experimental observation is consistent with the coalescence picture and can be attributed to the smaller average phase-space distance between nucleons in the jet cone as compared with the underlying event. The results presented in this Letter are compared to predictions from a simple nucleon coalescence model, where the phase-space distributions of nucleons are generated using pythia8 with the Monash 2013 tuning, and to predictions from a deuteron production model based on ordinary nuclear reactions with parametrized energy-dependent cross sections tuned on data. The latter model is implemented in pythia8.3. Both models reproduce the observed large difference between in-jet and out-of-jet coalescence parameters, although the almost flat trend of the B_{2}^{Jet} is not reproduced by the models, which instead give a decreasing trend.
Collapse
|
139
|
Zhang XX, Yang XF, Li S, Wu C, Hou XF. [Clinical analysis of immunotherapy rechallenge in advanced gastric cancer]. ZHONGHUA ZHONG LIU ZA ZHI [CHINESE JOURNAL OF ONCOLOGY] 2023; 45:605-612. [PMID: 37462017 DOI: 10.3760/cma.j.cn112152-20220418-00261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/20/2023]
Abstract
Objective: To evaluate the efficacy and influencing factors of programmed death protein 1 (PD-1) monoclonal antibody rechallenge therapy in advanced gastric cancer (GC). Methods: The clinical data of patients with advanced GC who were treated with anti-PD-1 rechallenge in Henan Cancer Hospital from January 2020 to December 2021 were collected retrospectively. The progression-free survival (PFS) was defined as the time from the first or second used of anti-PD-1 treatment to the date of disease progression or the last follow-up, named PFS(1) and PFS(2), respectively. Kaplan-Meier method and Log rank test were used for survival analysis, Cox proportional hazard model was used to analyze the influencing factors. Results: A total of 60 patients with anti-PD-1 rechallenge therapy were collected, the median follow-up time was 12.2 months. The median progression-free survival (PFS(2)) of anti-PD-1 rechallenge therapy was 2.9 months, the objective response rate (ORR) was 16.7%, and the disease control rate (DCR) was 55.0%. The median PFS(2) of the first and second anti-PD-1 identical and different rechallenge treatment was 3.5 months and 1.9 months (P=0.007) respectively. The median PFS(2) of positive PD-L1 expression in rechallenge therapy was 3.4 months, ORR was 22.7%, and DCR was 63.6%; the median PFS(2) was 4.5 months, ORR was 27.3%, and DCR was 54.5% in patients with median PFS(1)≥6 months. Multivariate analysis showed that peritoneal metastasis was independently associated with anti-PD-1 rechallenge therapy with PFS(2) (HR=2.327, 95% CI, 1.066-5.082, P=0.034). The incidence of adverse reactions in grade 1-2 and grade 3-4 of anti-PD-1 rechallenge therapy was 83.3%, and 35.0%, respectively, and the safety was controllable. Conclusion: Rechallenge therapy with anti-PD-1 is a feasible treatment in advanced GC, but the screening of suitable population for rechallenge therapy still needs prospective data analysis and verification.
Collapse
|
140
|
Zhang X, Chen Y, Li Z, Shang J, Yuan Z, Deng W, Luo Y, Han N, Yin P, Yin J. [Analysis of therapeutic mechanism of Liushen Wan against colitis-associated colorectal cancer based on network pharmacology and validation in mice]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2023; 43:1051-1062. [PMID: 37488787 PMCID: PMC10366510 DOI: 10.12122/j.issn.1673-4254.2023.07.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 07/26/2023]
Abstract
OBJECTIVE To explore the therapeutic mechanism of Liushen Wan (LSW) against colitis-associated colorectal cancer (CAC) by network pharmacology. METHODS TCMSP, BATMAN-TCM, CNKI, PubMed, Genecards, OMIM, and TTD databases were used to obtain the related targets of LSW and CAC. The common targets of LSW and CAC were obtained using Venny online website. The PPI network was constructed using Cytoscape 3.8.2 to screen the core targets of LSW in the treatment of CAC. GO and KEGG enrichment analysis were conducted using DAVID database. The therapeutic effect of LSW on CAC was evaluated in a C57BL/6J mouse model of AOM/DSS-induced CAC by observing the changes in body weight, disease activity index, colon length, and size and number of the tumor. HE staining and RT-qPCR were used to analyze the effect of LSW on inflammatory mediators. Immunohistochemistry and TUNEL staining were used to evaluate the effect of LSW on the proliferation and apoptosis of AOM/DSS-treated colon tumor cells. Immunohistochemistry and Western blotting were used to detect the effects of LSW on the expression of TLR4 proteins in CAC mice. RESULTS Network pharmacology analysis identified 69 common targets of LSW and CAC, and 33 hub targets were screened in the PPI network. KEGG pathway enrichment analysis suggested that the effect of LSW on CAC was mediated by the Toll-like receptor signaling pathway. In the mouse model of AOM/DSS-induced CAC, LSW significantly inhibited colitis-associated tumorigenesis, reduced tumor number and tumor load (P < 0.05), obviously improved histopathological changes in the colon, downregulated the mRNA levels of proinflammatory cytokines, and inhibited the proliferation (P < 0.01) and promoted apoptosis of colon tumor cells (P < 0.001). LSW also significantly decreased TLR4 protein expression in the colon tissue (P < 0.05). CONCLUSION LSW can inhibit CAC in mice possibly by regulating the expression of TLR4 to reduce intestinal inflammation, inhibit colon tumor cell proliferation and promote their apoptosis.
Collapse
|
141
|
Mai Z, Li J, Feng Y, Zhang X. [Diffusion tensor field estimation based on 3D U-Net and diffusion tensor imaging model constraint]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2023; 43:1224-1232. [PMID: 37488805 PMCID: PMC10366516 DOI: 10.12122/j.issn.1673-4254.2023.07.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 07/26/2023]
Abstract
OBJECTIVE To propose a diffusion tensor field estimation network based on 3D U-Net and diffusion tensor imaging (DTI) model constraint (3D DTI-Unet) to accurately estimate DTI quantification parameters from a small number of diffusion-weighted (DW) images with a low signal-to-noise ratio. METHODS The input of 3D DTI-Unet was noisy diffusion magnetic resonance imaging (dMRI) data containing one non-DW image and 6 DW images with different diffusion coding directions. The noise-reduced non-DW image and accurate diffusion tensor field were predicted through 3D U-Net. The dMRI data were reconstructed using the DTI model and compared with the true value of dMRI data to optimize the network and ensure the consistency of the dMRI data with the physical model of the diffusion tensor field. We compared 3D DTI-Unet with two DW image denoising algorithms (MP-PCA and GL-HOSVD) to verify the effect of the proposed method. RESULTS The proposed method was better than MP-PCA and GL-HOSVD in terms of quantitative results and visual evaluation of DW images, diffusion tensor field and DTI quantification parameters. CONCLUSION The proposed method can obtain accurate DTI quantification parameters from one non-DW image and 6 DW images to reduce image acquisition time and improve the reliability of quantitative diagnosis.
Collapse
|
142
|
Andriamirado M, Balantekin AB, Bass CD, Bergeron DE, Bernard EP, Bowden NS, Bryan CD, Carr R, Classen T, Conant AJ, Deichert G, Delgado A, Diwan MV, Dolinski MJ, Erickson A, Foust BT, Gaison JK, Galindo-Uribari A, Gilbert CE, Gokhale S, Grant C, Hans S, Hansell AB, Heeger KM, Heffron B, Jaffe DE, Jayakumar S, Ji X, Jones DC, Koblanski J, Kunkle P, Kyzylova O, LaBelle D, Lane CE, Langford TJ, LaRosa J, Littlejohn BR, Lu X, Maricic J, Mendenhall MP, Meyer AM, Milincic R, Mueller PE, Mumm HP, Napolitano J, Neilson R, Nikkel JA, Nour S, Palomino Gallo JL, Pushin DA, Qian X, Roca C, Rosero R, Searles M, Surukuchi PT, Sutanto F, Tyra MA, Venegas-Vargas D, Weatherly PB, Wilhelmi J, Woolverton A, Yeh M, Zhang C, Zhang X. Final Measurement of the ^{235}U Antineutrino Energy Spectrum with the PROSPECT-I Detector at HFIR. PHYSICAL REVIEW LETTERS 2023; 131:021802. [PMID: 37505961 DOI: 10.1103/physrevlett.131.021802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Revised: 02/14/2023] [Accepted: 05/11/2023] [Indexed: 07/30/2023]
Abstract
This Letter reports one of the most precise measurements to date of the antineutrino spectrum from a purely ^{235}U-fueled reactor, made with the final dataset from the PROSPECT-I detector at the High Flux Isotope Reactor. By extracting information from previously unused detector segments, this analysis effectively doubles the statistics of the previous PROSPECT measurement. The reconstructed energy spectrum is unfolded into antineutrino energy and compared with both the Huber-Mueller model and a spectrum from a commercial reactor burning multiple fuel isotopes. A local excess over the model is observed in the 5-7 MeV energy region. Comparison of the PROSPECT results with those from commercial reactors provides new constraints on the origin of this excess, disfavoring at 2.0 and 3.7 standard deviations the hypotheses that antineutrinos from ^{235}U are solely responsible and noncontributors to the excess observed at commercial reactors, respectively.
Collapse
|
143
|
Xue TT, Wang LM, Zhao ZP, Zhang X, Li C, Huang ZJ, Gao XX, Liu CY, Yu N, Zhang YS, Deng XQ, Wang L, Zhang M. [Cardiovascular health status of Chinese adults based on "Life's Essential 8" score]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2023; 44:1054-1062. [PMID: 37482706 DOI: 10.3760/cma.j.cn112338-20221020-00894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/25/2023]
Abstract
Objective: To assess the cardiovascular health status of adults in China by using the "Life's Essential 8" score, and provide reference for the development and improvement of cardiovascular disease prevention and control policies and measures. Methods: Chronic Disease and Nutrition Surveillance was conducted in 298 counties/districts in 2015 in 31 provinces (autonomous regions, municipalities) across China, multi-stage stratified cluster random sampling was used to select 45 households in each village or neighborhood, and 20 households were further selected to conduct dietary surveys. In this study, a total of 70 093 adults aged ≥20 years who completed the dietary survey and had complete information were included, their cardiovascular health status were assessed by using the "Life's Essential 8" score, a cardiovascular health scoring standard released by the American Heart Association in 2022. All results were adjusted using complex design-based sampling weights to achieve a better estimate of the population. Results: In 2015, the overall cardiovascular health score of Chinese adults aged ≥20 years was 73.3±12.6, the score was significantly higher in women (77.9±11.6) than in men (68.7±11.8), and higher in urban area (74.5±12.8) than in rural area (71.9±12.2), the differences were significant (P<0.001). It was estimated that about 0.25% (95%CI: 0.16%-0.33%) of adults in China had cardiovascular health score of 100, and 33.0% (95%CI: 31.6%-34.3%), 63.2% (95%CI: 62.1%-64.3%), and 3.9% (95%CI: 3.5%-4.2%) of adults had high, moderate and low cardiovascular health scores, respectively. The proportion of those with high cardiovascular health scores was relatively low in men, those with low education level, those with low income, those living in rural areas, and those living in southwest China (P<0.001). Of the eight factors, diet had the lowest mean score (46.0, 95%CI: 44.7-47.3), followed by blood pressure (59.4, 95%CI: 58.2-60.6) and tobacco exposure (61.4, 95%CI: 60.6-62.2). Conclusions: The cardiovascular health status of two-thirds of adult population in China needs to be improved. Diet, tobacco exposure, and blood pressure are the factors affecting the cardiovascular health of Chinese population, to which close attention needs to be paid, and men, rural residents, and those with lower socioeconomic status are key groups in cardiovascular health promotion.
Collapse
|
144
|
Wang L, Zhang M, Zhao ZP, Li C, Huang ZJ, Zhang X, Wang LM. [Analysis on trend of health examination rate and influencing factors in adults in China, 2010-2018]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2023; 44:1037-1045. [PMID: 37482704 DOI: 10.3760/cma.j.cn112338-20230207-00061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/25/2023]
Abstract
Objective: To understand the health examination rate and its changing trend in adults in China from 2010 to 2018, identify the main factors affecting the health examination rate and provide data support for decision making of health intervention. Methods: Data from China Chronic Disease and Risk Factor Surveillance in 2010, 2013, 2015 and 2018 were used. After complex weighting of the data, the rates of health examination, its changing trends and reasons for receiving health examination in adults were analyzed. Average annual percent change (AAPC) was used to describe the changing trend. Anderson model was used as the analysis framework. Multivariate logistic regression model was used to identify the influencing factors for the health examination rate. Results: From 2010 to 2018, the health examination rate in adults increased from 28.2% (95%CI: 24.8%-31.6%) to 41.0% (95%CI: 38.9%-43.1%, P for trend <0.001), the AAPC was 5.47%, the annual average increase was more obvious in those with lower education level and lower income level and in those living in rural area and in western China. In 2018, people received health examination mainly due to providing without charge by community (36.7%) and working unit (28.5%). The results of multivariate analysis showed that being women, age ≥45 years, education level of junior high school or above, living in urban areas, medical insurance, annual income ≥24 000 RMB, suffering from multiple chronic diseases, non-smoking, drinking, adequate physical activity were positive factors for receiving health examination. Conclusion: The rate of health examination in adults increased in China during 2010-2018, and the main reason for receiving health examination is free of charge.
Collapse
|
145
|
Ma LF, Zeng BJ, Wang XZ, Zhang X, Wang JY. [The prospect and challenge of liquid biopsy in the diagnosis and treatment of chest malignancy]. ZHONGHUA YU FANG YI XUE ZA ZHI [CHINESE JOURNAL OF PREVENTIVE MEDICINE] 2023; 57:968-975. [PMID: 37482733 DOI: 10.3760/cma.j.cn112150-20221108-01082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/25/2023]
Abstract
In recent years, the incidence of chest malignant tumors in China has increased year by year, which has seriously threatened the health problems of people. Among them, early screening and intervention of patients with chest malignancies is the key to cancer prevention. Early detection, early diagnosis, and early treatment as the "three early prevention" of clinical practice are conducive to improve the survival rate of tumor patients. As a non-invasive and real-time reflection of tumor status, liquid biopsy has gradually received attention in clinical diagnosis and treatment. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes as liquid biopsy "Three carriages" are not only widely used in the diagnosis, monitoring and prognostic evaluation of chest malignancies, but also face many unknown challenges. In this article, the application of liquid biopsy in chest malignancies in recent years is elaborated in detail, which provides a reference for the formulation of clinical tumor prevention and diagnosis and treatment strategies.
Collapse
|
146
|
Yin R, Zhang X, Wei JJ, Chang JB, Chen YH, Xu HS, Li PT, Yang L, Liu XY, Wang RZ. [Efficacy and outcomes of shunt surgery for secondary hydrocephalus]. ZHONGHUA YI XUE ZA ZHI 2023; 103:1936-1939. [PMID: 37402676 DOI: 10.3760/cma.j.cn112137-20230226-00276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/06/2023]
Abstract
Records of secondary hydrocephalus patients undergoing shunt surgery in the Department of Neurosurgery of Peking Union Medical College Hospital from September 2012 to April 2022 and their clinical characteristics and outcomes were retrospectively reviewed and analyzed. Among 121 patients who received first time shunt placement, the most common causes of secondary hydrocephalus were brain hemorrhage (55, 45.5%) and trauma (35, 28.9%). Cognition decline (106, 87.6%), abnormal gait (50, 41.3%) and incontinence (40, 33.1%) were the most prevalent manifestations. Postoperative central nervous system infection (4, 3.3%), shunt obstruction (3, 2.5%) and subdural hematoma/effusion (4, 3.3%) were the most frequent neurological complications. Overall incidence of postoperative complications was 9% (11 cases) in the current cohort. And 50.5% (54/107) of the patients receiving shunting achieved a Glasgow outcome scale (GOS) score of at least 4. Shunt surgery is preferred for secondary hydrocephalus, especially for secondary normal pressure hydrocephalus. Moreover, it is recommended to complete cranioplasty in staged operation or one-stage operation for the patients with decompressive craniectomy.
Collapse
|
147
|
Zhang X, Ma YS, Tian XD, Yang YM. [Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer]. ZHONGHUA WAI KE ZA ZHI [CHINESE JOURNAL OF SURGERY] 2023; 61:546-549. [PMID: 37402681 DOI: 10.3760/cma.j.cn112139-20230510-00199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/06/2023]
Abstract
Pancreatic cancer is a highly malignant tumor. About 75% of patients with pancreatic cancer who underwent radical surgical resection will still experience postoperative recurrence. Neoadjuvant therapy could improve outcomes in patients with borderline resectable pancreatic cancer,has become a consensus;however it is still controversial in resectable pancreatic cancer. Limited high-quality randomized controlled trial studies support the routine initiation of neoadjuvant therapy in resectable pancreatic cancer. With the development of new technologies, such as next-generation sequencing, liquid biopsy, imaging omics, and organoids, patients are expected to benefit from the precision screening of potential candidates for neoadjuvant therapy and individualized treatment strategy.
Collapse
|
148
|
Hu YY, Zhang X, Wang YD, Zhao CY. [Research progress of arginine vasopressin V2 receptor antagonist tolvaptan in the treatment of cirrhotic ascites]. ZHONGHUA NEI KE ZA ZHI 2023; 62:881-884. [PMID: 37394862 DOI: 10.3760/cma.j.cn112138-20220630-00488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
|
149
|
Liu T, Jiang L, Bai Q, Wu S, Yu X, Wu T, Wang J, Zhang X, Li H, Zhao K, Wang L. CLDN6 Suppresses Migration and Invasion of MCF-7 and SKBR-3 Breast Cancer Cells by Blocking the SMAD/Snail/MMP-2/9 Axis. Bull Exp Biol Med 2023; 175:376-381. [PMID: 37566248 DOI: 10.1007/s10517-023-05871-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Indexed: 08/12/2023]
Abstract
The study examined the mechanisms of action of signal protein claudin 6 (CLDN6) on migration and invasion of breast cancer cell lines MCF-7 and SKBR-3. To this end, the signal proteins SMAD were blocked with their inhibitor SB431542, the genes CLDN6 and SNAIL were knocked down with short hairpin RNAs, and MMP2 and MMP9 were inhibited with TIMP-1. Expressions of MMP2 and MMP9 mRNAs were evaluated by reverse transcription PCR, Expressions of MMP-2, MMP-9, E-cadherin, N-cadherin, and vimentin were examined by Western blotting. Migration and invasion were analyzed by scratch test and Matrigel invasion assay. SB431542 inhibited expression of MMP2 and MMP9 in both cell lines. Single use of SB431542 inhibited expression of MMP-2/MMP-9 and corresponding mRNAs, but subsequent silencing of CLDN6 gene reversed this effect. TIMP-1 reversed down-regulation of E-cadherin, upregulation of N-cadherin and vimentin, facilitation of migration and invasion evoked by CLDN6 knocking down. Silencing of SNAIL gene inhibited migration and invasion, upregulated the expression of E-cadherin, and down-regulated expression of MMP2, MMP 9, N-cadherin, and vimentin. Thus, CLDN6 suppresses the epithelial-mesenchymal transition, migration, and invasion via blocking SMAD/Snail/MMP-2/9 signaling pathway in MCF-7 and SKBR-3 cancer cell lines.
Collapse
|
150
|
Luan HY, Li QX, Zhang X, Gong RF, Lu XG, Li DY, Sun YY, Chen Q, Gao F, Sai XY. [Early identification and influencing factors of post-traumatic stress disorder in high-stress rescue workers]. ZHONGHUA YU FANG YI XUE ZA ZHI [CHINESE JOURNAL OF PREVENTIVE MEDICINE] 2023; 57:1032-1039. [PMID: 37400219 DOI: 10.3760/cma.j.cn112150-20230203-00077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/05/2023]
Abstract
Objective: To explore the risk intensity and related influencing factors of post-traumatic stress disorder (PTSD) among high-stress rescue workers, and to provide effective tools for the risk assessment of PTSD in military rescue workers. Method: From June to August 2022, cluster sampling was used to select the high-stress rescue personnel of an Army department as the survey subjects. The acute Stress reaction (ASD) scale and PTSD checklist were used to evaluate the risk of PTSD in military rescue personnel. Multivariate logistic regression were used to analyze the influencing factors of PTSD. Results: The age of 4 460 subjects was (24.38±4.072) years old, including 4 396 males (98.6%). The positive rate of initial screening for ASD was 2.85% (127/4 460). The positive rate of PTSD was 0.67% (30/4 460). Multivariate logistic regression model analysis showed that female, older age, recent trauma exposure history, passive smoking and alcohol consumption were at higher risk of ASD, the values of OR (95%CI) were 4.183 (1.819-9.618), 6.278 (1.363-28.912), 3.094 (1.500-6.379), 2.059 (1.298-3.267) and 2.607 (1.614-4.211), respectively; Lower education level was associated with lower risk of ASD, OR (95%CI) was 0.593 (0.359-0.978); People who are older, thinner, have a history of mental illness, and drink alcohol were at higher risk for PTSD, the values of OR (95%CI) were 20.144 (2.459-165.043), 10.287 (2.218-47.700), 91.104 (8.592-965.980) and 2.866 (1.144-7.180), respectively. Conclusion: Gender, age, education level, passive smoking, alcohol consumption, past history of mental illness and body mass index may be related to the potential risk of PTSD in rescue workers,passive smoking, alcohol consumption, and weight controlling should be focused on to reduce potential risks of PTSD.
Collapse
|